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ABSTRACT
PGE2 has been shown to possess both pro- and anti-inflammatory
properties. Four subtypes of EP-receptor, termed EPi, EP2, EP3 and
EP4 have been identified pharmacologically and have been cloned in
the human.
The aim of this thesis was twofold. Initial studies involved
confirmation and further characterisation of the newly described EP4
receptor subtype. For this purpose, a range of agonists and, where
possible, antagonists were investigated using the Chinese hamster
ovary (CHO) cells, pig saphenous vein (PSV) and rabbit jugular vein
(RJV) preparations. The second and primary aim of this thesis was to
classify the EP receptor subtype present in human monocytes.
PGE2 has been shown to have inhibitory effects on human
monocyte/macrophages which are likely to be mediated via the EP2
and/or EP4 receptors as these receptors have been associated with
relaxation and down-regulation. Little information has been
published with respect to the EP4 receptor, our aim was to use data
on the EP4 receptor obtained in the first part of this thesis along with
already published data on the EP2 receptor, to classify the inhibitory
EP receptor(s) expressed on human monocytes.
Our results showed that the native CHO cell line expresses EP4
receptors positively coupled to AC and demonstrated further that the
PSV is an EP4 receptor containing preparation. Studies with the RJV,
however, do not identify either an EP2 or an EP4 receptor containing
preparation. Studies with the human monocyte indicated that both
EP2 and EP4 receptors are expressed. The studies measuring
production of cAMP showed that predominately EP4 receptors
mediate the activation of AC. Work examining the functional response
of PGE2 at inhibiting formyl-Met-Leu-Phe (FMLP)-induced superoxide
anion generation demonstrated a predominately EP2 receptor
mediated response. Second messenger studies investigating the
inhibition of FMLP-induced superoxide anion generation by PGE2
indicated that this was via a non-cAMP-dependent pathway.
I
Butaprost has been important in the classification of the EP2 and EP4
receptor subtypes. Interestingly, butaprost showed no affinity for the
cloned EP4 receptor, whereas it demonstrated full agonist activity at
the cloned EP2 receptor. The observation that butaprost induces
complete relaxation to the PSV, an EP4 receptor containing
preparation, suggests that there is co-expression of EP2 and EP4
receptors in this preparation. This co-expression has also been
demonstrated here in the human monocyte and may be the case in
other experimental preparations.
The EP2 receptor has also been shown to mediate the effects of PGE2
in human neutrophils and eosinophils. Since all these leukocytes
express the EP2 receptor this may limit the potential for the
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Prostaglandin and their receptors - discovery and classification
1
1.1.- Introduction to prostaglandins
The first observation of prostaglandin activity was by Kurzrok and Lieb
in 1930 (Kurzrok & Lieb, 1930). This observation was supported and
extended by Goldblatt and von Euler in the late 30's and it was von
Euler's mistaken belief that the source of the biological activity present
in the semen was the prostate gland, that led to the name
"prostaglandin", (Goldblatt, 1933; von Euler, 1936). However, the first
prostaglandins (PG) were not successfully purified for another 20
years, and these were PGEi and PGFia (Bergstrom & Sjovall, 1957).
Currently 11 types designated A-J are known to exist of which PGA2,
PGB2, and PGC2 are extraction artefacts (Horton, 1979), and PGG2 and
PGH2 are unstable intermediates in the biosynthesis of this family of
mediators (Hamburg & Samuelsson, 1973). Prostaglandins E and Fa,
were so named because they partitioned into ether and phosphate
buffer (Swedish fosfat) respectively (Horton, 1979), whereas
prostaglandins A and B were so named because they can be produced
by treatment of prostaglandin E (PGE) with acid and base respectively,
(Bergstrom, 1967). The other prostaglandins were named to fill in the
alphabetic sequence. Thromboxane A2 (TXA2) was discovered and
named separately from the prostaglandins because it has a six- rather
than a five-carbon ring but is derived from the same precursors PGG2
and PGH2 (Needleman et al., 1976). The collective term for
prostaglandins and thromboxanes is prostanoids.
Prostanoids may be regarded as substituted derivatives of prostanoic
acid and are classified according to their substitution pattern on the
cyclopentane ring. They can be biosynthesised from three related fatty
acid precursors, 8,11,14-eicosatrienoic acid (dihomo-y-linolenic acid),
5,8,11,14-eicosatetranoic acid (arachidonic acid (AA)), and
5,8,11,14,17-eicosapentanoic acid (timodonic acid) generating
monoenoic, dienoic and trienoic PGs (Bergstrom et al., 1964;
Gryglewski et al., 1979; Knapp et al., 1978; Needleman et al., 1979).
These are better known as 1-, 2- and 3-series prostaglandins of which
dienoic, or 2-series, prostanoids whose precursor is AA are the most
abundant prostanoids formed by human and animal tissues
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(Bergstrom et al., 1964; Needleman et al., 1979). Leukotrienes,
lipoxins, and hydroxyeicosatetraenoic acids (HETEs) are also formed
from AA, and together with the prostanoids constitute the eicosanoids.
AA is incorporated in phospholipids in an esterified form (Billis et al.,
1975). It is generally located at the 2-position in phospholipids and
must first be released before enzymatic attack can occur; three
pathways have been proposed. Firstly that phospholipase A2 (PLA2)
catalyses the cleavage of AA from the 2-position (Flower & Blackwell,
1976; Vogt, 1978). This has been reported as the major pathway in
the prostanoid cascade of platelets (Broekman, 1986; Derksen 85
Cohen, 1975; Mahadevappa & Holub, 1986; Purdon et al., 1987).
However, others believe there is insufficient PLA2 activity to account
for the burst of AA release that occurs after platelet stimulation (Bell
et al., 1979). They do however detect enough diglyceride lipase
activity and propose that the PLC pathway is responsible by first
forming diacylglycerol (DAG) from which diglyceride lipase releases
AA. Another study (Billah et al., 1980) suggests the involvement of
both PLC and PLA2 sequentially, with PLC producing phosphatidic
acid from phosphatidyl inositol and PLA2 subsequently releasing AA.
Irrespective of the phospholipase involved, free AA is converted to
prostanoids by a series of oxidation steps. The first step is a double
oxidation or cyclo-oxygenase reaction (bis-dioxygenation: Ogino et al.,
1978), combining two oxygen molecules on the polyunsaturated
precursor. A cyclic molecule is produced exhibiting both 9, 11
endoperoxide and 15-hydroperoxyl groups and called endoperoxide G
or PGG2 (Samuelsson, 1972). All the natural prostaglandins are








There are five primary active AA metabolites:- PGD2, PGE2, PGF2a,
PGI2 and TXA2. Five major receptor-types that mediate the actions of
these prostanoids have been proposed and named DP, EP, FP, IP and
TP respectively (Coleman et al., 1984, 1990). Receptor classification is
based on the principal that each natural prostaglandin is more potent
at its own receptor by at least one order of magnitude than the other
natural prostaglandins.
This thesis is particularly concerned with EP receptors which have a
wide distribution in terms of both the tissues and species in which
they have been identified, and in the responses which they mediate.
The EP receptor has been further subdivided into four subtypes
termed EPi, EP2, EP3 and EP4 (Coleman et al., 1994), and as such, is
currently the only prostanoid receptor to have defined subtypes.
There is some controversy as regards the TP receptor with certain
groups believing the existence of subtypes (Morinelli et al., 1989),
however, these results may reflect mRNA splice variants of the TP
receptor (Raychowdhury et al., 1994). Since this thesis is concerned
with EP-receptor identification and characterisation, only original
classification of these subtypes will be discussed.
It was first suggested that two subtypes of PGE2 receptor may exist by
Bennett 8s Posner (Bennett 85 Posner, 1971). They found that SC-
19220 and polyphloretin phosphate (PPP) blocked the contractile
action of PGE2 on the longitudinal muscle of the guinea-pig ileum
whereas the relaxant action of PGE on the circular muscle was
unaffected. Since then SC-19220 has been shown to inhibit PGE2 in
only some of a range of EP-receptor containing preparations, such as
the guinea-pig ileum and fundus, but not the guinea-pig lung, dog
saphenous vein, rabbit aorta, dog and cat iris or cat trachea. EP-
receptors blocked by SC-19220 have been classified as EPi-receptors.
This subclassification of the EP-receptor has been confirmed and
extended by the identification of the selective agonists, sulprostone and
AY23626. These two compounds showed a different activity profile on
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tissues insensitive to SC-19220 or AH6809, another EPi-receptor
antagonist (Coleman et ah, 1985), which lead to the division of non-EPi
receptors into two further subtypes, EP2 and EP3 (Coleman et ah,
1987a,b,c). Sulprostone has a high potency at EPi- and EP3- (chick
ileum) receptors, and is inactive at EP2-receptors (cat trachea), whereas
AY23626 has high potency at EP2- and EP3-receptors, having weak or
no activity at EPi-receptors.
From these data, EP-receptors were originally classified into three
subtypes EPi, EP2, and EP3 (Coleman et ah, 1990). However, work on
hamster uterus (Coleman 1983; Yeardley et al., 1992a), rabbit jugular
vein (RJV) (Lawrence & Jones, 1992) and rat trachea (Lydford &
McKechnie, 1993) all provided evidence for the existence of a fourth
subtype of EP-receptor. This has now been confirmed by the discovery
of a receptor antagonist for this subtype (AH23848B (Louttit et ah,
1992a; Coleman et ah, 1994, 1995; Milne et al., 1995)) and work on
the pig saphenous vein (PSV) an EP-receptor containing preparation
with a non-EPi, -EP2 or -EP3 subtype profile (Louttit et ah, 1992b).
The effects associated with EPi- and EP3-receptors may be considered
as excitatory, and are believed to be mediated by a stimulation of
phosphatidylinositol turnover and/or inhibition of adenylate cyclase
(AC) activity, with a resulting decrease in intracellular cAMP (Gutman
et ah, 1979; Namba et ah, 1993; Strong et ah, 1992; Sugimoto et ah,
1992a). In contrast, the effects associated with EP2- and EP4-receptors
may be considered as inhibitory, and are believed to be associated with
a stimulation of AC and an increase in intracellular cAMP (Coleman et
al., 1994, 1995; Creese & Denborough, 1981; Honda et ah, 1993;
Jumblatt & Paterson, 1991; Milne et ah, 1995; Reimer et ah, 1992;
Yeardley et ah, 1993).
The constant problem throughout the classification of prostaglandin
receptors has been the lack of selective antagonists, see Table 1.1.
TXA2 is a potent inducer of platelet aggregation and contraction of
vascular and respiratory smooth muscle (Moncada et ah, 1978) and
the development of antagonists at this receptor has yielded many
potent compounds such as GR32191X which has a pA2 of 8.2-8.8
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(Lumley et at, 1989) and EP092 with a pA2 of 7.2-8.4 (Armstrong et
at, 1985).
Interestingly, very few antagonists have been discovered for the PG
receptor subtypes and may reflect the fact that most analogues have
been based on the structure of PGs, Figures 1.2-1.5. It seems that
basing structures on PGs produces agonists rather than antagonists
and that to develop antagonists, compounds have needed to be
distinctly different from PGs, such as AH6809, Figure 1.5,. This has
made the discovery of antagonists difficult because there are no
indications as to what structural confirmation will allow a non-
prostaglandin like compound to bind to a receptor but exhibit no
agonism.
Nevertheless, there are now selective agonists for almost every
prostanoid receptor plus a few selective antagonists and this, coupled
with preparations containing specific receptor populations, has
allowed the development of a working classification for the prostanoid
receptors (Coleman et al., 1984, 1990) as shown in Table 1.1.
There are currently several PG analogues being marketed or
undergoing clinical trials as abortifacients (gemeprost, misoprostol 8s
sulprostone), antiulcer (misoprostol), antihypertensive (limaprost;
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Figure 1.4: Structure of PG analogues
II
BW A868C
Figure 1.5: Structure of PG antagonists
i a.
EPi receptors
With regards to the EP receptors, there are now many selective
agonists and some antagonists, see Table 1.1 and 1.2. Sulprostone is
equipotent with PGE2 at the EPi receptor (Coleman et al, 1987a) but
has also been shown to stimulate EP3 receptors, and although
sulprostone was first identified as an EPi agonist, it is actually a
more potent agonist at EP3 receptors, Table 1.2 (Coleman et al.,
1987c). 17-phenyl-co-trinor PGE2 is an EPi agonist but with limited
selectivity having only a 10-fold greater potency at the EPi receptor
than EP2 and EP3 receptors (Lawrence et al., 1992). There are a few
antagonists for EPi receptors. SC-19220 was the first identified EPi
receptor antagonist (Coleman et al., 1985, 1987a) followed by
AH6809, a more potent EPi antagonist (Coleman et al., 1985, 1987a).
AH6809, however, has also been shown to have DP antagonist
activity (Keery & Lumley, 1988) and, most recently, it has been
reported to also have antagonist activity at the recombinant human
EP2 receptor (Woodward et al., 1995).
EP2 receptors
EP2 agonists have helped in the initial classification of EP receptor
subtypes as described above. AY23626 is equieffective with PGE2 in
the cat trachea, Table 1.2 (Coleman et al., 1987b), but is also an
agonist at EP3 receptors (Coleman et al., 1987a,b). Butaprost (first
published as TR4979) and AH 13205 are reported to be selective EP2
agonists (Gardiner, 1986; Nials et al., 1993) but are both less potent
compounds than PGE2 at the EP2 receptor, see Table 1.2. AH6809 is
the only reported compound with antagonist activity at EP2 receptors
(Woodward et al., 1995; personal communication Prof. R. L. Jones &
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EP3 receptors
The development of EP3 agonists has been helped by the market for
potential antiulcer drugs (Collins, 1986). Misoprostol was developed
as such a compound and is equieffective with PGE2 at EP3 receptors.
However, it also has potent EP2 agonist activity (Reeves et al., 1988;
Bunce et al., 1990; Lawrence et al., 1992), Table 1.2. Sulprostone has
been shown to have potent agonist activity at EP3 receptors
(Lawrence et al., 1992), but again is limited by its lack of selectivity,
also being a potent EPi agonist (Coleman et al., 1987a). GR63799X is
reported as being a EP3 agonist and is more potent at the EP3
receptor than PGE2 with an equieffective concentration (EEC) of 0.1
(Bunce et al., 1990). GR63799X has been tested in vivo in rats for its
inhibition of lesion formation and was as effective as misoprostol.
Furthermore, it produced fewer side-effects of uterine stimulation.
However, like sulprostone, GR63799X also has agonist activity at EPi
receptors (Bunce etal, 1990).
EP4 receptors
As mentioned earlier, EP4 receptors have been the most recent EP
receptor subtype to be identified and were first described in the PSV
using the antagonist AH23848B (Louttit et al., 1992a). To date there
are no published data on EP4 agonists, but there are two published
antagonists AH22921 and AH23848B (Coleman et al., 1994, 1995).
These two compounds are both weak antagonists with pA2S of 5.3
and 5.3-6.2 respectively, see Table 1.2.
With the available agonists and antagonists it is now possible to
identify which receptor subtypes are present in tissues by functional
profile. However, this information has been superseded by the cloning
of all prostanoid receptors currently identified and the availability of
selective probes (Pierce et al., 1995).
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1.3.- Receptor cloning
The purification of a TP receptor from human platelets was the first
step in the cloning of prostanoid receptors. From the partial amino
acid sequence, an oligonucleotide probe was designed and a cDNA
encoding a full length TP receptor cloned from a human placenta
library (Hirata et al., 1991). The deduced amino acid sequence of this
receptor consisted of 343 amino acids and showed structural
similarity with other previously cloned G-protein-coupled receptors.
Homology based studies rapidly led to the cloning of cDNAs encoding
the human DP (Boie et al., 1995), FP (Abramovitz et al., 1994), IP
(Boie et al., 1994) and four subtypes of the EP receptor; EPi, EP2, EP3
and EP4 (reviewed in Pierce et al., 1995).
From their predicted secondary structure, the cloned prostanoid
receptors lit the general model for the G-protein-coupled receptors
like the rhodopsin-type receptors (Savarese & Fraser, 1992) in which
there are seven putative transmembrane domains, an extracellular
amino terminus and an intracellular carboxyl terminus. Functional
expression of the cloned receptors is also consistent with a single
subunit structure, which contains both the ligand binding and
second messenger coupling site.
Like the other subfamilies of the G protein-coupled receptors (e.g.
adrenoceptors and 5-HT receptors), the prostanoid receptors do not
share extensive overall amino acid identity. Comparison of all
members of the human prostanoid receptor family shows 28% to 45%
amino acid sequence homology between any two members (Boie et al.,
1995). There are a total of 28 amino acid residues conserved in all
prostanoid receptors, 8 of which are also conserved in all rhodopsin-
like G-protein-coupled receptors.
Two regions are particularly well conserved in all the prostanoid
receptors, see Table 1.3. One of these is in the second extracellular
loop, connecting the fourth transmembrane domain with the fifth
transmembrane domain, and contains the non-variable and unique
tripeptide WCF. The cysteine residue within the tripeptide forms a
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putative disulfide bridge with the conserved cysteine residue in the
first extracellular loop (Boie et al, 1995). In this same sequence there
is a seven residue motif, PGTWCFI, conserved among all the
prostanoid receptors that bind PGE2 suggesting a role in specificity,
see Table 1.3.
The second region in the seventh transmembrane domain contains
approximately 15 residues that are highly conserved, including five
non-variable residues. The non-variable Arg in the seventh
transmembrane domain corresponds to the Lys residue in rhodopsin,
which is essential for retinal binding, suggesting the possibility that
the Arg provides a binding site for the a-carboxylic acid group of the
prostanoids (Hirata et al., 1991). There is also another invariant
tripeptide, DPW, which includes the proline residue conserved in all
G-protein-coupled receptors (Probst et al., 1992).
For all the cloned prostanoid receptors, except the EP receptors, there
has been a good correlation between the pharmacology of each
heterologously expressed receptor and the pharmacology as defined
in native tissues. The EP receptors, however, did not show a good
correlation. A mouse clone (Honda et al., 1993) initially designated as
the EP2 receptor was found to be inactive with respect to the binding
of butaprost, a previously characterised selective EP2 receptor
agonist. The recombinant human homologue (Bastien et al., 1994),
originally designated as an EP2 receptor, also failed to bind butaprost.
The subsequent cloning of a fourth subtype of EP receptor, for which
butaprost had affinity, suggested that it was the human EP2 receptor
(Regan et al., 1994a), and that these previously cloned 'EP2' receptors
represented a different subtype. It has recently been reported that the
previously cloned TCP2' receptors (Bastien et al., 1994; Honda et al.,
1993) are probably EP4 receptors. Comparing the primary sequences
of the cloned EP2 and EP4 receptors shows that they only share
approximately 40% amino acid identity in their transmembrane

















Table 1.3 - Sequence homologies of two regions in the cloned human
prostanoid receptors.
Non-variable residues shown in bold
Source - Boie et al, 1995
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Phylogenetic analyses (Boie et al., 1995; Pierce et al., 1995), show two
major branches of the prostanoid receptors with one group (IP, DP,
EP2 and EP4 receptors) activating AC and the other group either
stimulating phosphatidylinositol hydrolysis (TP, FP and EPi
receptors) or inhibiting AC (EP3 receptors).
Of interest in the EP subtypes is the presence of multiple EP3
isoforms, i.e. mouse EP3a, EP3p and EP3Y, and bovine EP3A, EP3B, EP3C
and EP3D, which differ only in their carboxyl-terminal tails (Sugimoto
et al., 1992b; Namba et al., 1993; Irie et al., 1993). Furthermore,
rabbit and rat EP3 subtypes also have multiple isoforms with
divergent carboxyl-terminal tails (Takeuchi et al., 1993; Breyer et al.,
1994). In humans, seven different cDNAs have been cloned that can
give rise to different isoforms (Adam et al., 1994; An et al., 1994;
Regan et al., 1994b; Kotani et al., 1995; Schmid et al., 1995).
Structurally, this extensive alternative splicing of the EP3 receptor
only affects the carboxyl terminus and all the isoforms have the same
amino termini and transmembrane domains and only begin to differ
eleven residues in the direction of the carboxyl terminus from
transmembrane seven (Pierce et al., 1995). Since phosphorylation of
the carboxyl terminus is involved in the desensitisation of G-protein-
coupled receptors (Lefkowitz, 1993), these splice variants may explain
differences in desensitisation seen between the mouse (Negishi et al.,
1993a) and human (An et al., 1994) EP3 isoforms. Another way in
which the EP3 receptor isoforms may functionally differ from one
another is in their coupling to second messenger pathways. It has
been suggested that the carboxyl terminus may help determine the
specificity of G-protein coupling (Namba et al., 1993). Kotani and co¬
workers even suggest that certain effects of PGE2 on smooth muscle
relaxation, which are believed to be mediated by EP2 receptors, may
be partially due to two isoforms EP3-11 and EP3-1V which, when
transfected into COS-7 cells, generate increases in intracellular cAMP
in the presence of the EP3 agonist M&B28767 (Kotani et al., 1995).
High receptor expression and choice of cell type may, however, be the
reason these splice variants couple to multiple second messenger
pathways. The G-protein content of cells such as the CHO cell and
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COS-7 cell may be different from that found in vivo for the tissues
which express these subtypes. If a receptor has high affinity for Gi
over Gs in vivo but is expressed in a cell line containing mainly Gs,
then high receptor expression could favour Gs activation and any
subsequent measurement of intracellular changes would not reflect
the true nature of the receptor.
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1.4.- Background
At the start of my thesis, January 1993, the EP receptors were
classified into three subtypes, EPi, EP2 and EP3 (Coleman et al.,
1990). Certain publications, however, indicated the existence of
another EP receptor subtype (Lawrence & Jones, 1992; Yeardley et
al., 1992a). These receptors generate relaxation in the presence of
PGE2 but give much higher EEC ratios for certain EP2 receptor
agonists when compared to PGE2. For example, Lawrence and Jones
(1992), showed butaprost to have an EEC ratio of 685 against PGE2
in the RJV which is about 40 times greater than the EEC of 17 for
butaprost against PGE2 in the cat trachea, an accepted EP2 receptor
containing preparation (Gardiner, 1986). Yeardley and co-workers
were investigating the EP receptor subtype involved in the inhibition
of uterine activity (Yeardley et al., 1992a). The group found that
PGE2, but not sulprostone or AH 13205, inhibited electrically-induced
uterine contractions and caused concentration-related increases in
cAMP levels in hamster uterus. They concluded that the high potency
of PGE2 supported the involvement of EP receptors, but the lack of
activity of sulprostone and AH 13205 cast doubt on the involvement of
EPi, EP2 or EP3 receptor subtypes.
The differences in these particular systems which suggested the
involvement of a second relaxant EP receptor subtype were only just
beginning to be explained in January 1993. Two abstracts published
at the 8th International Conference on Prostaglandins and Related
Compounds in Montreal by James Louttit (Louttit et al., 1992a,b)
demonstrated that the PSV contained an EP receptor which did not
appear to be of the EPi, EP2 or EP3 subtypes (Louttit et al., 1992a).
They also demonstrated selective antagonist activity for AH23848B at
the EP receptor subtype present on the PSV (Louttit et al., 1992b) and
concluded the presence of a novel EP receptor subtype and suggested
naming it the EP4 receptor.
Our group's interest in the field at the time concerned the RJV. It had
previously been described as an 'atypical EP2' receptor containing
preparation and we wished to further investigate this classification.
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Allergan Inc., USA, were funding the PhD thesis and at the time were
attempting to develop antiglaucoma agents based on the knowledge
that PGF2a lowers intraocular pressure (IOP) (Aim & Villumsen,
1989). PGF2a, however, also causes the undesirable side effect of
hyperaemia, redness around the white of the eye (Protzman &
Woodward, 1990). David Woodward and co-workers had discovered
that compounds which induced hyperaemia also relaxed the RJV and
that this preparation was a useful negative screen. However, the
mechanism by which PGF2a mediated these responses had not been
elucidated.
The Chinese hamster ovary (CHO) cell line had been discovered to
contain an EP receptor linked to AC which was sensitive to block by
AH23848B (Dr. R. A. Coleman personal communication), and our
group decided that this could prove a useful preparation to collect
more data about the EP4 receptor, if this was indeed the receptor
expressed in these cells.
Several studies on monocyte/macrophages have shown that PGE2 is
capable of acting as an endogenous negative feedback control on
physiological responses such as locomotion, phagocytosis and colony
formation (Pelus et al., 1979; Oropeza-Rendon et al., 1979, 1980;
Bonney et al., 1980). However, little work has been carried out to
determine which subtype(s) of EP receptor are present, and whether
these are directly linked to the physiological functions observed with
PGE2. Binding studies have been carried out on human monocyte
membranes (Eriksen et al., 1985) but using only PGE2 and other
natural prostanoids as displacing agents. Misoprostol has been
investigated along with PGE2 (Haynes et al., 1992; Reder et al., 1994)
but only from the objective of inhibiting whole animal disease onset
and growth as well as cytokine release by mouse and human
monocyte/macrophages. As yet, the inhibitory EP receptors present




The aim of this thesis was twofold. Initial studies involved the
confirmation and further characterisation of this newly described EP4
receptor subtype. For this purpose, a range of agonists and, where
possible, antagonists were investigated using the CHO cells and the
PSV and RJV preparations. The strategy being to build up
information on the EP4 receptor subtype.
The second and main aim of this thesis was to classify the EP
receptor subtype present in human monocytes. As described
previously, PGE2 has been shown to have inhibitory effects on human
monocyte/macrophages, and these effects are likely to be mediated
via EP2 and/or EP4 receptors. As little information had been
published with respect to EP4 receptors, our aim was to use data on
EP4 receptors obtained in the first part of this thesis along with
already published data at EP2 receptors, to classify the inhibitory EP
receptor(s) expressed on human monocytes.
The EP receptors present on human monocytes was studied to see if
they were directly coupled to AC, and how different EP agonists and
the antagonist AH23848B affected the resultant accumulation of
cAMP. The whole cell system and the functions of PGE2 on the
human monocyte were then investigated. PGE2 was studied from the
standpoint that it is an inhibitor of certain monocytic cell functions,
and thus only inhibition of stimulatory systems by PGE2 were
investigated. It is well documented that PGE2 also possesses
stimulatory and pro-inflammatory actions, but the objective of the
second part of this thesis was to identify if there was a role for
selective EP agonists targeted at the human monocyte. Studies on the
effects of PGE2, and the receptor mediating the response, were carried
out on IL-la and IL-ip release and superoxide anion generation from
the human monocyte. The second messenger system mediating the




Investigation of the EP-receptor subtype(s) expressed by the
Chinese Hamster Ovary cell line, and further investigation of the




Investigation of the EP-receptor subtype(s) expressed in the
Chinese Hamster Ovary cell line
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2.1.1.- Introduction
The Chinese Hamster Ovary (CHO) cell line was first developed by Tjio
and Puck in 1957 (Tjio & Puck, 1957). The uses of the CHO cell line
have been diverse since its discovery, but it is mainly used nowadays
for expression of transfected cloned sequences. Cells are generally
grown in a minimal essential medium or Hams F12 medium
supplemented with 5-10% foetal calf serum and antibiotics/fungicides
(amounts of antibiotics/fungicides ranged between publications as
well as the types used).
Literature on transfected CHO cells show a diverse field both in terms
of systems studied and species involved, i.e. rat dopamine D2 receptor
(Kanterman et al., 1990), human D4 receptors (Asghari et al., 1995),
mouse T-cell IL-1 receptor (Curtis et al., 1989) human lipoxin A4
receptor (Fiore et al., 1994) and almost all the prostanoid receptors
from a variety of species (Sugimoto et al. 1992; Watabe et al., 1993;
Hirata et al., 1994; Ito et al., 1994; Namba et al., 1994; Katsuyama et
al., 1995).
Prostaglandin receptors linked to activation of AC have been
transfected in CHO cells. Mouse DP and EP2 receptors were cloned
and transfected into CHO cells which have been used for cAMP assays
and binding analysis to verify functional characteristics of the
expressed receptors (Hirata et al., 1994; Katsuyama et al., 1995). The
mouse IP receptor has also been cloned and transfected into CHO
cells allowing cAMP measurement and [3H]iloprost binding studies
which confirmed stable expression of the IP receptor (Namba et al.,
1994).
Receptors which stimulate phosphatidylinositol have also been
transfected and expressed in CHO cells. Bovine FP receptors have
been shown to elevate [Ca2+]i and purified Gqa antibody was shown to
inhibit receptor activation (Ito et al., 1994), thus linking FP receptor
activation with Gq coupling. With mouse recombinant EPi receptors
expressed in CHO cells, 17-phenyl-co-trinor PGEi, sulprostone and
PGE2 were equipotent at displacing bound [3H]PGE2 from crude
membrane fractions confirming the expression of EPi receptors
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(Watabe et al, 1993). Signal transduction in the cloned EPi receptor
was later studied in these EPi receptor expressing cells and shown to
be mediated by PKC, and not PKA or PLC, activation (Katoh et al.,
1995)
The CHO cell line has been used extensively to study EP3 receptor
splice variants and their G-protein coupling. The mouse EP3 receptor
has been cloned and expressed in CHO cells (Sugimoto et al. 1992)
and later identified as expressing different isoforms, EP3a and EP3p, by
alternative splicing of the EP3 gene (Sugimoto et al., 1993). These two
isoforms were shown to have the same ligand binding properties in
transfected COS-1 cell membranes, but different profiles for inhibition
of forskolin induced cAMP generation and stimulation of GTPase
activity in transfected CHO cells (Sugimoto et al., 1993). Further work
with the same transfected CHO cell line showed different
desensitisation profiles to PGE2 for these two subtypes (Negishi et al.,
1993). These two isoforms expressed in CHO cells have also been
shown to enhance AC activity after initially sensitising the cells with
PGE2 (Harazono et al., 1994), again showing different profiles and
highlighting the capacity of DNA splicing to generate functionally
different end-products with identical binding capacity.
A third isoform of mouse EP3, EP3Y, was identified, and expressed in
CHO cells, and shown to both stimulate and inhibit AC (Irie et al.,
1993). In CHO cells expressing these three isoforms of mouse EP3
receptors, PGE2 increased [Ca2+]i and accumulation of IP3 (Irie et al.,
1994). This effect was sensitive to block by pertussis toxin and a PLC
inhibitor U-73122. The group concluded that these EP3 isoforms are
linked to PLC activation via Gi, and that PLC activation leads to Ca2+
mobilisation.
Namba and co-workers studied further the G-protein specificity of EP3
receptors in CHO cells with four splice variants from bovine adrenal
medulla (Namba et al., 1993). The group found that three of the splice
variants EP3B-EP3D increased cAMP after stimulation with M&B28767
in transfected CHO cells, which was inhibited by a specific anti-GSa
antibody, and that two isoforms EP3A and EP3D inhibited forskolin
induced cAMP generation, which was potentiated by pertussis toxin.
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With further studies on IP3 generation and [Ca2+]i measurement, the
group concluded that EP3A receptors couple to Gi/G0 protein, EP3B and
EP3C couple to Gs, and EP3D couple to Gi, Gs and Gq (Namba et al.,
1993). Interestingly, using CHO cell membranes transfected with EP3C
receptors, Negishi and co-workers have demonstrated that these
receptors stimulate the GTPase activity of Gs, while they inhibit that of
Go by increasing the binding affinity of G0 for GDP (Negishi et al.,
1993b) showing further diversities for G-protein coupling and second
messenger systems of EP receptor splice variants
Human isoforms of the EP3 receptor have also been identified and
expressed in CHO cells (Kotani et al., 1995). Currently four isoforms
have been identified, EP3-1, EP3-11, EP3-111 and EP3-1V, which, like the
bovine isoforms have similar affinities to PGE2 with divergent
downstream signalling pathways. M&B28767 increased cAMP in cells
expressing EP3-11 and EP3-1V, whereas it inhibited forskolin induced
cAMP accumulation in cells expressing all EP3 isoforms. M&B28767
also stimulated phosphoinositide turnover in cells expressing EP3-1
and EP3-11 showing similar variability with the human isoforms as for
the bovine splice variants (Namba et al., 1993).
The usefulness of the CHO cell is highlighted by the number of
different receptors transfected into them, and the number of diverse
studies carried out with these transfected cells. CHO cells transfected
with prostanoid receptors have helped immensely in the
characterisation of those prostanoid receptors and have even been
used as screens for selective compounds. Negishi and co-workers,
used CHO cells transfected with IP, EPi, EP2 and EP3 receptors to
identify TEI-3356, a potent and highly selective EP3 agonist,
equieffective with sulprostone at the EP3 receptor but with limited EPi,
EP2 and IP agonist activity (Negishi et al., 1994). As many tissues
express multiple EP receptor subtypes along with other prostanoid
receptors, evaluation of the potency of an agonist or antagonist for a
single type of receptor is very difficult. Negishi and co-workers
conclude that assay systems involving transfected cells allow clearer
evaluation of the potency and selectivity of agonists or antagonists at
a single receptor.
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EP4 receptors have only been studied in smooth muscle, with studies
concentrating mainly on the antagonists selective for this receptor
(Louttit et al., 1992a,b; Milne et al., 1995; Coleman et al., 1994,1995).
Interestingly, the Chinese hamster ovary (CHO) cell line has been
found to express endogenously an EP receptor positively coupled to
AC with characteristics of the EP4 receptor , i.e. sensitivity to block
with AH23848B (Dr. R. A. Coleman, personal communication). This is
surprising as cells used for transfection are chosen because they lack
the receptor to be transfected. As such, binding studies for EP
receptors transfected into the CHO cell line should have detected EP
receptors on the native cells, but this has not been documented.
EP2 receptors have been shown to be positively coupled to AC and
induce accumulation of cAMP in rat cortical collecting tubule (RCCT)
cells (Sonnenburg & Smith, 1988). PGs of the E-series were most
potent at stimulating cAMP, and sulprostone failed to stimulate cAMP
production, suggesting the involvement of the EP2 receptor in cAMP
generation. In cultured RCCT cells, PGE2 was shown to bind to a
single class of receptors, and this binding was inhibited by guanine
nucleotide derivatives, indicating the involvement of a G-protein
(Sonnenburg et al., 1990). The CHO cell line thus offered a good
opportunity to study receptor stimulation versus second messenger
stimulation and to see if the putative EP4 receptor present on these
cells was positively coupled to AC activation.
We have used a range of agonists at EP receptors and the antagonist,
AH23848B (Louttit et al., 1992a), to investigate cAMP generation in
native CHO cells. These cells were bought from the European
Collection of Animal Cell Cultures (ECACC) to be sure that they were
homologous with other CHO cell lines and the passage number was
always kept below twenty. Initially, a sensitive RIA for acetylated cAMP
was set up and with this assay it was possible to measure cAMP from
cells at low adherent concentrations avoiding the possible changes




HBSS - Hanks' Balanced Salt Solution without Phenol Red stored at
20°C.
DMSO - Sterile dimethyl sulphoxide stored at 20°C
IBMX - 3-Isobutyl-l-methylxanthine (C10H14N4O2 - FW=222.2). Stored
as dry powder at 20°C
HAMS F-12 - Nutrient Mixture F-12 (HAM) with L-Glutamine. Stored
at 4°C.
Pen/Strep - Penicilin-Streptomycin Solution, containing 10000 U/ml
Penicillin and 10000 pg/ml Streptomycin. Stored at -20°C.
FCS - Foetal Calf Serum Heat Inactivated. Mycoplasma and virus
screened. Stored at -20°C.
Trypsin - Trypsin-EDTA Solution (IX) prepared in modified PUCK's
saline A and stored at -20°C.
Cell culture medium - Cell culture medium was made up with HAMS
F-12 minimal alpha medium (500 ml), FCS (50 ml) and Pen/Strep (5
ml), and stored at 4°C. The medium was always warmed to 37°C
before use.
Drugs - All drugs dilutions were prepared fresh each day in 0.9%
saline from dry powder or ethanol stocks. AH23848B solution was
sonicated for 30 min prior to use.
Chinese Hamster Ovary cell culture
The Chinese Hamster Ovary (CHO) cell line was obtained from the
European Collection of Animal Cell Cultures (ECACC). The vial was
left to defrost fully for 2 min at room temperature then placed in a
water bath at 37°C for a further 2 min. Warmed cell culture medium
(1 ml) was added, and the contents of the vial diluted to 30 ml with
medium. Since the cells are stored in DMSO 10%, it is important to
dilute out and completely remove DMSO, as this can cause
differentiation of some growing cell cultures. The suspension was
centrifuged, 450 g for 10 min at room temperature, and the
supernatant discarded. The pellet was immediately resuspended in
medium (5 ml) and aliquoted into a 800 ml cell culture flask
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Figure 2.1.1- Haemocytometer slide
The crossed sections were counted to obtain cell count and cell
concentration counted as follows:
Total cells counted/4 = Yx 104 cells/ml
x5 (dilution factor of cells in Trypan Blue®) = cells/ml in flask
x ? (aliquot volume) = cells in flask
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Cyclic AMP extraction from CHO cells
Cells were harvested from their flasks as described above,
resuspended in culture medium and seeded to 12 well plates at a
concentration of 1 x 106 cell/well. The plates were then placed back in
the incubator for 1 hr to allow the CHO cells to adhere to the wells.
Once adhered, the medium was removed and the cell monolayer
washed twice with 0.9% saline. Drugs were made up fresh each day in
HAMS-F12 medium with indomethacin 5 pM and IBMX 0.25 mM,
without FCS or Pen/Strep and added immediately in 1 ml aliquots to
the cell monolayer. The plates were returned to the incubator and
incubated at 37°C. After incubation the medium was removed to tubes
and the reaction stopped with ice cold 100% ethanol (1 ml) added
directly to the wells or 2 ml to the tubes of medium. The wells were
scraped with the rubber tip of a syringe plunger and the ethanol
removed. Another 1 ml ethanol 100% was added to each well and
again the wells scraped before removing this ethanol. Cell debris was
removed from the samples by centrifugation at 450 g for 10 min. The
ethanol layer was then decanted to clean, labelled tubes which were
evaporated to dryness at 55°C in heating blocks under a stream of air.
The dry tubes were covered and stored at -20°C until assayed.
A time course was run initially to determine the optimum incubation
time for the CHO cells. In addition samples were taken from both the
cellular and medium fractions to determine which samples produced
the maximum increase in cAMP levels within a 30 min time course,
Figure 2.1.5. From these, it was decided that 5 min was the optimum
incubation time, and this was used throughout all the other
experiments.
For antagonist studies, antagonists were added to the monolayer, 10
min prior to the agonist, in 0.9 ml aliquots of HAMS F-12 and
incubated at 37°C. Agonists were then added in 100 pi aliquots and




50 mM sodium acetate buffer, pH-6.0 - 0.05 M sodium acetate
anhydrous (MW = 82.03) - 4.10 g/1 + 0.05 M acetic acid - 2.86 ml
glacial acetic acid/1. Sodium acetate buffer was brought to pH 6.0 by
adding sodium hydroxide and stored at 4°C. 0.1% BSA is not added
until just before use because BSA encourages bacterial growth.
50 mM phosphate buffer, pH-7.4 - 50 mM Na2HP04 (MW = 141.96) -
7.098 g/1 + 50 mM Na2HP04.2H20 (MW = 156.01) - 7.8 g/1. Na2HP04
was brought to pH 7.4 by adding Na2HP04.2H20. Na azide (5 ml) was
added as a preservative and stored at 4°C.
1° Antibody - The 1° antibody was a gift from Dr. B. Williams of the
Western General Hospital, Edinburgh. Our stock was a 1:100 dilution
in 50 mM acetate buffer of the rabbit serum and it was stored frozen.
Donkey Anti-Rabbit Serum (DARS) - DARS was ordered from the
Scottish Antibody Production Unit (SAPU) in 20 ml samples which
were split to 2 ml aliquots and stored frozen. DARS was used as 1:10
dilution with Phosphate Buffer (+0.1% w/v BSA), and the diluted
serum was never kept.
Normal Rabbit Serum (NRS) - NRS was also ordered from SAPU in 20
ml bottles but was split to 1 ml aliquots before storing frozen. NRS
was used as 1:100 dilution with Phosphate Buffer and again the
diluted serum was never kept.
Cyclic AMP Standards - A stock solution of cAMP (Sigma) in acetate
buffer of 32 mM was used and stored at -20°C. Standards of 320, 32,
16, 8, 4, 2, 1, 0.5, 0.25, 0.125, and 0.0625 nM cAMP were made up in
acetate buffer. Acetate buffer was used as the zero. Standards were
stored frozen in their unacetylated state.
Acetylating Reagents - Triethylamine (TEA) and acetic anhydride
(AA). The acetylating mixture consisted of 2:1 TEA to AA which was
always made up in a glass tube and mixed well before use. The
mixture was never stored but made up fresh before use and if TEA
showed any signs of yellowing it was replaced
PEG 200 - PEG (Polyethyleneglycol) 200 (Aldrich)
Triton X-100 - Triton X-100 (Aldrich)
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Background
In initial experiments, cAMP was measured using a cAMP assay that
was already working in our laboratory which used a cAMP binding
protein (BDH) to competitively bind cAMP and [3H]cAMP (Armstrong et
al., 1985). However, the determination limit of this assay was not
sufficiently low to detect any significant amounts of cAMP from the
CHO cells (data not shown) and a new RIA was set up which was
capable of measuring much lower concentrations of cAMP.
A primary antibody for acetylated cAMP was kindly made available to
us from Dr. B. Williams, Department of Medicine, University of
Edinburgh, Western General Hospital, Edinburgh. The only assays
carried out with the 1° antibody used a charcoal solution to bind 'free'
cAMP which was pelleted arid counted after removing the supernatant.
This assay method therefore counted the 'free' rather than the 'bound'
cAMP and our preference was to set up an assay that would
accurately measure the 'bound' fraction because of the very low levels
of cyclic AMP being generated.
Before starting, dilution curves for the 1° antibody were run to
determine the optimum concentration for the RIA. Aliquots (200 pi) of
serially diluted 1° antibody from 1:1000 to 1:64000 were incubated
overnight with 125I-cAMP ( 50 pi, -50000 cpm), DARS (50 pi, 1:3
dilution) and NRS (50 pi, 1:40 dilution). After centrifugation the
supernatant was removed and the pellet counted which gave a curve
for the dilution factor versus cpm (bound 125I-cAMP) as shown in
Figure 2.1.2a. From this a dilution factor of 1:20000 was chosen
which produced -50% binding as this would produce the most
significant changes in cpm values for a small change in displacement.
This was lowered to 1:40000 in later experiments to conserve the 1°
antibody.
Once the dilution factor was determined, the assay was run arid other
factors optimised. One of these was the dilution of DARS and NRS to
use. The initial protocol suggested mixing NRS and DARS at 1.5 ml
NRS to 20 ml DARS, leaving the antibodies to bind overnight at 4°C
before pelleting the conjugate, which was then resuspended in 50 ml
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0.05 M phosphate buffer. This was attempted once and found to be
inefficient and wasteful. Firstly, it was extremely difficult to resuspend
the pellet evenly, because there was so much conjugate, and secondly,
because the conjugate could not be refrozen, as it would breakdown
the protein further, any unused conjugate could not be stored for
more than a couple of days which meant discarding at least 50% after
only one or two assays.
Another RIA assay protocol in use was one for PGF2a- In this protocol
NRS and DARS dilutions were added in 50 pi aliquots to the assay
tubes after they had been incubating with ligand and 1° antibody for 1
hr. This matched the protocol for incubation of ligand in my assay and
suggested using dilutions of 1:3 for DARS and 1:40 for NRS. This
worked well initially, but still meant a large consumption of serum
especially the DARS, data not shown. Dilutions of 1:10 for DARS and
1:100 for NRS were therefore tested, and gave the best standard
curves with a larger range, Figure 2.1.2b.
The final factor investigated in setting up this assay was the washing
of tubes after overnight incubation before pelleting the conjugate, to
limit non specific binding, and the method of discarding the
supernatant. To determine the best washing conditions two standard
curves were ran with being one washed with 1.5 ml 6% PEG 200 and
the other with 1.5 ml 1% Triton X-100. The results are shown in
Figure 2.1.2c and from these PEG 200 was chosen being more readily
available and cheaper. To discard the supernatant there are a couple
of methods: tubes can be 'tipped' and allowed to drip dry or the
supernatant can be removed by aspiration. This assay used 125I-cAMP
as the radioactive source and aspiration was chosen as the method of
removing supernatant.
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Figure 2.1.2.- (a) RIA dilution curve for l°Ab (•) from which 1:20,000
was selected as the optimum dilution factor, n=4. (b) An example RIA
standard curve (•), n=l. (c) The effects of washing with PEG 200 (•) or
Triton X-100 (■) and PEG 200 was chosen as the wash solution, n=l.
3?
RIA protocol
1 - 500 pi aliquots of samples and standards were acetylated with 20
pi of the 2:1 TEA/AA mixture, whirlimixed immediately and left for 2-3
min to acetylate.
2 - The number of assay tubes required was calculated, e.g. have 82
unknown samples. Assayed in duplicate = 164 tubes.
Need 164 + 28 (standard curve + total counts) = 190 tubes.
3 - The volume of 125I-cAMP/l° antibody mixture was determined, e.g.
190 tubes in the assay (round up to 200) 200 x 200 pi = 40 ml.
Measured out 40 ml of acetate buffer and added 0.1% w/v BSA.
4 - 125I-cAMP was counted and a volume calculated that gave -5000
cpm/tube, e.g. 10 pi 125I-cAMP = 2000000 cpm
With a 200 tube assay require 200 x 5000 = 1000000 cpm, so added
5pl of 125I-cAMP ligand to 40 ml acetate buffer
5 - Volume of 1° antibody required was determined, e.g. used 1:20000
end dilution. Stock was 1:100, so added 200 pi of 1:100 stock to 40 ml
buffer = 1:20000 dilution
6 - The 125I-cAMP/l° antibody mixture was sealed and vortexed. This
must be made up quickly, mixed well and used immediately otherwise
the 125I-cAMP has time to non-competitively bind to the 1° antibody.
7 - The reagents were added to the tubes as shown in Table 2.1.1.
8 - All tubes were incubated for 1 hr at 4°C.
9 - 50 pi of DARS (1:10 dilution in 50 mM phosphate buffer) and 50 pi
of NRS (1:100 dilution in 50 mM phosphate buffer) were added.
The tubes were vortexed, and incubated overnight at 4°C.
10 - 1.5 ml 6% PEG was added to all tubes, except T/T. The tubes
were then vortexed and spun for 30 min at 1900g, 4°C.
11 - The supernatant was removed.
12 - All tubes were counted, including T/T, for 1 min on a Beckman y-
counter. The counter was pre-programmed to plot a standard curve
from the standards and to calculate a best-fit hyperbola from the
points using a 'Logit' fit of log x versus y. From this curve the counter
also calculated the unknowns in fmol of cAMP present. As
experiments were carried out in duplicate and assayed for cAMP in
duplicate, the program also calculated the mean result.
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Tube No. Volume added Definition
Standard/ 125I-cAMP/
Unknown 1° Ab mix
rp jr^-k - 200 Ml Total counts




cc cc 0.0625 nM cAMP
9/10
cc cc 0.125 nM cAMP
11/12
cc cc 0.25 nM cAMP
13/14
cc cc 0.5 nM cAMP
15/16
cc cc 1.0 nM cAMP
17/18
cc cc 2.0 nM cAMP
19/20
cc cc 4.0 nM cAMP
21/22
cc cc 8.0 nM cAMP
23/24
cc cc 16.0 nM cAMP
25/26 50 Ml 200 Ml 32.0 nM cAMP
27/28 50 Ml 200 Ml Unknown
29/30 50 Ml 200 Ml Unknown
50 Ml 200 Ml Unknown
Table 2.1.1. - cAMP RIA setup
*
- tubes containing total radioactivity, these are not centrifuged and
allow a calculation of the degree of binding of 1° antibody
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All values are expressed as increases from basal. To obtain this, the
blank cell value was subtracted from each sample in each experiment
before the results were pooled to give average ± SEM.
EEC values were calculated for each experiment by dividing the drug
concentration that produces a 50 or 30% maximal response by the
PGE2 concentration that produces an equivalent response.
pA2 values are calculated as the average -log Kb values for each
experiment. These are "apparent" pA2 values, as they assume a Schild
plot with a gradient of 1. For AH23848B, it was not possible to
calculate the Schild gradient as the only effective concentration was




Initially a time course was run to determine the optimum incubation
time for sampling cAMP generation. PGE2 1 pM produced a maximum
cAMP production in the cellular fraction after 2 min of 1010 ± 260
fmol cAMP/105 CHO cells which decreased after 30 min to 770 ±210
fmol cAMP/105 CHO cells, n=4, Figure 2.1.3. However, the maximum
production observed in the medium after 5 min incubation was only
210 ± 170 fmol cAMP/105 CHO cells, n=4, Figure 2.1.3. Five min was
chosen as the optimum incubation time with all samples taken from
the cellular fraction.
Antagonist and partial agonist studies
AH23848B 30 pM reduced the concentration-dependent production of
cAMP by PGE2, n=6, Figure 2.1.4a. This inhibition was not significant
when analysed by ANOVA but point analysis using a paired two-tailed
Student f-test show significant differences for 100 nM and 10 pM
PGE2 (p<0.05). These data suggest the involvement of the EP4 receptor
subtype in mediating the production of cAMP by PGE2.
An "apparent" pA2 value for AH23848B of 6.2 was calculated from Kb
values using the formula:
CR-1 = [B]/Kb ,
where [B] is the concentration of the antagonist and CR is the
Concentration Ratio.
Butaprost was examined for antagonist activity in this preparation.
Butaprost was used at 10 pM, the maximal concentration used as an
agonist, and did not significantly reduce the concentration-dependent
increases in cAMP observed with PGE2, n=4, Figure 2.1.4b. Statistical
analysis of this data with ANOVA and paired Student t-test for each
point showed no significant effect, p>0.05. Interestingly, though,
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Time (minutes)
Figure 2.1.3.- Time course of PGE2 (1 pM) stimulated cAMP
production in CHO cells (•) and medium (■), n=4. 2 min incubation
produced a maximum increases of cAMP in the cellular fraction of
1010 ± 260 fmol cAMP/105 CHO cells. 5 min was selected as the




Figure 2.1.4.- PGE2-induced increases in cAMP levels in CHO cells, (a)
Effect of PGE2 in the absence (•) and presence (■) of AH23848B (30
pM), n=6 (p>0.05 with ANOVA), and (b) Effect of PGE2 in the absence
(•) and presence (■) of butaprost (10 pM), n=4 (p>0.05 with ANOVA).
*
- p<0.05 compared with basal production, f - p<0.05 between control
and AH23848B, using paired two-tailed Student t-test.
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butaprost did produced a trend towards the right in the
concentration-effect curve for PGE2.
Effect of agonists at increasing intracellular cAMP
PGE2 increased cAMP generation in CHO cells in a concentration-
dependent manner with an EC30 of 21 ± 12 nM and an EC50 of 94 ± 28
nM, maximal production of 1980 ± 270 fmol cAMP/105 CHO cells at a
concentration of PGE2 10 pM, n=7, Figure 2.1.5a. PGE2 produced
significant increases in cAMP from basal at 10 nM and greater
concentrations (p<0.05, two-tailed paired Student t-test).
16,16-dimethyl PGE2 and 11-deoxy PGEi also increased cAMP in CHO
cells in a concentration-dependent manner, Figure 2.1.5a. 16,16-
dimethyl PGE2 produced significant increases in cAMP at 1-10 pM
concentrations with an EC30 of 560 ± 260 nM, n=4, and an EC50 of 2.5
± 1.3 pM, n=3. 11-deoxy PGEi only significantly increased cAMP at 10
pM with an EC30 of 430 ± 230 nM and an EC50 of 5.2 ± 2.4 pM, n=4.
11-deoxy PGEi and 16,16-dimethyl PGE2 gave EEC values of 134 and
163 with respect to PGE2. Although these EEC values are determined
relative to PGE2 and indicate that these compounds have a lower
potency, when taken relative to their own maximal responses 16,16
dimethyl PGE2 produced an EC50 of 110 ± 40 nM and 11-deoxy PGEi
190 ± 60 nM which are similar to that of PGE2 (EC50 = 94 ± 28 nM)
and suggest these compounds could be partial agonists at the EP4
receptor.
Neither AH 13205 nor butaprost significantly increased cellular cAMP
above basal in the CHO cell line, Figure 2.1.5b. AH 13205 and
butaprost produced maximal increases of 150 ± 180 and 100 ±110
fmol cAMP/105 CHO cells respectively. This suggests that EP2
receptors are not involved in mediating cellular increases in cAMP in





Figure 2.1.5.- (a) Effect of PGE2 (•), n=10, 11-deoxy PGEi (■), n=4,
and 16,16-dimethyl PGE2 (A), n=4, and, (b) effect of PGE2 (•), n=10,
AH 13205 (■), n=4, and butaprost (A), n=4, at increasing cellular cAMP
in the CHO cell line.
*
- p<0.05 for PGE2 , f - p<0.05 for 16,16 dimethyl PGE2 and $ -
p<0.05 for 16,16 dimethyl PGE2 and 11-deoxy PGEi compared with





Figure 2.1.6.- (a) Effect of PGE2 (•), n=10, and misoprostol (■), n=4,
and, (b) effect of PGE2 (•), n=10, sulprostone (■), n=3, and GR63799X
(A), n=l, at increasing cellular cAMP in the CHO cell line.
&
Misoprostol, sulprostone and GR63779X had no significant effect on
cellular cAMP generation, Figure 2.1.6a 8s b. Sulprostone tended to
produce a very small reduction in basal cAMP levels which may have
been due to its activation of EP3 receptors negatively coupled to AC.
However that was not significant. Misoprostol has agonist activity at
EP2 receptors and its inactivity here further suggests that the PGE2-
induced increases in cAMP are not mediated via EP2 receptors.
The naturally-occurring prostaglandins, PGD2 and PGF2a, produced




Figure 2.1.7.- (a) Effect of PGE2 (•), n=10, and PGF2a (■), n=3, and, (b)
effect of PGE2 (•), n=10, and PGD2 (■), n=l, at increasing cellular
cAMP in the CHO cell line.
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2.1.5.- Discussion
AH23848B was used as an EP4 antagonist to determine the effects of
EP4 receptor antagonism on cAMP production in CHO cells stimulated
with PGE2. AH23848B produced a slight rightward shift in the
concentration-response curve for PGE2 with an apparent pA2 of 6.2,
Figure 2.1.4a. This is higher than the pA2 of 5.4 observed in the PSV
(Louttit et al., 1992a) and 5.3 in transfection studies using the cloned
EP4 receptor (Nishigaki et al., 1995). Nevertheless, these data support
the involvement of the EP4 receptor in the generation of cAMP by PGE2
in the CHO cell.
Butaprost was examined for antagonist activity, and tended to shift
the PGE2 concentration-response curve to the right. However, this
effect was not statistically significant and provides only an interesting
observation.
11-deoxy PGEi and 16,16 dimethyl PGE2 concentration-dependently
increased cAMP in the CHO cell, Figure 2.1.5a, whereas AH13205 and
butaprost produced no significant increases in cAMP levels, Figure
2.1.5b. Interestingly, when the EC50 values for 16,16 dimethyl PGE2
and 11-deoxy PGEi were calculated relative to their own maxima, they
produced similar values to PGE2 of about 100 nM, which suggests
that these two compounds could be partial agonists at the EP4
receptor expressed in CHO cells. The assumption made here, however,
is that all three compounds have reached their respective maximum
responses but, when looked at in Figure 2.1.5a, only the
concentration-response curve for 16,16-dimethyl PGE2 has reached a
plateau, and that higher concentrations of both PGE2 and 11-deoxy
PGEi might produce even greater increases in cellular cAMP and,
thus, increased EC values.
Together with the effect observed for AH23848B in this cell line, these
results suggest that the EP receptor positively coupled to AC in the
CHO cell is not the EP2 receptor subtype but rather the EP4, and that
11-deoxy PGEi and 16,16 dimethyl PGE2 have agonist activity at the
EP4 receptor.
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Further to these observations, Honda and co-workers report that at
the EP4 receptor, originally classified as EP2, butaprost does not
displace bound [3H]PGE2 (Honda et al., 1993). This is followed up by
observations in the same transfected cell line that butaprost does not
stimulate cAMP generation (Nishigaki et al., 1995). They also observed
that AH23848B displaces [3H]PGE2 binding and antagonised PGE2-
stimulated cAMP formation. Interestingly, this mouse EP4 receptor has
been transfected in the CHO cell line, and although it is shown here
that these cells endogenously express the EP4 receptor the levels of
receptor expression is probably far greater in the transfected cells.
Reported levels of cAMP generation are greater than those observed in
our studies, for example PGE2 10 pM induces an increase of about 20
pmol/105 cells in the transfected CHO cell compared to only 2
pmol/ 105 cells in the native CHO cells.
Misoprostol produced no significant increases in cAMP over basal
levels, Figure 2.1.6a. It is interesting to note, though, that Honda and
colleagues observe almost complete displacement of [3H]PGE2 from
their cloned EP4 receptor with misoprostol (Honda et al., 1993), and
use this information to conclude that their expressed receptor is the
EP2 receptor subtype, irrespective of a complete inactivity observed
with butaprost. This information suggests that misoprostol has a high
binding affinity for the EP4 receptor, about 50% displacement of
[3H]PGE2 was observed with PGE2 10 nM and misoprostol 100 nM
(personal estimation from Figure 2, Honda et al., 1993), but has
limited, if any, efficacy at this CHO cell EP4 receptor.
Sulprostone and GR63799X had no effect on cAMP levels in the CHO
cell, Figure 2.1.6b. This does not rule out any expression of EPi or EP3
receptors in the CHO cell line, but rather shows that these
compounds have no agonist activity at the EP4 receptor endogenously
expressed by these cells. PGF2a and PGD2 both increased cAMP levels
in the CHO cell at their highest concentrations of 1 mM and 10 pM
respectively, Figure 2.1.7a & b. These are probably due to cross
reactivity with the EP4 receptors expressed in these cells as Honda
and co-workers, 1993, observed almost complete displacement of
[3H]PGE2 from the COS-1 cell membranes by PGF2a 10 pM and PGD2
10 pM (Honda et al., 1993).
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It seem likely that the CHO cell line endogenously expresses an EP
receptor positively coupled to AC and cAMP generation that resembles
the EP4 receptor proposed by Louttit and co-workers in 1992 (Louttit
et al., 1992a). This work has been further supported by studies
involving cloned EP receptors. Regan and colleagues have cloned the
human EP2 receptor subtype and shown that butaprost and AH 13205,
selective EP2 agonists, produced concentration-dependent increases in
cAMP as well as displacing bound [3H]PGE2. Further to this, cloning
and expression of the mouse EP4 receptor in COS-1 cells by Namba
and co-workers (Namba et al., 1993) and the further stable expression
in CHO cells (Nishigaki et al., 1995), show inactivity of butaprost, and
another selective EP2 agonist 19(R)OH-PGE2 (Woodward et al., 1993),
to displace bound [3H]PGE2 and increase intracellular cAMP levels.
Furthermore, Nishigaki and colleagues also observe antagonism of
PGE2-stimulated cAMP accumulation by AH23848B at the cloned EP4
receptor.
In conclusion, the CHO cell endogenously expresses the EP4 receptor
which is positively coupled to AC activation and generation of
intracellular cAMP. This is the first published observation to link the
native EP4 receptor with AC activation, and these results demonstrate
that the CHO cell line offers a good in vitro system in which to study
the EP4 receptor. However, one of the limitations of this system is the
small increase in cAMP generation, possibly due to a small receptor
number. Also, unfortunately, we did not correlate changes in cAMP
with a physiological response in CHO cells since we did not have
access to the required technology to measure responses such as cell
acidification or Ca2+ flux.
CHAPTER 2.2
Further characterisation of the EP4 receptors present on the pig




The original classification of EP-receptor was based largely on data
obtained using smooth muscle preparations, and demonstrated four
subtypes. Typically, EPi receptors mediate contraction (e.g., guinea-
pig gastric fundus) and EP2 receptors mediate relaxation of smooth
muscle (e.g., rabbit ear artery, cat trachea), via activation of PLC, and
AC, respectively. EP3 receptor activation is more varied and includes
inhibition of neuronally-mediated contractions (e.g., guinea-pig vas
deferens), potentiation of platelet aggregation, inhibition of gastric acid
secretion, and contraction of some smooth muscle preparation (e.g.,
chick ileum), linked either to activation of phospholipase C or
inhibition of AC. The most recently described subtype, EP4 (Louttit et
al., 1992a), is a relaxant EP receptor coupled to AC activation (Honda
etal, 1993; Nishigaki etal, 1995)
The RJV has been used extensively as a model preparation in which to
study prostanoid receptors, and has been shown to contain DP (Giles
et al., 1989), IP (Giles et al., 1990) and TP receptors (Lumley et al.,
1989). The RJV also relaxes in response to PGE2 and is currently
classified as an 'atypical EP2' preparation, based on the low potency of
the EP2 agonist butaprost (Lawrence 85 Jones, 1992).
Our interest in this study was to classify the relaxant EP receptor
present in the RJV from the perspective of anti-glaucoma therapy.
Drugs currently available for topical use to reduce intraocular
pressure (IOP) in glaucoma patients include adrenoceptor agonists,
(e.g. adrenaline), cholinoceptor agonists (e.g. pilocarpine) and p~
adrenoceptor antagonists (e.g. timolol). The mechanism of action by
which these currently used therapies for glaucoma treatment reduce
IOP are not known. There is evidence which suggests that the
antiglaucoma effects of adrenaline may be mediated via stimulation of
PG synthesis. Indomethacin, an inhibitor of PG synthesis, was shown
to inhibit the hypotensive response to chronically administered
adrenaline in both the rabbit and human eye (Bhattacherjee &
Hammond, 1977; Camras et al., 1985), and adrenaline has been
shown to increase AA release and PG synthesis by the iris-ciliary body
both in vitro (Yousufzai & Abdel-Latif, 1983, 1984) and in vivo
(Yousufzai & Abdel-Latif, 1987). It has now been shown that PGs
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themselves can produce a significant and prolonged reduction in IOP,
and can increase aqueous outflow (Camras et al., 1977; Stern 8& Bito,
1982; Lee et al., 1984). PGD2 has been shown to lower IOP in rabbits
(Woodward et al., 1990) as has PGA2-l-isopropylester in cats (Bito et
al., 1990). PGF2a, or its isopropylester derivative, PGF2a-isopropylester,
though, are more potent ocular hypotensive agents in rabbits (Camras
et al., 1977; Lee et al., 1984), cats (Stern & Bito, 1982), dogs
(Groeneboer et al., 1989), monkeys (Camras 85 Bito, 1981; Stern 85
Bito, 1982; Lee et al., 1984; Crawford et al., 1987; Crawford 86
Kaufman, 1991) and humans (Kerstetter et al., 1988; Lee et al., 1988),
and can reduce IOP when applied topically to patients with glaucoma
(Camras et al., 1989). However, the mechanism underlying these PG
effects remains to be elucidated.
PGF2a and PGE2 are the two major PGs produced by ocular tissue
(Abdel-Latif, 1991), but information about the functional aspects of
PGs and the relevant receptors in the eye is sparse. It has been
demonstrated that iris sphincter muscles of cats and dogs contain
predominately FP receptors, (Kennedy et al., 1982), whereas those of
bovine iris sphincter muscle are predominately EP receptors (Dong et
al., 1986). Autoradiographic imaging of receptors in human eyes with
[3H]PGE2 and [3H]PGF2a have shown co-localisation at a high level in
the areas of the ciliary muscles and iris sphincter muscles (Matsuo 85
Cyander, 1992). Matsuo 86 Cyander, 1992, suggest that PGF2a and
PGE2 could modulate uveoscleral outflow, thus lowering IOP, by
binding to their receptors located on the ciliary muscles and inducing
their relaxation. However, Woodward et al., 1989, showed, with a
range of compounds, that the rank order of potency for decreasing IOP
was PGF2a > PGFia > 16-phenoxytetranor PGF2a > 17-phenyl trinor
PGF2a - fluprostenol (inactive) whereas that for FP receptor selectivity
was the reverse implying that the conventional FP receptor is not
involved in lowering IOP (Woodward et al., 1989). TP receptor
activation has also been shown to have no effect on IOP in cats (Bito,
1984).
A study in rabbits implicates the involvement of the EP3 receptor
subtype in lowering IOP (Waterbury et al., 1990). Sulprostone and two
analogues RS-61565 and RS-20216, lowered IOP up to a maximum of
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12 hr in rabbits after topical administration. In contrast U46619 had
no effect, whereas PGEi, and PGE2, both induced a hypertensive
response before eliciting a decrease in IOP. This has been supported
by a study using more selective prostaglandin analogues and
comparing radioligand binding studies with functional assays
(Woodward et al., 1994). The group concluded that EP3 and FP
receptors co-existed as discrete entities and activation of either, or
both, lowered IOP.
An interesting point to note is that short term desensitisation of PGF2a
receptors, by a 30 min pre-incubation with PGF2U, in the bovine iris
sphincter, a species which produces very little ocular PGs, increased
cAMP formation and reduced IP3 production and muscle contraction
induced with PGF2a (Yousufzai et al., 1989). In bovine iris sphincter,
Tachado and co-workers demonstrated that preincubation with PGF2a
results in AC activation upon further challenge with PGF2a (Tachado et
al., 1993). They suggest that PGF2a induced desensitisation might
uncouple the FP receptor from the Gq and Gi proteins and enhance
PGF2<x mediated stimulation of AC activity through Gs. Recent work
shows that PGD2, PGE2, and PGF2a to a lesser extent, added
exogenously to bovine ciliary muscle induced increases in cAMP
formation (Yousufzai et al., 1994). In species which produce large
amounts of ocular PG, it is possible that normal Gq and Gi coupled
receptors are desensitised.
Irrespective of the receptor system which lowers IOP, a hindrance to
drug development in this field has been that PGF2a, and other
compounds which lower IOP, have the undesirable side-effect of
causing hyperaemia, redness around the eye (Protzman & Woodward,
1990). Attempts have been made to synthesise analogues which
induce minimal hyperaemia while still retaining the ability to
effectively lower IOP. Studies by D.W. Woodward (personal
communication), found that compounds which reduced IOP but
induced hyperaemia were capable of relaxing the RJV, whereas,
compounds which reduced IOP but showed little hyperaemia, did not
relax the RJV. Thus it was decided to try to identify the receptor which
mediated PGF2a-induced relaxation of the RJV and, in particular, to
establish if PGF2a induces relaxation of RJV by interaction with a
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discrete FP receptor or by interacting with the atypical EP receptor
previously described. The nature of the 'atypical EP2' receptor on the
RJV was also investigated to see if it could be characterised as an EP4
receptor. The PSV was used as a known EP4 receptor containing
preparation to confirm and extend previous findings.
The aim of the present study was to examine in detail and compare
the pharmacology of prostanoid-induced relaxation of the isolated PSV
and RJV by determining the activity of prostaglandin agonists with
selectivity for specific prostanoid receptors. Compounds examined
along with PGE2 in these preparations include 16,16-dimethyl PGE2
(Lawrence & Jones, 1992), 11-deoxy PGEi (Banjeree et al., 1985),
AH 13205 (Nials et al., 1991), butaprost (Gardiner, 1986) and
nocloprost (Tauber et al., 1988). Possible antagonism by AH23848B,
AH6809 (Keery & Lumley, 1988), and BW A868C (Giles et al., 1989)
has also been investigated along with the effects of nitric oxide with a
stable nitric oxide synthase inhibitor L-NG-monomethyl arginine (L-




Krebs Solution - Krebs solution was prepared either on the morning
of the experiment or the day before, in which case no CaCh was added
until just before the experiment, after storage overnight at 4°C.








N.B. It was important to add the CaCl2 after dissolving the chemicals
completely and to add it slowly allow it to mix well. If the Krebs
solution turned cloudy after adding the CaCl2 it was discarded and the
flask washed thoroughly before making up new Krebs solution.
Sagatal - Pentobarbitone Sodium B.P. 60mg/ml, made up as a 1:1
solution with 0.9% saline.
Heparin - Heparin Sodium (Mucous) 5000 units/ml, made up as
1:100 solution with 0.9% saline.
Drugs - All drugs were prepared fresh each day in 0.9% NaCl from
ethanol or dry powder stocks stored at -20°C. AH23848B was
sonicated for 30 min before use.
Pig Saphenous vein
Saphenous veins were taken from Chinese Meishen pigs which had
been killed by intracardiac injection of pentobarbitone. An incision
was made in the skin proximal to the ankle joint and the saphenous
vein excised into Krebs solution. The veins were stripped of all fat and
connective tissue before use. The vessel was cut into four equal pieces
of 3-5 mm in width, suspended in an overflow organ bath between two
silver alloy hooks at 2-3 g tension and washed with Krebs solution
containing indomethacin (1 pM), bubbled with 02/C02 (95/5 v/v) and
maintained at 37°C. Changes in tension were measured using Grass
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FT03 isometric transducers connected to a Maclab® data acquisition
system using Maclab® v3.3 software. All drugs were added in 100 |nl
aliquots to the bath and all concentrations quoted are bath
concentrations.
The experimental procedures for PSV and RJV were essentially the
same except for the fact that phenylephrine was used as a contractile
stimulus for the PSV, as for Louttit et al., 1992a,b, whereas histamine
was used for the RJV. Initially, histamine was used as a contractile
agent for both preparations since this would give a more direct
comparison between the two, unfortunately histamine did not induce
consistent contractions of the PSV, sometimes these were huge which
were impossible to reverse when washing out, or they were phasic, in
a fashion which was difficult to stabilise. The second protocol change
was the addition of adenosine deaminase (lU/ml) to PSV organ baths
before phenylephrine to limit fade of the tissue. It has been observed
before that the PSV spontaneously releases adenosine upon
stimulation, and that adenosine is a vasodilator relaxing the vessel
and potentiating the effects of any relaxant compounds. It was
important to remove this effect and lU/ml of adenosine deaminase
was selected as a high enough concentration to be effective without
disrupting the viability of the tissue.
Phenylephrine was added as the stimulating agent at an initial
concentration of 10 pM to determine the maximal contraction of the
tissue. A concentration was then chosen which gave 60-80% of this
maximal response which was usually 0.5-1 pM (range 0.1-2 pM).
When each phenylephrine induced contraction plateaued, cumulative
concentrations of a PG analogue were added to the organ bath, with
each response being allowed to plateau before adding the next
concentration. All compounds were tested in the presence of
GR32191X (10 pM) to block any contractile action at TP receptors





Figure2.2.1.-Exampleconcentration-responsecurvinthPSVfo PGE2(0.1nM-30n ).Allconcentration-responsecurvewercarri d outat37°CinKrebssolutionwithGR 2191X10pM,indomethacinpM andadenosinedeaminase1U/ l. .-additionofPGE2(0.1-30nM)
Rabbit Jugular Vein
Male New Zealand white rabbits (2-3 kg) were anaesthetised with 30
mg/kg Sagatal (pentobarbitone) injected into the marginal ear vein
and Sagatal administered as required to ensure that the animal
remained fully anaesthetised. The external jugular veins were then
exposed on either side of the trachea, after shaving and opening the
neck, and tied at the proximal end. Once the vessels had filled with
blood they were tied at the distal end before excising into a beaker of
Krebs solution. The inflated sections (2-3 cm in length) were first
cleared of fat and connective tissue in a petri dish filled with Krebs
solution before cutting into 3-5 mm sections for the experiment. These
were suspended as for the PSV but at a lower tension of 0.75-1.25 g.
After equilibrium of the tissues for 1 hr, the maximum contraction to
histamine (10 pM) was measured, and a concentration was selected,
usually 1 pM (range 0.1-5 pM), that produced 60-80% of the
maximum concentration. Cumulative concentration-response curves
for a range of prostanoid receptor agonists were then carried out, as
described above, in the presence of GR32191X (10 pM).
Fade was an important consideration in both preparations, and in
each experiment, all preparations were left in the presence of a
submaximally effective concentration to observe the effects of fade.
Very often one or two of the tissues would show extreme fade but still
be included in the experiment in case they stabilised. If the tissues did
not stabilise, the data obtained from these preparations would not be
used in the analysis. Adenosine deaminase extensively limited fade in
the PSV, but fade still remains a problem with this experimental set¬
up. If a tissue exhibits slight fade and is not noted while running the
experiment then the effects of any relaxant PG analogue will be greatly
exaggerated.
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Figure 2.2.2- Examples ofcumulative concentration-response curves in the
RJV for (a) PGE2 (0.1 -100 nM), (b) 16,16 dimethyl PGE2 (0.1 nM-1 pM)
and (c) AH13205 (1-30 pM). All concentration-response curves were carried
outat37°C in Krebs solution with GR32191X lOpMand indomethacin 1 pM.
•- addition ofdrug
CI
Figure 2.2.3- Examples ofcumulative concentration-response curves in the RJV
for (a) PGE2 (0.1-100 nM), (b) PGE2 (0.1-100 nM) + AH23848B (30 pM), (c)
isoprenaline (1 nM-1 pM) and (d) isoprenaline (1 nM-1 pM) + AH23848B
(30 pM). All concentration-response curves were carried out at 37°C in Krebs




Concentration-response curves for PGE2 were carried out at the start
and finish of each experiment. PGE2 was used as the control in all
experiments and complete relaxation of the precontracted tissues by
PGE2 was taken as the maximal relaxation (100%). All subsequent
results were expressed as percentages of the PGE2 maximum. Log
concentration-response curves were plotted and the IC50 values
determined using Kaleidagraph® software. Each mean equi-effective
concentration ratio (EEC) was calculated as the IC50 for the EP
agonist/the IC50 for PGE2.
Statistical tests
Results are presented as the mean ± SEM. Student's paired 1- or 2-
tail f-tests were used for comparison of IC25 and IC50 data. ANOVA was
used to compare concentration-response curves in the absence or




PGE2, the standard agonist, concentration-dependently inhibited
phenylephrine-induced contractions of the PSV with an IC25 of 0.7 ±
0.4 nM and an IC50 of 2.0 ± 0.9 nM, Figure 2.2.4a. Pre-incubation
with the EP4 receptor antagonist AH23848B (30 pM, 30 min) shifted
the concentration-response curve for PGE2 to the right giving a CR of
5.94 ± 1.45 and an apparent pA2 of 5.27, p<0.05 comparing IC50
values (paired two-tailed t-test), Figure 2.2.3a. Pre-incubation with
AH6809 (10 pM, 10 min) had no significant effect on relaxant
concentration-effect curves to PGE2, with a CR of 2.95 ± 1.31, p>0.05,
Figure 2.2.3b.
Comparison of the ability of various agonists, with activity at the EP2
receptors, to relax the PSV gave a rank order of potency of PGE2 >11-
deoxy PGEi > 16,16-dimethyl PGE2 > butaprost >> AH 13205, Figures
2.2.4a & b. All the agonists induced at least 95% of the maximum
induced by PGE2, IC50 values and EECs are shown in Table 2.2.1.
PGF2a was also tested in this system, and concentration-dependently
relaxed the PSV to 45.7 ± 6.6 % of the PGE2 maximum giving an IC25
of 23.8 ± 7.3 nM and an EEC of 34 with respect to PGE2, Figure 2.2.5.
Rabbit Jugular Vein
PGE2 concentration-dependently inhibited histamine-induced
contractions in the RJV with an IC25 of 2.08 ± 0.38 and an IC50 of 8.73
± 1.90 nM, Figure 2.2.11a. Pre-incubation with the EP4 antagonist
AH23848B had no effect on PGE2-induced relaxation (CR = 1.75 ±
0.67, Figures 2.2.3a & b, 2.2.7a). AH23848B also had no effect on
relaxant responses to isoprenaline, butaprost and PGF2a on the RJV,
Figures 2.2.3c 85 d, 2.2.8a, b 85 c. Interestingly, AH23848B increased
significantly the below maximum relaxation induced with 11-deoxy
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Figure 2.2.4.- (a) Log concentration-response curves on the PSV for PGE2
alone (•), and in the presence of AH23848B 30 gM (■), n=4, p<0.05 with
ANOVA. (b) Log concentration-response curves on the PSV for PGE2 alone
(•), and in the presence of AH6809 10 juM (■), n=3, p>0.05 with ANOVA.
Relaxation in all curves reached >80% of the PGE2 maximum.
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Figure 2.2.5.- (a) Log concentration-response curves on the PSV for PGE2
(•), n=7, 16,16-dimethyl PGE2 (■), n=3, and 11-deoxy PGEi (A), n=5, and
(b) for PGE2 (•), n=7, butaprost (■), n=4, and AH13205 (A), n=4.

















-11 -10 -9 -8
Log Drug Concentration (M)
i
-7
ire 2 2 6. Log concentration-response curves on the PSV for PGEr
n-7, and PGF*. P), n-3. PGF2„ achieved a maximum relaxahon o




1 1 1 1
-11 -10 -9 -8 -7 -6
Log PGE2 Concentration (M)
(b)
-10 -9 -8 -7 -6 -5
Log 11-deoxy PGE, Concentration (M)
Figure 2.2.7.- (a) Log concentration-response curves on the RJV for
PGE2 alone (•), and in the presence of AH23848B 30 pM (■), n=4, and (b)
for 11-deoxy PGEi alone (•), and in the presence ofAH23848B 30 pM (■),
n=4. AH23848B had no effect on the concentration-response curves for
both compounds and p>0.05 with ANOVA for both graphs.












Figure 2.2.8.- (a) Log concentration-response curves on the RJV for
butaprost alone (•), and in the presence of AH23848B 30 pM (■), n=4, (b)
for PGF2a alone (•), and in the presence of AH23848B 30 pM (■), n=6,
and (c) for isoprenaJine alone (•), and in the presence of AH23848B 30
pM (■), n=4. AH23848B had no effect on the concentration-response
curves for any of the compounds, p>0.05 with ANOVA in all experiments.
Pre-incubation with AH6809 (10 pM, 10 min) and BW A868C (5.4 |uM,
10 min) also had no significant effects on the PGE2 concentration-
response curve, producing CRs of 0.78 ± 0.33 and 1.75 ± 0.84
respectively, Figures 2.2.8a & c. AH6809 was also examined against
PGF2a induced relaxation of the RJV and produced no effect, Figure
2.2.8b.
L-NMMA was examined in this preparation to measure the
dependency of an intact endothelial layer. Used at a concentration of
100 pM (15 min pre-incubation), L-NMMA had no significant effect on
PGE2, 16,16-dimethyl PGE2, PGF2a and 17-phenyl trinor PGF2u
induced relaxation of the RJV, Figures 2.2.9a & b, 85 2.2.10a 85 b.
A range of EP receptor agonists were examined for their relaxant
effects on the RJV. The rank order of potency obtained for these
agonists was PGE2 > nocloprost > 11-deoxy PGEi > 16,15 dimethyl
PGE2 > butaprost >> AH13205, Figures 2.2.11a & b, Table 2.2.1. All
these agonists, except 11-deoxy PGEi, produced a maximal relaxation
equivalent to at least 90% of that to PGE2, 11-deoxy PGEi only
achieved a maximal relaxation of 73.1 ± 7.2%, Figure 2.2.1 la.
The naturally-occurring prostaglandins, PGD2 and PGF2a, were
examined in this preparation along with the FP selective agonist, 17-
phenyl trinor PGF2a. All three compounds produced relaxation of the
RJV giving EECs of 13.5 ± 11.2, 6.1 ± 3.0 and 25.4 ± 16.6
respectively, however, only PGF2a produced greater than 60 %
relaxation compared to the maximum response for PGE2, Figure
2.2.12a.
Agonist data in Table 2.2.1 confirm the relatively low potency of
butaprost on the RJV (Lawrence & Jones, 1992). However, although
the IC50 values for butaprost are similar in the two studies, 381.0 ±
240.5 nM here compared to 199.5 nM, the EEC values of 43 and 685
are different and reflect the potency of PGE2 in the two studies (IC50S
of 8.73 ± 1.9 nM and 0.46 nM, respectively), Table 2.2.2. The reasons
for the difference in sensitivity of the RJV to PGE2 in these two studies
are still not entirely clear, but there are two possibilities for the
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Figure 2.2.9.- (a) Log concentration-response curves on the RJV for
PGE2 alone (•), and in the presence of AH6809 10 pM (■), n=4, and (b)
for PGF2a alone (•), and in the presence of AH6809 10 pM (■), n=3.
AH6809 had no effect on the concentration-response curves for both
compounds, p>0.05 in both experiments, (c) Log concentration-response
curves on the RJV for PGE2 alone (•), and in the presence of BW A868C
5.4 pM (■), n=3. BW A868C had no effect on the concentration-response




Figure 2.2.10. - Log concentration-response curves on the RJV for PGE2
alone (•), and in the presence of L-NMMA 100 pM (■), n=8, and (b) for
16,16-dimethyl PGE2 alone (•), and in the presence of L-NMMA 100 pM
(■), n=5. L-NMMA had no effect on the concentration-response curves for
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Figure 2.2.11.- (a) Log concentration-response curves on the RJV for
PGF2a alone (•), and in the presence of L-NMMA 100 gM (■), n=6, and (b)
for 17-phenyl trinor PGF2a alone (•), and in the presence of L-NMMA 100
pM (■), n=3. L-NMMA had no effect on the concentration-response curves
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Figure 2.2.12.- (a) Log concentration-response curves on the RJV for
PGE2 (•), n=10, nocloprost (■), n=4, 16,16-dimethyl PGE2 (A), n=5, and
11-deoxy PGEi (▼), n=4, and (b) PGE2 (•), n=10, AH13205 (■), n=5, and
butaprost (A), n=4. Relaxation for all compounds reached >80% of the
PGE2 maximum, except 11-deoxy PGEi which only produced 73.1 ±
7.2%.
Log PGE2 Concentration (M)
Figure 2.2.13.- (a) Log concentration-response curves on the RJV for
PGE2 (•), n=10, and PGF2a (■), n=14, 17-phenyl trinor PGF2a (▼), n=4,
and PGD2 (A), n=3. Maximal relaxation compared to PGE2 are 65.7 ±
6.3%, 50.0 ± 4.7% and 50.6 ± 4.4% respectively, (b) Effect of high
concentration (5 pM) (•), and low concentration (2 pM) (■) histamine on
the PGE2 dose-response curve in the RJV.





pge2 2.05 ± 0.93 nM 8.73 ± 1.90 nM
nocloprost 14.87 ± 3.13 nM
11-deoxy pgei 3.17 ± 1.41 nM 61.32 ± 52.91 nM
16,16 dimethyl pge2 3.37 ± 1.23 nM 87.03 ± 34.18 nM
butaprost 83.9 ± 21.8 nM 381.0 ± 240.5 nM
AH 13205 6.36 ± 2.58 pM 20.26 ± 8.30 pM
Table 2.2.1- ic50 values for a range of EP agonists in the PSV and
RJV
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differences and taken together these may account for the apparent
loss of sensitivity in our preparation.
One possibility is the concentration of histamine used to precontract
the RJV. While submaximally-effective concentrations were used in
our studies, usually 2-5 pM, Lawrence and Jones (1992) typically
used 1 pM. Relaxation by PGE2 of the histamine-induced contractions
is a form of functional antagonism, so perhaps a smaller contraction
is easier to block than a larger contraction. This can be seen to a
limited extent in Figure 2.2.12b, where significantly more relaxation
was observed with PGE2 0.14 pM and 0.45 pM using 2 pM compared
with 5 pM histamine (p<0.05).
Secondly, definition of the maximal relaxation induced by PGE2 is
different in the two studies. Lawrence and Jones, 1992, used the
contractile response to histamine as 100%, whereas we have used the
complete relaxation induced by PGE2 as 100%. Since the tissues are
already under tension before the addition of histamine, PGE2 usually
relaxes the tissue to a level below the basal tension prior to the
addition of histamine (see Figure 2.2.2). Calculating the IC50 value for
PGE2 by these two methods in the same preparations gives values of
7.9 ± 2.4 nM using the observed relaxation induced by PGE2 as the
maximum, and 3.8 ±1.5 nM when relaxation of the precontraction
induced by histamine is taken as the maximum.
While these points may partly explain the lower sensitivity to PGE2 in
our experiments compared to those of Lawrence and Jones, 1992, this
should not affect the EEC values calculated in both studies and so
does not explain the greater sensitivity to butaprost seen here. The
EECs of 6.6 and 9.9 for 11-deoxy PGEi and 16,16-dimethyl PGE2
found in this study, Figure 1.1.2, compare more favourably with those
of 1.4 and 2.1 found by Lawrence and Jones (1992).
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2.2.4.- Discussion
The purpose of these experiments was to further characterise the EP
receptor subtype present in the PSV with a range of EP receptor
agonists and to characterise the relaxant EP receptor(s) present in the
RJV. Ideally, the determination of the specificity of an agonist requires
an estimation of both the affinity and efficacy of the compound at a
particular receptor. The most reliable method for determining these
variables involves irreversible receptor blockade (Furchgott, 1966), but
unfortunately no irreversible antagonists have been described yet at
EP receptor subtypes. In this study the comparison of the relative
potencies of EP agonists, and possible block by receptor antagonists
where available, have been used in an attempt to characterise the
receptor subtypes involved.
The PSV has been confirmed to contain EP4 receptors, with the
antagonist AH23848B, Figure 2.2.4a, giving an apparent pA2 of 5.3.
This agrees favourably with that previously obtained this preparation
by Louttit et al., (1992a) and Coleman et. al., (1994), and on the
cloned EP4 receptor by Nishigaki et al., (1995). As only one
concentration of AH23848B was tested, the pA2 value for AH23848B
can only be estimated with the assumption that it would generate a
Schild plot -log (antagonist concentration) against log (concentration
ratio-1) with a gradient of 1. It is unlikely that a component of the
relaxation observed with PGE2 is mediated by DP receptors as AH6809
did not affect the concentration-response curve for PGE2, Figure
2.2.4b. Furthermore, Coleman et al., 1994, demonstrated the rank
order of potency for the natural prostanoids and the synthetic TxA2
mimetic, U-46619, at relaxing the PSV was PGE2 >> PGI2 ~ PGF2a ^
PGD2 > U-46619, which shows, by definition, that only EP receptors
are involved in mediating relaxation of the PSV.
The IC50 determined for PGE2 on this preparation is 2.05 ± 0.93 nM,
which agrees well with the value of 2.5 nM determined by Coleman et
al., 1994. 11-deoxy PGEi, 16,16-dimethyl PGE2, butaprost and
AH 13205 all produced full relaxation of the PSV with relative activities
of PGE2 > 11-deoxy PGEi = 16,16-dimethyl PGE2 > butaprost >>
AH 13205, Figure 2.2.5a & b. From these results it can be suggested
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that 11-deoxy PGEi and 16,16-dimethyl PGE2 are putative agonists at
the EP4 receptor, with EEC values relative to PGE2 of 2 and 2.8
respectively, Table 2.2.1. This has now been confirmed with work on
the cloned EP4 receptor where these two compounds both displaced
membrane-bound [3H]PGE2 with identical KiS of 7.3 relative to PGE2.
11-deoxy PGEi was also tested for its ability to increase cAMP
accumulation in intact transfected CHO cells and produced an EEC of
0.75 relative to PGE2 (Nishigaki et al., 1995).
The RJV is known to contain a heterogeneous population of
prostanoid receptors, namely thromboxane-sensitive (TP) receptors
mediating contraction (blocked here with the TP receptor antagonist
GR32191X) and receptors for PGE2, PGD2, and PGI2 mediating
relaxation (Giles et. al., 1990; Leff 8s Giles, 1992; Lawrence 85 Jones,
1992).
The EP4 antagonist AH23848B (Louttit et al., 1992b) was examined in
this preparation and had no effect against PGE2, butaprost or PGF2a
which suggests that EP4 receptors are not involved in mediating the
relaxation properties of these compounds, Figures 2.2.7a, 2.2.8a 85 b.
AH6809 and BW A868C were also studied but did not block the
relaxant response of PGE2. Similarly, AH6809 did not block PGF2a,
Figures 2.2.9a-c, indicating that PGE2 and PGF2a induced relaxation
are not mediated by DP receptors. Furthermore, the relaxant activity
of PGD2 compared with PGE2 and PGF2a illustrates the limited
relaxation obtained with DP receptor agonists in this preparation,
Figure 2.2.13a.
The NO synthase L-NMMA did not significantly affect relaxation
induced by PGE2, 16,16-dimethyl PGE2, PGF2a or 17-phenyl PGF2a,
Figure 2.2.10a & b, 8s 2.2.11a & b, indicating that the receptor
mediating relaxation by these compounds is present on the smooth
muscle and is not endothelium-dependent.
Agonist studies on the RJV demonstrated that 11-deoxy PGEi and
16,16-dimethyl PGE2 relaxed the RJV with EEC values of 6.6 and 9.9,
Figures 2.2.12a, Table 2.2.1, which are similar to their activities on
the cat trachea, an EP2-receptor containing preparation, where they
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produced EEC values of 13 and 9.4 (Dong et al., 1986). Butaprost and
AH 13205, selective EP2-agonists, however, gave much lower EEC
values of 43 and 2780 respectively which do not compare as
favourably with those obtained for the two compounds in cat trachea
and rabbit ear artery, EP2 receptor containing preparations. Butaprost
has an EEC of 6-30 in these preparations and AH 13205 an EEC of
30-100 (Gardiner, 1986; Humbles et al., 1991; Nials et al., 1993).
None of the above data define any particular EP receptor system in the
RJV, nevertheless, the ability of a range of EP receptor agonists to
completely relax histamine contraction in the RJV and the inactivity of
selective antagonists leaves the RJV still classified as an atypical EP2-
receptor. Further to this is a recent publication which demonstrates
that AH6809 has antagonist activity at the recombinant EP2 receptor
(Woodward et al., 1995). AH6809 10 pM had no effect in this system
and provides further evidence to classify this system 'atypical EP2'.
Interestingly, comparison of the agonist profiles for the PSV and RJV
could suggest that the RJV is a preparation containing EP4 receptors
at which the EP4 antagonist AH23848B is less potent, Table 2.2.2. If
this was the case there could be a few reasons for explaining the lack
of AH23848B activity. It has been documented elsewhere that TP
antagonists have lower affinity for TP receptors in the rabbit than for
other TP receptor-containing preparations (Tymkewycz et. al., 1991),
and this may be true here for EP receptors, with AH23848B
interestingly originally being described as a TP antagonist (Brittain et
al., 1985). Unfortunately, it is difficult to test AH23848B at
concentrations above 30 pM in the organ bath due to its insolubility
and experiments with the more recently described EP4 receptor
antagonist AH22921 (Coleman et. al., 1994) might help answer this
question. However, against this possibility is the demonstration that
AH23848B is active in the rabbit and has been shown to inhibit PGE2
induced relaxation of indomethacin and KC1 precontracted rabbit







11-deoxyPGEi J. 2.0 6.6
16,16 dimethyl PGE2 2.8 9.9
butaprost 42 43
AH 13205 3100 2780
Table 2.2.2- EEC values for a range of EP agonists in the PSV and
RJV
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The possibility that antagonism with AH23848B was masked by an
additional action of AH23848B to potentiate the relaxant effect of
PGE2 was investigated. Such potentiation has been observed in
human neutrophils using both PGE2 and an adenosine analogue as
agonists (Talpain et al., 1995). However relaxation of the RJV by
isoprenaline (see Figures 2.2.3c 8s d, Figure 2.2.8c) was unaffected by
AH23848B (30 pM) suggesting that this explanation is unlikely to
account for the lack of antagonism observed.
The exclusion of interaction at IP receptors has not been addressed
here as there are no selective IP antagonists available, but this
mechanism seems unlikely, as PGE2 is more potent on the RJV than
are PGI2 or selective IP agonists (Giles et. al., 1990, Lawrence 86 Jones,
1992).
The possible existence of a novel relaxant FP receptor was also
investigated in this study. PGF2a and 17-phenyl PGF2a both relaxed
the RJV, Figures 2.2.13a. PGF2a-induced relaxation was not inhibited
by AH23848B or AH6809, Figures 2.2.8b 86 2.2.9b, and L-NMMA
failed to inhibit either agonist suggesting the receptor(s) are present
on the smooth muscle, Figures 2.2.11a 86 b. From this it is difficult to
exclude the presence of a novel receptor since these drugs only rule
out EP4-receptors, EPi/DP-receptors and endothelium dependency
respectively. Also, the EEC of PGF2a with respect to PGE2 is only 6.1
which, by prostanoid receptor classification, is too close to exclude
presence of FP receptors, albeit mediating a relaxant response. PGF2a
produced only partial relaxation of the PSV with a similar EEC of 11.9
compared with 6.1 in the RJV, Figure 2.2.6. Unfortunately, the effects
of AH23848B on PGF2a-induced relaxation in the PSV were not
examined in this study to see if PGF2a could be mediating relaxation
via EP4 receptor activation. Agonism of EP3 receptors positively
coupled to AC was excluded in the RJV by Lawrence 86 Jones as
sulprostone generated an EEC of >3000 relative to PGE2 (Lawrence 86
Jones, 1992). To determine if the RJV contains a novel FP receptor or
whether FP is acting via EP4 receptor activity, a more potent EP4-
antagonist will need to be examined.
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The ability of FP agonists to lower IOP has a few possible
explanations. The results by Woodward and co-workers indicating a
negative correlation between FP selectivity in agonists and their ability
to lower IOP led to the conclusion that FP receptors are not involved in
this system (Woodward et al., 1993). However, a later study by the
same group showed the presence of FP receptors through binding
studies (Woodward et al., 1994). Possible pathways in both IOP
reduction and hyperemia might be the involvement of desensitised FP
receptors which couple to AC, or an EP receptor for which PGF2a has
high affinity. The latter of these may be the case as PGF2a induces
greater relaxation in the RJV than the more selective FP agonist 17-
phenyl trinor PGF2a and has a lower EEC relative to PGE2. However,
further studies are required to identify how PGF2a and other
analogues mediate their actions.
It is interesting that the cloning of the EP receptors has been based
functionally on the activities of certain selective agonists and
antagonists. Butaprost has been shown to exhibit no activity at the
cloned EP4 receptor either functionally or at displacing radioactive
ligand (Honda et al., 1993; Nishigaki et al., 1995), whereas it exhibits
both functional and binding activity at the cloned EP2 receptor (Regan
et al., 1994). Of interest here is the ability of butaprost to induce
complete relaxation of the RJV and PSV, as does AH 13205, another
selective EP2 agonist. If the cloning data are correct, and butaprost
has no activity at EP4 receptors, this suggests that there must be co-
expression of EP2 and EP4 receptors in both the PSV and the RJV. The
reason that AH23848B is not active in the RJV, may relate to
differential expression of the EP2 and EP4 receptors subtypes. Block of
a small EP4 component may not be identified, because PGE2 could still
induce complete relaxation at EP2 receptors. This explanation would
however require a different proportion of EP2/EP4 receptor subtypes in
the RJV and PSV preparation to account for the differential
antagonism observed with AH23848B only in the PSV.
Interestingly, the maximum response observed with 11-deoxy PGEi in
the RJV was increased in the presence of AH23848B. The co-
expression of EP2 and EP4 receptors may explain this result. If 11-
deoxy PGEi is a partial agonist at the EP4 receptor (this is supported
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by observations in the CHO cell line where it produced a submaximal
response relative to PGE2) but a full agonist at the EP2 receptor, then,
11-deoxy PGEi may possess higher affinity for the EP4 rather than the
EP2 receptor. Block of the EP4 receptor with AH23848B may then
favour the binding of 11-deoxy PGEi to the EP2 receptor where it
might induce complete relaxation of the RJV.
It is interesting to note that in the cloned EP4 receptor 11-deoxy PGEi
completely displaces [3H]PGE2 but only produces about 70% of the
maximal cAMP generation seen with PGE2 with an EEC of 0.75,
suggesting that it is a partial agonist at this receptor (Nishigaki et al.,
1995). Data from the cloned EP2 receptor, however, demonstrates that
11-deoxy PGEi only produces about 80% displacement of [3H]PGE2
and it is not clear whether 11-deoxy PGEi is a full or partial agonist at
this receptor (Regan et al., 1994). Calculating the Ki values for 11-
deoxy PGEi at the EP2 and EP4 receptor, using the Ki and EEC values
of Nishigaki and co-workers (1995), gives 100.7 nM and 58.4 nM
respectively showing that 11-deoxy PGEi has a higher affinity for the
EP4 receptor. The existence of both receptors in the RJV may account
for these results with 11-deoxy PGEi.
In conclusion, the PSV has been confirmed to be an EP4 receptor
containing preparation and 11-deoxy PGEi and 16,16 dimethyl PGE2
have been shown to have agonist activity at the EP4 receptor subtype.
The RJV, however, remains an atypical EP2 receptor containing
preparation due to the inactivity of AH23848B and the high EEC
values for butaprost and AH 13205 with respect to PGE2. Therefore,
further studies are required with the RJV before a system can be
defined in which anti-glaucoma drugs can be screened, and the RJV,
although used, remains uncharacterised for relaxant EP receptors. A
possible explanation for the observed results with butaprost,
AH13205, 11-deoxy PGEi and AH23848B may be that both the PSV
and the RJV co-express the EP2 and EP4 receptor subtypes.
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2.3.- Conclusion
Comparison of data obtained for all the currently described EP4
receptor containing preparations, Table 2.3.1, show that in most cases
the 50% active concentration for PGE2 is less than 20 nM, and that
11-deoxy PGEi and 16,16-dimethyl PGE2 are equipotent at all EP4 and
EP2 receptor containing preparations.
Interestingly, it is only in the CHO cell that PGE2 has an EC50 of
greater than 20 nM and 11-deoxy PGEI and 16,16 dimethyl PGE2
have EEC values of greater than 100. Also, it is only in the native CHO
cell receptor that AH23848B has a pA2 of greater than 6.0. As
discussed previously, these differences may be due to a low receptor
expression and a sensitive system which is easily inhibited.
Nevertheless, these results may also show that these cells only
express EP4 receptors, with little or no expression of the EP2 subtype.
Another study with the Jurkat T-cell line demonstrates no agonist
activity for butaprost and AH 13205 with AH23848B acting as a non¬
competitive antagonist (De Vries et al., 1995). The group suggests that
the EP receptor has a pharmacological profile different from the other
EP subtypes and suggest it might be a variant of the EP4 receptor.
Compared to the cloned receptor, it is only in these cell line
preparations that butaprost and AH 13205 demonstrate no agonist
activity. It could be suggested that the two cell lines, CHO and Jurkat,
express only EP4 receptors and that the smooth muscle preparations
co-express EP2 and EP4 receptors.
In the cloned EP4 and native CHO cell line butaprost produces no
accumulation of cAMP (Nishigaki et al., 1995; Chapter 2.1), whereas
in the PSV it has an EEC only just larger than its EEC at the EP2
receptor, Table 2.3.1. As discussed previously, this agonist data may
not reflect the cross-reactivity of butaprost but instead result from co-
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The antagonism observed with AH 13205 in the RDA (Smith et al.,
1994) may also be the result of receptor co-expression. Smith and co¬
workers demonstrated that both AH23848B and AH 13205, at lower
concentrations than those which relaxed the RDA, caused rightward
shifts in the concentration-response curves to PGE2 and BW245C, a
DP agonist. It could be supposed that each compound is inducing
these agonists to preferentially bind at the other EP receptor subtype.
However it must be notesd that while butaprost has been shown to
have no affinity for the cloned EP4 receptor, AH 13205 has not been
tested and so at this stage it is not clear if AH 13205 acts as a partial
agonist at EP4 receptors. This could be resolved with ligand binding
experiments using cells expressing the cloned EP4 receptor and
AH 13205 as the displacing agent. It is interesting to note that the
presence of AH23848B produces a slight flattening of the relaxation
curve to PGE2 in the RDA, whereas, AH 13205 induces no shape
change. To determine if this is a real effect the efficacy of PGE2 at each
receptor needs to be measured.
The key experiment required to answer whether there are both EP2
and EP4 receptors expressed in smooth muscle preparations, would be
to examine butaprost in the presence of AH23848B in the PSV where
AH23848B has been shown to block PGE2. Since butaprost is a full
agonist in the PSV, if no shift in the concentration-response curve to
butaprost is induced by AH23848B then the PSV must express both
EP2 and EP4 receptors, verifying that butaprost is a selective EP2
agonist. Whereas, if antagonism was observed with AH23848B it could
be suggested that the PSV contained only EP4 receptors and that
butaprost was also an EP4 agonist. This, however, would bring into
doubt the results observed with the cloned receptors, since it was the
inactivity of butaprost which originally identified the cloned EP4
receptor (Honda et al., 1993), and its activity which aided
classification of the cloned EP2 receptor (Regan et al., 1994).
Antagonism of the concentration-response curve to butaprost would
suggest that the cloned receptors were another EP receptor subtype,
possibly EP5.
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Clearly it is important to resolve this issue of co-expression of EP2 and
EP4 receptors and to ascertain the selectivity of both butaprost and
AH 13205 as EP2 receptor agonists. Further work using Northern blots
and probes for the EP2 and EP4 receptors may help elucidate the exact
nature of the EP receptor systems present in these preparations.
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CHAPTER 3
Investigation of the inhibitory EP receptors present on human
monocytes and their role in some functional responses
89
CHAPTER 3.1
General introduction to monocytes and their functions
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Monocyte/Macrophage
The blood monocyte is generally thought to be an immature member
of the reticuloendothelial system (Florey 86 Gowans, 1962). Monocytes
and their differentiated tissue forms, the macrophages, collectively
comprise the mononuclear phagocyte system. Macrophages are
essential for organ moulding, wound healing, phagocytosis of
senescent cells in leaking vessels and host defence against microbes
and invading pathogens (Nathan, 1987). Macrophages also recognise
and ingest apoptotic neutrophils which aids in the resolution of
inflammation (Haslett et al., )
Monocytes are normally present in the circulation in small numbers
and account for 3-8% of the total leukocytes (Wintrobe, 1951). Their
origin is in the bone marrow (Volkman 85 Gowans, 1965a 86 b) and
they have a short half-life in the circulation. Monocytes leave the
blood randomly by diapedesis and migrate to tissues where they
differentiate into macrophages (Spector 85 Willoughby, 1963).
Monocyte production is activated by macrophage-specific colony
stimulating factor (CSF-1, also referred to as M-CSF) which stimulates
hematopoietic stem cells to form colonies containing monocytes and
macrophages (Stanley etal, 1978; 1983).
Mature monocytes are the largest blood cells, with a diameter from 16
to 18 gm and range in concentration from 200 to 800 cells/pi whole
blood. The transit time in marrow from first precursive monoblast to
mature monocyte is about 6 days; in comparison to the neutrophil,
there is no marrow reserve of monocytes.
Monocytes travel in the blood nearly 80% of the time, making them
readily available for activation by cytokines released from sites of
inflammation. Monocytes migrate much slower than neutrophils and
arrive in appreciable numbers at inflammatory sites only after hours
to days, rather than the minutes to hours for the neutrophil. During
inflammation, the rate of monocytopoesis is increased because of
increased levels of M-CSF and autocrine IL-1 and the newly recruited
monocytes undergo rapid differentiation often terminating in the
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formation of large epitheloid cells, and sometimes accompanied by the
generation of multinucleated giant cells.
Mononuclear phagocytes are recognised in the bone marrow on a
morphological basis. They undergo a series of differentiation steps to
form monocytes which are released into the bloodstream. Monocytes
do not undergo further division after entering the bloodstream. Upon
leaving the bloodstream, monocytes distribute widely throughout the
body, differentiating into many forms for which a variety of names are
used, including the broadly applied term macrophage, see Table 3.1.1.
Diapedesis of selected monocytes is triggered by IL-1 and TNFa several
days after release into the circulation. During diapedesis monocytes
transiently down-regulate receptors linked to phagocytic, respiratory
and secretory functions as they migrate towards chemotactic signals.
Once across the vascular barrier, tissue monocytes regain their
functional capacity within 20 to 30 minutes, and transform to
macrophages in response to surface activation by IFNy (Nathan et al,
1983)
Collectively, tissue macrophages outnumber blood monocytes by over
100-fold and are very large 25-50 gm across, and it is estimated that
the greatest number, more then half of the total, are found in the liver
as Kupffer cells.
Monocyte differentiation
Macrophages are monocytes that have undergone transformation after
leaving the circulation and are generated by the bipotential stem cell.
The stem cell is driven to spawn monocytes preferentially by M-CSF,
whereas bacterial LPS stimulates expression of the G-CSF gene in the
stem cell. Co-ordination of monocyte and granulocyte production is
achieved by feedback regulation involving the two opposing CSFs and
by a balanced synergy between IL-1 and TNFa. As macrophages are
the major source of both M-CSF and G-CSF, they are capable of










Renal Glomeruli Mesangial Cells
Peritoneum Peritoneal Macrophages
Cervix Hofbauer Cells
Table 3.1.1.- Distribution ofmonocyte/macrophage and the different
nomenclature associated with their distribution
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There axe several features which typify the differentiation of mature
mononuclear phagocytes. They become larger in size, develop an
active endoplasmic reticulum and Golgi apparatus and have many
secondary lysosomes in their cytoplasm, all of which are indicators of
increased biosynthetic and intracellular degradative activity as well as
the secretion of various soluble products.
Capabilities of macrophages
Activated macrophages enlarge and spread out further, become
hypermotile and release an arsenal of noxious secretions, including an
intense and sustained oxidative burst. The respiratory burst
accompanying phagocytosis leads to the formation of reactive oxygen
metabolites including superoxide anion (O2") and hydrogen peroxide
(H2O2).
When macrophages come in contact with foreign matter it is either
engulfed or trapped and neutralised by an array of lysosomal
substances. Macrophages, unlike neutrophils, are designed to survive
combat and are capable of ingesting micro-organisms, red blood cells
and other material. The list of secretory products released by activated
macrophages is greater than 100 kinds of molecules (Johnston, 1988),
some are shown in Table 3.1.2.
High affinity binding sites for chemotactic stimuli have now been
identified on the surface of mononuclear phagocytes as members of
the G-protein-linked seven transmembrane family of receptors. They
include receptors for products of the activation of the complement
system, notably C5a, certain bacterial products and cell-derived
substances including LTB4 and platelet factor 4. Triggering of these
receptors sets in motion a series of cellular events leading to the
assembly of contractile and cytoskeletal proteins to allow the














































Table 3.1.2 - Some secretory products of mononuclear phagocytes
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These chemotactic agents also stimulate a number of other responses
in phagocytic cells including the formation of eicosanoids and the
release of oxidants and hydrolytic enzymes, all of which may facilitate
the emigration of monocytes from the bloodstream into sites of
inflammation.
Once they have arrived at sites of inflammation mononuclear
phagocytes remove inflammatory stimuli and mediate subsequent
tissue repair by a number of highly integrated systems intended for
the recognition and removal of inflammatory stimuli and infectious
agents, see Diagram 3.1.1.
Human implications of malfunctioning
The intensity of microbicidal response to infection is stimulated by
IFNy and subdued by PGE2, secretory products of T-cells and of
macrophages themselves, that respectively enhance and suppress
activation. Some organisms can resist the deadly potential of the
secretory response by selectively stimulating PGE2 secretion by both
cell types, thereby quenching both oxygen-dependent and independent
antimicrobicidal mechanisms. Included among pathways that are
constitutively capable of surviving and even of replicating within
macrophages are such diverse intracellular organisms as
Mycobacterium avium intracellular, Histoplasma capsulatum, various
protozoa, and the human immunodeficiency virus (HIV) (Murray,
1988). Lymphocytes from patients with some of these infections are
immuno-compromised and unable to secrete enough IFNy to activate
macrophage host cells, a defect that can be overcome by
administration of either recombinant IFNy or inhibitors of
prostaglandin synthesis such as indomethacin. In the case of
protozoa, macrophages actually provide sanctuaries essential to
protozoan survival.
Monocyte/macrophages are also involved in atherogenesis, as the first
sign of atherosclerosis in the vessel wall is the formation of a fatty
streak, which consists mainly of lipid-loaded monocyte/macrophages,
the foam cells (Gerrity, 1981; Schaffner et al., 1980).
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Diagram3.1.1.-Somefunctionsfthhu anmonocyte/ acrophage
Leslie & Dubey, 1994, investigated whether PGE2 metabolism in the
human monocyte was influenced by gender and by the stage of the
menstrual cycle. Monocytes isolated from the female and activated in
vitro with LPS produced on average significantly more PGE2 into the
medium than those from males. Among females, significantly more
PGE2 was found in the medium from cells isolated during the luteal
phase of the cycle than during the early follicular phase. It was also in
this luteal phase in which the female differed substantially from the
males. They suggest that the in vivo hormonal changes associated with
the menstrual cycle modulate monocyte synthesis of PGE2 and other
immune modulators such as IL-1. This could, they suggest, be a key
to understanding differences in vulnerability between males and
females to immune and inflammatory insult and also differences
observed within phases of the menstrual cycle.
Prostaglandin production in monocyte/macrophages
Human monocytes are known to possess all the machinery required to
synthesis cyclooxygenase- and lipoxygenase-derived eicosanoids
(Schade et ah, 1989). PGE2 was originally thought to be the major
eicosanoid released by monocytes (Kurland & Bockman, 1978;
Kennedy et ah, 1980; Bockman, 1981), but it was subsequently found
that TxA2 was the predominant eicosanoid metabolite, being produced
in marked excess of PGE2 (Pawlowski et al., 1983; Orlandi et ah, 1989;
Jones et ah, 1989). Allan and co-workers (Allan 85 Halushka, 1994)
have characterised the binding site for TXA2 on the human monocyte
using [125I]-BOP. Scatchard analysis reveals a single class of binding
sites (Kd = 1.49 ± 0.14 nM and Bmax = 696 ±113 fmol/mg membrane
protein). 125I-BOP caused a dose-dependent increase in intracellular
free calcium which was attenuated by preincubation with the
prostanoid TP-receptor antagonist, SQ29548. The receptor which
binds PGE2 on human peripheral blood monocytes has also been
characterised kinetically, although the subtype remains
uncharacterised (Eriksen et ah, 1985). Kinetically, receptor binding
was saturable, specific, and reversible at physiological temperature
and pH and Scatchard analysis of binding data revealed a linear plot
with a Kd of 1.1 pM and Bmax of 4.1 fmol/107 cells. Exogenous PGE2
addition increased intracellular cAMP by a maximal factor of three.
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Whereas, PGF2a and AA showed low binding to the cells and had no
stimulatory effects on AC.
Another study showed that both human peripheral blood monocytes
and murine peritoneal macrophages synthesise and release PGE2 in
vitro. This was markedly enhanced by LPS, and completely suppressed
by indomethacin (Kurland & Bockman, 1978). In contrast, PGE2 was
not detected in the supernate fluids from cultures of human
lymphocytes, granulocytes, T-, or B-lymphomas.
Aim
Treatment of monocyte/macrophages with PGE2 induces increases in
intracellular cAMP (Gemsa et al, 1975; Bonta et al., 1981). This
increase in cAMP has been associated with inhibition of phagocytosis
and shape change (Oropeza-Rendon et al., 1980), inhibition of viral
infection (Haraguchi et al., 1995; van de Pouw Kraan et al., 1995),
oxidative burst (Elliott & Leonard, 1989) and osteoclast cell formation
(Lacey et al., 1995) in monocyte/macrophage populations.
Our aim was to classify the prostanoid EP receptor which mediates
these inhibitory effects. The above results all implicate a role for cAMP
in the inhibition of cell activation and this was used as a starting
point. Initially, the cAMP assay system described in Chapter 2.1 was
used to investigate the EP receptor positively coupled to AC present on
human monocytes. After this we hoped to correlate this receptor
activation with inhibitory functions of the human monocyte.
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CHAPTER 3.2




PGE2 is released from the human monocyte and can act as a negative
feedback control on many functions of the cells. It has been
demonstrated that during infiltration of the macrophage into
inflammatory tissue, the sensitivity of AC to activation by PGE2
increases (Bonta et al., 1981), and that in leukocytes, PGE2 stimulates
AC resulting in elevated intracellular cAMP levels and activation of
PKA (Kammer, 1988).
Studying the effect of incubation on human blood monocytes, Coffey
and co-workers, observed that PGE2 stimulated increases of cAMP in
freshly isolated monocytes and that this stimulation was attenuated in
cells aged in culture 1-2 days (Coffey et al., 1990). They observed
heterologous desensitisation, since the AC responses to 5'-(N-
ethylcarboxamido) adenosine, an A2 receptor agonist, isoprenaline, a
P-adrenoceptor agonist, and histamine also declined during culture.
The observation that indomethacin prevented the desensitisation,
suggested the role of a cyclooxygenase product. The above result
indicate that, while PGE2 inhibits monocyte functions via cAMP, its
accumulation paradoxically permits cells to escape this regulation
through a heterologous desensitisation of the cAMP response to itself
and other agonists.
Monocytes/macrophages are associated with chronic inflammatory
lesions, such as peridontal disease and rheumatoid arthritis, in which
there is extensive connective tissue destruction. Matrix
metalloproteinases (MMP) have been associated with the extensive
tissue damage seen in diseases like rheumatoid arthritis. Mertz and
co-workers observed that stimulation of human monocytes resulted in
the production of MMP (Mertz et al., 1994). The group found that IL-
10, which modulates many functions of monocytes, decreased the
production of MMP. IL-10 also decreased the production of PG by
inhibiting COX-2 up-regulation, since the release of AA was unaffected
by IL-10. Exogenously added PGE2 or dibutyryl cAMP restored the
production of MMPs in IL-10-treated monocytes. Additionally, COX-2
activity was restored by PGE2 or dibutyryl cAMP, indicating that COX-
2 is regulated through a PGE2-CAMP amplification pathway. Another
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study examined the effects of G-protein ADP-ribosylating agents,
cholera toxin (CT) and pertussis-toxin (PT), on the signal transduction
pathway that culminates in the production of monocyte MMPs
(Corcoran et al., 1994). They found that although CT elevated cAMP
levels in both unstimulated and concanavalin A (Con A)-stimulated
monocytes, it enhanced the production of COX-2 protein, PG, and
interstitial collagenase only in Con A-stimulated monocytes. PT
treatment suppressed the levels of cAMP, COX-2, PGE2 and interstitial
collagenase in Con A-stimulated monocytes. These two studies both
suggested that activation of human monocytes induced production of
MMPs is through a PGE2-cAMP-dependent pathway.
Experimental allergic encephalomyelitis (EAE) is described as an
autoimmune inflammatory disease of the CNS, and an animal model
of MS. Misoprostol, and indomethacin, were tested and found to
inhibit clinical and histological EAE (Reder et al., 1994) and the
combination of indomethacin plus misoprostol inhibited the disease
further than each agent alone suggesting that cAMP elevating agents
have an inhibitory role in EAE, and may also have a role in MS.
In HIV infection and allergic diseases, characterised by a dominant
Th2 response, overproduction of PGE2 has been observed. A recent
study demonstrated that PGE2 almost completely inhibited LPS
induced IL-12 production, an essential chemical in induction of Thl
responses, whereas IL-6 production was only partially inhibited by
PGE2 (Van der Pouw Kraan et al., 1995). In contrast, the production of
IL-10 was enhanced approximately twofold under these conditions.
The effects of PGE2 in this system were due to its cAMP-inducing
capacity, since they could be mimicked by other cAMP activating
agents like dibutyryl cAMP and IBMX. This suggests that PGE2 is a
major inhibitory agent in HIV infection and that it mediated its effects
via cAMP generation.
The effects of TNF-a on the regulation of M-CSF gene expression in
human promyelocytic HL-60 cells were studied during monocytic
differentiation with PGE2 or dibutyryl cAMP (Sherman et al., 1990).
The combination of a protein synthesis inhibitor, cycloheximide, and
TNF-a increased levels of M-CSF mRNA compared with treatment by
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TNF-a alone. Inhibitors of PLA2 activity blocked TNF-a-induced
increases in M-CSF transcripts in a concentration-dependent manner,
while inhibitors of the 5-lipoxygenase pathway, had no detectable
effect on induction of M-CSF RNA. The group suggest that PGE2 or
dibutyryl cAMP treatment is regulated, at least in part, by both
transcriptional and post-transcriptional mechanisms, and that PGE2
and cAMP regulate transcriptional activation of the M-CSF gene by
TNF-a. Interestingly, another study showed that theophylline
concentration-dependently reduced TNF-a release by human
monocytes and alveolar macrophages to the same extent (Spatafora et
ah, 1994). Northern blot analysis demonstrated that theophylline was
able to reduce TNF-a gene expression and the group proposed that,
since TNF-a is known to be involved in the pathogenesis of bronchial
hyperresponsiveness and asthma, the therapeutic activity of
theophylline might be partly related to its effects on TNF-a release.
In monocyte/macrophages, increases in intracellular cAMP have
generated different responses in the synthesis and release of IL-la and
IL-1 p. IL-la and IL-ip are peptide hormones produced by macrophages
as well as several other cell types, which stimulate growth and
differentiation of numerous cells including lymphocytes, neutrophils,
fibroblasts, synovial cells, osteoclasts, hepatocytes and adipocytes
(Oppenheim et ah, 1986). They are also potent fever inducers and have
been suggested to play an important role in the pathophysiology of a
variety of chronic inflammatory diseases (Dinarello, 1984).
cAMP was thought to inhibit IL-1 synthesis post-transcriptionally
(Dinarello, 1989). However, more recent evidence has shown that
cAMP analogues, and other agents that elevate cAMP, increase IL-1
mRNA accumulation and IL-1 production several-fold (Kassis et ah,
1989; Scales et ah, 1989; Sung & Walters, 1991). It has also been
suggested that cAMP and cGMP play a role in the LPS-signal
transduction pathway that triggers cytokine production and release
(Molnar-Kimber et ah, 1993). However, when monocytes were
stimulated by toxic shock supernatant, they synthesised less IL-1
when intracellular cAMP level were increased by PGE2 (Knudsen et ah,
1986) and it seems that the effects of cAMP on IL-1 synthesis are
stimulus dependent.
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LPS is commonly used to stimulate IL-1 production in a variety of cell
systems. Sung and Walters showed that peripheral monocytes and
myelomonocytic cell lines could be stimulated by LPS to express IL-1
mRNA (Sung & Walters, 1991). They found dibutyryl cAMP, 8-bromo-
cAMP, forskolin, cholera toxin, PGEi, and PGE2 synergised with LPS
to increase the accumulation in cell lines of IL-1 a and IL-1 p mRNA by
up to 50-fold. However, despite this marked increase in IL-1 mRNA
accumulation, IL-1 protein synthesis in these cells was increased by
only twofold suggesting that cAMP potentiates the expression of IL-1
mRNA but not its translation. Interestingly, increased intracellular
cAMP has been demonstrated to have an inhibitory effect on the
release of IL-1 p after stimulation with LPS (Hurme, 1990; Viherluoto et
al., 1991; Verghese et al., 1995b). Viherluoto and co-workers also
observed only a small change in cellular IL-1 p activity after increasing
intracellular cAMP. Nevertheless, studies in astrocytes show a
decrease in LPS stimulated IL-1 p mRNA levels (Willis & Nisen, 1995)
These results suggest that cAMP stimulates LPS induced IL-1 mRNA
synthesis, whereas cAMP has little effect on the translation of IL-1
mRNA, and actually inhibits IL-1 release, in monocytes and monocytic
cell types.
Direct PKC activation with phorbol-esters is also used to stimulate IL-
1 release from monocytes and macrophage cell types. Increased
intracellular cAMP in phorbol myristate acetate (PMA) stimulated cells
augmented IL-1 mRNA expression markedly, and slightly increased
release of IL-1 (Hurme, 1990; Sung & Walters, 1991) which suggests
that the effects of increased cAMP are stimulus dependent.
Other cytokines are also affected by cAMP modulation. Inhibition of
TNFa and IFNy production have been demonstrated in human
monocytes by PGE2, whereas IL-6 transcription and release are
increased in the same experiments (Bailly et al., 1990; Haynes et al.,
1992).
Interestingly, PGE2 in the presence of a phosphodiesterase inhibitor
IBMX was capable of stimulating IL-1 and IL-6 gene expression and
104
protein production in monocytes (Serkkola et al., 1992; Dendorfer et
al., 1994)
Receptor expression is also mediated by cAMP in
monocyte/macrophages. Takii and co-workers (1992) showed that
stimulation with human recombinant IL-la or IL-1(3 increased IL-1
receptor mRNA. Exogenously added PGE2 increased further the levels
of both IL-1 receptor mRNA and intracellular cAMP indicating that
PGE2 also acts as a pro-inflammatory agent.
It has been reported that cAMP levels in inflammatory cells are
regulated by a cyclic nucleotide PDE belonging to the PDE IV family,
characterised by their selectivity for cAMP over cGMP and their
sensitivity to the antidepressant drug rolipram (Livi et al., 1990;
Verghese et al., 1995a). Verghese and co-workers also demonstrated
that rolipram and Ro20-1724, selective PDE IV inhibitors, were the
most potent compounds at enhancing cAMP levels and inhibiting the
release of TNF-a and IL-ip in human monocytes (Verghese et al.,
1995b).
All the above data are conflicting as they show a major role for cAMP
in both potentiating and inhibiting properties of the monocyte and
macrophage. It is of important scientific interest to determine which
EP-receptor subtype is linked to AC and thus mediates the effects of
both endogenous and exogenous EP-receptor agonists. Additionally,
previous studies have putatively characterised the AC coupled EP-
receptor present on the human neutrophil as the EP2 subtype
(Wheeldon & Vardey, 1993; Talpain et al., 1995),
We have attempted to characterise the EP-receptor subtype positively
coupled to AC present on the human monocyte. A sensitive RIA was
set up, as described in CHO cell methods, to directly measure intra-
and extra-cellular cAMP from monocytes stimulated with an array of
EP-receptor agonists. The effects of the EP4-receptor antagonist,




1 - 200 ml of blood was removed from the forearm of healthy donors
and heparinised with 100U/50 ml blood.
2 - Red blood cells were sedimented by mixing the blood 50:50 with
3% dextran and leaving to sediment for about 1 hr.
3 - The leukocyte-rich plasma was removed from above the red blood
cell pellet and dispensed into 50 ml tubes. These were then
centrifuged for 10 min at 220g to pellet the leukocytes.
4 - The supernatant was discarded and the pellet resuspended in 55%
Percoll® before layering carefully onto a gradient of 81% (5 ml) and
70% Percoll® (3 ml).
5 - The gradients were centrifuged for 30 min at 450g to differentially
separate the mononuclear cells from the neutrophils. The two layers
were clearly visible, the mononuclear cells being the higher layer
between the 70% and the 55% Percoll®. Each layer was pipetted into
50 ml tubes, diluted to 50 ml with 0.9% saline and centrifuged for 10
min at 220g.
6 - The mononuclear cells were resuspended in RPMI 1640 + 10%
foetal calf serum (FCS) + 1% Penicillin/Streptomycin and seeded into
12 well plates (1.0 ml/well) and incubated for 1 hr at 37°C to allow
the monocytes to adhere.
7 - The lymphocytes were removed by carefully removing the culture
medium and gently washing the wells twice with sterile Hanks
balanced salt solution (HBSS) before assaying for cAMP production.
8 - Drugs were added directly to the wells, in 1 ml aliquots of HAMS-
F12 medium containing indomethacin 5 pM and IBMX 0.25 mM,
immediately after washing and incubated at 37°C. If antagonist
studies were being carried out, antagonists were added in 900 pi
aliquots 10 min prior to the agonists, and drug dilutions added in 100
pi aliquots. Again all dilutions were made up in medium with




EC and EEC values
EC values were calculated relative to the maximum cAMP generation
for PGE2. EEC values were calculated by dividing the concentration of
drug by the concentration of PGE2 that generated the same increase in
cAMP. All values were calculated separately for each experiment and
pooled to give average ± SEM.
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3.2.3.- Results
Initially a time course was carried out to determine the optimum time
for incubation with PGE2 (1 pM). Samples were taken from both the
cellular and medium fractions to compare the data. The basal value
for the cellular fraction was 40 ± 28 fmol cAMP/105 monocytes which
increased to a maximum of 168 ± 36 fmol/105 cells after 5 min
incubation before decreasing to 108 ± 32 fmol/105 cells after 30 min
incubation, Figure 3.2.1. The medium fraction had a similar basal
value of 43 ± 18 fmol cAMP/105 cells but only increased to a
maximum of 78 ± 12 fmol/ 105 cells after 10 min. From these results 5
min was chosen as the incubation time and all samples were taken
from the cellular fraction. All subsequent values are expressed as
increases from basal.
Antagonist Studies
AH23848B is a weak antagonist at the EP4 receptor and has been
used in previous studies at a concentration of 30 pM (Chapters 2.1 &
2.2). In initial studies with the human monocyte AH23848B was
tested at 30 pM with a 10 min preincubation time. AH23848B 30 pM
inhibited PGE2 induced cAMP production. This effect was significant
(ANOVA, p<0.05), Figure 3.2.2a. Indeed the concentration-effect
relationship for PGE2 was considerably flattened, such that
determination of CR and pA2 were not possible.
AH23848B was also tested at 10 pM and while this apparently
inhibited cAMP production in the presence of PGE2, it was non¬
significant (p>0.05 with ANOVA). The PGE2 curve shows
concentration-dependent increases in cAMP to a maximum production
of 1100 ± 850 fmol cAMP/105 monocytes with PGE2 10 pM. This
maximum production is lowered in the presence of AH23848B 10 pM
to 780 ± 530 fmol cAMP/ 105 monocytes.
An apparent pA2 was calculated from the results observed with
AH23848B 10 pM since the shift to the right allowed calculation of
EC50 values in the presence and absence of AH23848B. An apparent
pA2 of 5.58 was obtained, which compares favourably with those
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Time (minutes)
Figure 3.2.1.- Time course of PGE2 (1 pM) stimulated cAMP
production in human monocytes in cells (•) and medium (■), n=4. 5
min incubation generated a maximum increase in cAMP production in
the cellular fraction of 168 ± 35 fmol cAMP/105 monocytes, this was
chosen as the incubation time in all subsequent experiments and all
samples were taken from the cellular fraction.
PGE2 concentration (pM)
PGE2 concentration (pM)
Figure 3.2.2.- PGE2-induced increases in intracellular cAMP in
human monocytes, (a) Effect of PGE2 in the absence (•) and presence
(■) of AH23848B (30 pM), n=3, (p<0.05 with ANOVA), and (b) Effect of
PGE2 in the absence (•) and presence (■) of AH23848B (10 pM), n=3,
(p>0.05 with ANOVA, apparent pA2 = 5.58).
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obtained in other EP4 receptor containing preparations, see Table
2.3.1, and suggests the EP4 receptor subtype mediates PGE2 induced
cAMP generation in the human monocyte.
Butaprost 1 pM was examined for antagonism in this preparation and
produced an apparent rightward, but non-significant, shift in the
concentration-response curve for PGE2 (ANOVA, p>0.05), Figure 3.2.3.
Paired Student f-test point analysis of the maximum response
observed with PGE2 alone, and in the presence of butaprost 1 pM,
however, gave a p<0.05 indicating that butaprost significantly
inhibited the cAMP generation with PGE2 10 pM.
Agonist studies
PGE2, the standard agonist, concentration-dependently increased
cAMP generation in human monocytes after 5 min incubation, Figure
3.2.4a 16,16-dimethyl PGE2 and 11-deoxy PGEi also produced
concentration-dependent increases in cAMP but were less effective
giving lower EEC values than that of PGE2, Figure 3.2.4a, Table 3.2.1.
Butaprost and AH 13205, in comparison, did not significantly increase
cAMP in the human monocyte, Figure 3.2.4b. These results further
indicate the involvement of the EP4 receptor in cAMP generation in the
human monocyte.
Misoprostol and sulprostone produced no significant increases from
basal levels of cAMP, Figure 3.2.5a, Table 3.2.1, and it is unlikely that
the cAMP generation in human monocytes is mediated by a AC
coupled splice variant of the EP3 receptor. PGD2 and PGF2a also
generated no significant increases in cAMP levels, Figure 3.2.6.
Interestingly, nocloprost (up to lOOnM) gave a concentration-
dependent increase in cAMP equipotent with PGE2, but with higher
concentrations of nocloprost, no further increase in cAMP was
observed. This suggests that nocloprost is a partial agonist in this
preparation, Figure 3.2.5b, Table 3.2.1.
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Figure 3.2.3.- PGE2-induced increases in intracellular cAMP in
human monocytes. Effect of PGE2 in the absence (•) and presence (■)
of butaprost (1 pM), n=3, (p>0.05 with ANOVA). Point analysis at PGE2





Figure 3.2.4.- (a) Effect of PGE2 (•), n=8, 11-deoxy PGEi (■), n=5, and
16,16-dimethyl PGE2 (▲), n=5, and (b) PGE2 (•), n=8, AH13205 (■),
n=6, and butaprost (A), n=5, at increasing cellular cAMP in the human
monocyte.
*- p<0.05 for PGE2, paired one-tailed Student t-test,




Figure 3.2.5.- (a) Effect of PGE2 (•), n=8, sulprostone (■), n=4, and
misoprostol (A), n=4, and (b) PGE2 (•), n=8, and nocloprost (■), n=4,
at increasing cellular cAMP in the human monocyte,
f- p<0.05 for nocloprost, paired one-tailed Student t-test.
p<0.05 for nocloprost, paired two-tailed Student t-test.
Ill
Drug concentration (pM)
Figure 3.2.6.- Effect of PGE2 (•), n=8, PGF2a (■), n=4, and PGD2 (▲),
n=3, at increasing cellular cAMP in the human monocyte.
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pge2 390 ± 180 nM 1540 ± 430 1
nocloprost 40 ± 10 nM 650 ± 80 0.1
11-deoxy PGEi 1.2 ± 0.5 pM 510 ± 100 3.1
16,16 dimethyl PGE2 1.3 ± 0.6 pM 1450 ± 570 3.4
AH13205 >10 pM 10 ± 30 >25
butaprost >10 pM 540 ±470 >25
misoprostol >10 pM 320 ±210 >25
sulprostone >10 pM 280 ± 270 >25
Table 3.2.1 - EC30, maximum response and EEC values for a range of
EP-receptor agonists at elevating cAMP in the human monocyte
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3.2.4.- Discussion
Gemsa et al., 1975, measured macrophage and medium cAMP from
rat peritoneal macrophages. Their time course data for PGE2
incubation showed a peak production in the cellular fraction after 5
min incubation (-30 ± 5 pmol cAMP/107 macrophages). This
decreased after 30 min incubation and fell below the medium level
after 60 min whereas the production of cAMP in the medium was a
slow linear increase in cAMP. This compares favourably with our data
for the human monocyte/macrophage.
AH23848B was used as an EP4 antagonist to determine the effects of
EP4 receptor antagonism on cAMP production in human monocyte
stimulated with PGE2. AH23848B 30 pM produced a significant
antagonistic effect. A lower concentration of AH23848B, 10 pM, was
also examined and produced a small rightward shift in the PGE2
concentration-response curve giving an apparent pA2 of 5.58 which
compares well with the pA2 of 6.2 found in the CHO cells and with the
pA2S of 5.3 and 5.4 found in the PSV (Chapter 2.1 85 2.2; Louttit et al.,
1992a; Milne et al., 1995; Coleman et al., 1995). These data support
the involvement of the EP4 receptor in the generation of cAMP by PGE2
in the human monocyte.
However, there is an alternative explanation which relates to the
demonstarted TP agonist activity of AH23848B in some preparations
(Brittain et al., 1985; Lumley et al., 1986). In this context, AH23848B
may not necessarily be acting as an EP4 antagonist in this preparation
and may instead be acting as a physiological antagonist. TP receptor
activation could inhibit any EP receptor stimulated increases in cAMP
either by Gi activation so inhibiting AC activation, or by increasing
[Ca2^ and indirectly inhibiting the cAMP activation pathway.
Butaprost was examined in the human monocyte for antagonist
activity and inhibited the production of cAMP only at the highest
concentration of PGE2 used (10 pM). However, these data do not allow
us to conclude which receptor is mediating this response.
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The EP2 receptor agonists butaprost and AH 13205 did not
significantly increase the levels of cyclic AMP in the human monocyte,
Figure 3.2.4, Table 3.2.1. In EP2 receptor containing preparations
these compounds have EEC values of between 10 and 30 relative to
PGE2. Here, butaprost and AH 13205 produced EEC values of >25,
confirming that the cAMP response is mediated by EP4 receptors in
the human monocyte, Table 3.2.2. Misoprostol, another EP2 agonist
also had no effect in this system. Interestingly, misoprostol displaced
bound [3H]PGE2 from COS-7 cells expressing the mouse EP4 receptor
(Honda et al., 1993), which suggests that it binds the EP4 receptor but
has little or no efficacy.
11-deoxy PGEi concentration-dependently increased cAMP in this
preparation which is consistent with its agonist activity at the EP4
receptor and 16,16-dimethyl PGE2, although non-significant,
generated a maximal "cAMP production similar to PGE2. Neither
compound, though, was equipotent with PGE2, as was seen with the
PSV and, as they also demonstrated a lower potency in the CHO cell
line, may suggest a larger receptor reserve of EP2 receptors in the PSV
than the human monocyte, Table 3.2.2.
Exclusion of AC coupled EP3 receptors, possibly splice variants, has
been demonstrated with the inactivity of sulprostone and misoprostol
in this preparation. However, this does not rule out the existence of
inhibitory EP3 receptors on the human monocyte.
Nocloprost produced a partial agonist-like curve in this preparation,
generating an increase in cAMP production, but only to 50% of that
observed with PGE2 and, although nocloprost has not been tested for
partial agonism in this system, the curve was reproducible. This may,
however, be due to activity at EP3 receptors present in the human
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To test whether there is expression of negatively coupled EP3 receptors
in the human monocyte, the cellular cAMP levels would first have to
be increased with AC activating compounds such as isoprenaline,
which positively couples to AC, or forskolin, which directly activates
AC. Once elevated cAMP levels could be measured, incubation with
sulprostone or GR63799X would demonstrate EP3 receptor activity if
they decreased the observed elevation in cAMP.
These studies show that PGE2 and other EP4 agonists positively
couple to AC to increase the levels of cAMP in human monocytes and
are consistent with the involvement of the EP4 receptor subtype in
mediating cAMP production in the human monocyte.
This work confirms earlier findings that PGE2 stimulates cAMP
production in human monocytes (Gemsa, 1975; Pelus & Strausser,
1977; Oropeza-Rendon et al., 1979; Bonney et al., 1980; Oropeza-
Rendon et al., 1980). These groups demonstrated a concentration-
dependent stimulation of cAMP levels in the presence of PGE2 but did
not investigate which receptor subtype was involved. The work here
strongly favours the involvement of the EP4 receptor subtype.
One potential use for EP4 receptor agonists could be to selectively
down-regulate human monocyte functions without affecting other
leukocytes in the circulation, and so mimic the body by using one of
its own down-regulatory signals. Previous studies have suggested that
the neutrophils and eosinophils express the EP2 receptor positively
coupled to AC and that this may mediate inhibition of functional
responses (Kita et al., 1991; Wheeldon & Vardey, 1993; Talpain et al.,
1995; Dr. E. Milne, personal communication). It has been shown that
PGE2 is released by monocytes in response to stimulation with IL-1
(Takii et al., 1992), and observed that CNS microglia cells stimulated
with IFNy produce IL-ip and PGEi (Porrini et al., 1994), suggesting
that PGE2 acts as a negative feedback system.
120
Further studies are required to evaluate the functional role of the EP4
receptor in the human monocyte and the inhibition of IL-la and IL-ip
release by PGE2 was investigated to try and determine a physiological
role for the EP4 receptor.
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CHAPTER 3.3
Investigation of the EP-receptor mediating inhibition of IL-la
and IL-ip release from human monocytes
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3.3.1.- Introduction
Interleukin-1 (IL-1) is a group of hormone-like polypeptides mainly
produced by cells of the monocyte/macrophage lineage after
infection, injury, or antigenic challenge (Oppenheim et ah, 1986;
Beutler & Cerami, 1987; Dinarello, 1988) and it has been shown that
LPS-stimulated blood monocytes produced significantly more IL-1
than peritoneal macrophages (Friedlander, 1994). IL-1 is also
produced by several other cell types including lymphocytes,
neutrophils, fibroblasts, synovial cells, osteoclasts, hepatocytes, and
adipocytes (Shirakawa et ah, 1988).
The cloning of cDNA for mouse (Lomedico et ah, 1984), rabbit
(Furutani et ah, 1985) and human (Auron et ah, 1984; March et al.,
1985; Tocci et ah, 1987) IL-1 molecules has shown that there are two
distinct forms of IL-1, IL-1a and IL-1 p. In human
monocyte/macrophages the IL-1 genes are not constitutively
expressed, but their expression can be readily induced with a wide
variety of factors; bacterial LPS, muramyl peptides, silica and urate
crystals, phorbol esters and other cytokines (Di Giovine & Duff,
1990).
Processing of IL-1 precursors appears to occur in conjunction with
externalisation, since only 31 kDa precursors are found
intracellularly, whereas the mature 17.5 kDa form is exclusively
extracellular (Bayne et ah, 1986; Limjuco et ah, 1986; Giri et ah,
1985). The apparent absence of a leader sequence on the 31 kDa
precursor, in addition to the observed accumulation of precursors for
human IL-1 (Bayne et ah, 1986; Limjuco et ah, 1986; Matsushima et
ah, 1986) and mouse IL-1 (Limjuco et ah, 1986; Gery et ah, 1981)
within activated monocytes and macrophages, suggests that the
mechanism of IL-1 secretion is distinct from that of typical secretory
proteins. The IL-1 precursor in the cytoplasm needs to be processed
prior to release, which may represent a novel pathway of protein
secretion.
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The IL-la precursor is phosphorylated in LPS-stimulated murine
macrophages and the principal, if not the only, site of
phosphorylation is residue serine 90 (Beuscher et al., 1988). The
group also demonstrated that the 10% fraction of the phosphorylated
IL-la precursor that is membrane-bound is associated with lysosomal
vesicles. Singer and co-workers found that IL-ip is not anchored to
the plasma membrane, but localised in the cytosolic ground
substance and showed that there were no significant amounts of IL-
ip detected in the ER or Golgi apparatus (Singer et al., 1988). Also,
IL-la, but not IL-lp, has been detected on the surface of activated
human monocytes by flow cytometry using monoclonal antibodies
specific to IL-la and IL-ip (Conlon et al., 1987). These data suggest
that the intracellular precursors of IL-1, pre-IL-la and pre-IL-lp are
differently post- or co-translationally modified. Another group
demonstrated this further by examining the phosphorylation of
intracellular pre-IL-1 (Kobayashi et al., 1988). It is known that the
human IL-la and IL-ip molecules are post-translationally cleaved
from the 31 kDa precursor into 17.5 kDa biologically active
molecules. They looked at LPS-induced production of both
intracellular IL-la and IL-ip in human monocytes. [32P]-
orthophosphate labelling of these cells revealed that pre-IL-1 a was
phosphorylated at least 10-fold more than intracellular pre-IL-ip.
However, no [32P]-incorporation could be detected in the 17.5 kDa
processed IL-la and IL-1 p.
Analysis by thin layer chromatography revealed that the major
phosphorylation site occurred at serine residue(s). The [32P] was being
incorporated into multiply cleaved precursors of IL-la, which
appeared in the absence of protease inhibitors and the smallest
molecular weight pre-IL-la that was labelled wdth [32P] was 22 kDa,
so the phosphorylated serine residue must be located adjacent to a
sequence of four basic amino acids located in the 4 kDa region at the
amino terminus of the 22 kDa precursor of IL-la. This serine residue
might also be a major phosphorylation site for a cAMP-dependent
protein kinase. The group found that a synthetic peptide analogue of
this region (residue 84 to 112) could be similarly phosphorylated in
vitro by a cAMP-dependent protein kinase. In conclusion, Kobayashi
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and co-workers suggested that there is no comparable amino acid
sequence in IL-1(3 which could be expected to be phosphorylated by a
cAMP-dependent protein kinase. Thus phosphorylation of truncated
pre-IL-la greatly enhances its susceptibility to digestion by trypsin,
promoting the conversion of pre-IL-la to the more biologically active
IL-la. Their findings suggest that the phosphorylation of serine close
to dibasic/tetrabasic amino acid sequence functions to facilitate the
processing and/or release of IL-la.
It is now accepted that IL-la and IL-ip are released through non-
classical secretory pathways (Rubartelli et al., 1990). Other studies
have implicated protein kinase C and extracellular regulated kinase
(ERK) signalling pathways as targets of LPS stimulation in different
cell types (Weinstein et al., 1992; Hurme et al., 1990).
Cells that are stimulated by IL-la and IL-ip include cells of the
immune system as well as a wide range of non-immune cells.
Responses of non-immune cells to IL-1 include proliferation of
mesangial cells, keratinocytes, and fibroblasts, increased proteinase
synthesis by chondrocytes, and increased synthesis of eicosanoids by
fibroblasts, neutrophils, and monocytes (Dinarello, 1988, 1989; Mizel
et al., 1981; Canalis, 1986; Pasternak et al., 1987; Dayer et al., 1986;
Newton & Covington, 1987). Immune cell-related actions of IL-1
include participation in the activation and functions of T cells, B
cells, and NK cells (Gery et al., 1972; Lipsky et al., 1983; Herman et
al., 1985). IL-1 also enhances the response of T cells to other factors,
particularly when these factors are at suboptimal concentrations
(Gery et al., 1972; Simon, 1984; Arya 85 Gallo, 1984; Matsushima &
Oppenheim, 1985). IL-1 p can even induce its own production through
an autocrine loop (Schindler et al., 1990).
When injected into animals IL-1 p is an inflammatory cytokine causing
fever, neutrophilia and other acute phase responses (Dinarello,
1988), and has proinflammatory and procoagulant activities
(Dinarello, 1984). It is one of many cytokines that display
immunologic, metabolic, hematopoietic, and inflammatory activities,
both individually and in combination. IL-1 p is a major effector
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molecule in the pathogenesis of septic shock and bacterially-mediated
local tissue destruction (Bone, 1991; Morrison & Ryan, 1987). IL-ip
does not appear to be constitutively produced in healthy individuals,
but is present in a number of disease states, including rheumatoid
arthritis and infection (Dinarello, 1991).
The presence of IL-ip may have an important function in the
development of rheumatoid arthritis by inducing the synthesis of
other cytokines, proteolytic enzymes, and stimulation of fibroblast
proliferation, leading to degeneration of the affected joint (Arend &
Dayer, 1990; Shirakawa et ah, 1993). The synovial fluid from affected
joints of rheumatoid patients has been shown to contain products
primarily of macrophage origin. Some of the most prominent of these
macrophage products are IL-1 itself, TNF-a, IL-6, M-CSF, GM-CSF
and prostaglandins (Firestein et ah, 1990).
cDNA clones corresponding to the 80 kDa receptor for IL-1 were
isolated by mammalian expression (Sims et ah, 1989). McMahan and
co-workers reported the expression and isolation of human and
murine cDNA encoding a second type of IL-1 receptor with a Mr of 60
kDa which they proposed to be a type II receptor for IL-1 (McMahan
et ah, 1991). This mature type II IL-1 receptor consisted of (i) a ligand
binding portion comprising three immunoglobulin-like domains; (ii) a
single transmembrane region; and (iii) a short cytoplasmic domain of
29 amino acids. This last contrasts with the -215 amino acid
cytoplasmic domain of the type I receptor, and suggests that the two
IL-1 receptors may interact wdth different signal transduction
pathways. Another group has also shown that human monocytes
express a 63 kDa IL-1 receptor type II that is immunologically
distinct from the IL-1 receptor type I (Spriggs et ah, 1990).
It has been shown that treatment of human T cell/fibroblasts with IL-
la or IL-1 p increased IL-1 receptor mRNA expression, PGE2 release
and a secondary accumulation of intracellular cAMP (Takii et ah,
1992). The exogenous addition of PGE2 increased both IL-1 receptor
mRNA and intracellular cAMP levels in untreated cells and forskolin,
cholera toxin and 8-bromo-cAMP all increased IL-1 receptor mRNA
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levels indicating that cAMP elevation can increase IL-1 receptor
expression
IL-lra was first reported in 1985 as an IL-1 inhibitory bioactivity of
22-25 kDa in the supernatants of human monocytes cultured on
adherent IgG. IL-lra is structurally related to IL-1 a and IL-ip (26% &
30% nucleotide sequence identity, respectively) (Eisenberg et al.,
1991) and the cDNA has been cloned from a human monocyte library
(Eisenberg et al., 1990). Human IL-lra has also been purified from
supernatants of the human myelomonocytic cell line U937, after PMA
stimulation (Carter et al., 1990).
IL-lra binds to IL-1 receptors, both type I and type II, on various
target cells without inducing any specific biological response (Dripps
et al., 1991a & b). IL-lra represents the first described naturally
occurring cytokine that has specific receptor antagonist functions.
In contrast to IL-1 a and IL-ip, IL-lra has a classic secretory leader
peptide and is glycosylated at a consensus N-linked glycosylation site
(Hannum et al., 1990; Poutsiaka et al., 1991). The protein is therefore
excreted through the Golgi-endoplasmic reticulum route. However, it
has been described that up to 10%-50% of IL-lra produced by
monocytes remains cell associated at any time point during its
synthesis (Granowitz et al., 1992), and a truly intracellular form of IL-
lra without a signal peptide has been described in keratinocytes, but
has not been detected in monocytes or monocytic cells.
IL-1 a, IL-ip and IL-lra bind with equal affinity to the 80 kDa IL-1
type I receptor present on T cells, endothelial cells and fibroblasts
(Hannum et al., 1990), and with 40-times lower affinity to the 67 kDa
type II receptor found on human neutrophils, macrophages and B
cells (Granowitz et al., 1991). The specificity of IL-lra, and the fact
that it is produced by the same cells that produce IL-1, support the
view that it is a physiologically significant regulator of IL-1.
Considerable information has accumulated pertaining to the blockade
of IL-1 receptors using the naturally occurring IL-lra (Dinarello,
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1991). IL-lra appears to be a pure receptor antagonist, since IL-lra
alone at concentrations as high as 1 pg/ml does not induce IL-la, IL-
ip or TNF-a synthesis in human monocytes (Granowitz et al., 1992).
In a Phase 1 trial in normal subjects, plasma IL-lra concentrations of
25-30 jug/ml caused no symptoms or changes in vital signs and did
not alter white blood cell counts or routine biochemical and
endocrinological tests which is consistent with the concept that IL-1
does not play a role in normal homeostasis.
A particular protease has been described that appears highly specific
for cutting the IL-1 (3 precursor from 31 kDa to 17.5 kDa, its most
active form (Dinarello, 1993). This enzyme is known as the IL-1 p
converting enzyme (ICE). ICE is a member of the cysteine protease
family but it does not cleave the IL-la precursor. Blocking ICE with
ICE-specific substrate inhibitors reduced the amount of mature IL-1 p
produced by activated monocytes. So far, only peptide-based
inhibitors of ICE have been identified, but there may be a therapeutic
role for such agents as neutralising antibodies to IL-1 p reduce
endotoxin-induced fever in animals and decrease the proliferation of
leukaemia cells in vitro.
One of the major outer membrane components of Gram-negative
bacteria, LPS, is a potent activator of human monocytes and
macrophages, resulting in the release of IL-1 (Krakauer, 1984;
Nathan, 1987). LPS has been demonstrated to induce IL-1 p mRNA
transcription which is rapid, peaking within 2- 3 h and disappearing
to barely detectable levels within 6 h (Fenton et al., 1987). This rapid
on/off regulation is thought to be characteristic of the regulation of
IL-1 p in monocytes.
LPS stimulation of monocytes has been found to be mediated through
a cell surface protein, CD14 (Wright et al., 1990). However, several
studies have suggested that CD 14 is not the only LPS receptor to be
involved in the secretory response of LPS-stimulated monocytes
(Raetz et al., 1991; Couturier et al., 1992). In support of this,
Morrison and colleagues (1993) have shown the existence of more
than one type of LPS-binding site on the monocyte membrane.
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Studies have shown that LPS causes rapid tyrosine phosphorylation
in human macrophages (Weinstein et al., 1990) and that this is
mediated by CD 14 (Weinstein et al., 1993). Mitogen-activated protein
kinases and other proteins have also been identified as substrates for
LPS-induced protein tyrosine kinase (PTK) activity (Dong et al.,
1993a,b; Weinstein et al., 1992; Han et al., 1993) and several studies
have suggested that LPS activates pertussis toxin-sensitive G-
proteins (Jakway 8s DeFranco, 1986; Zhang & Morrison, 1993).
Protein kinase C (PKC) has also been found to play a role in induction
ofmonocyte tumoricidal activity by LPS (Novotney et al., 1991; Chung
et al., 1992; Taniguchi et al., 1989; Coffey et al., 1992; Dong et al.,
1989). Although, Coffey and co-workers (1992) have shown that LPS
cannot stimulate phospholipase C (PLC) activity in human monocytes
and these results suggest that LPS induces cellular activation via
many second messenger pathways.
The signal transduction pathway involved in LPS-stimulated TNF-a
and IL-ip secretion has been investigated in monocytes (Shapira et
al., 1994). TNF-a and IL-ip secretion were completely blocked by H-7,
an inhibitor of both PKC and cyclic-nucleotide-dependent protein
kinase, but were not affected by H-89, a specific cyclic nucleotide-
dependent PKA inhibitor. LPS stimulation only slightly increased
intracellular levels of diacylglycerol (DAG), the natural activator of
PKC, and pre-treatment of monocytes with the DAG-kinase inhibitor,
R59022, did not affect LPS-stimulated TNF-a secretion. LPS-induced
PKC activation was also found not to be affected by blocking of CD 14,
the putative LPS receptor, with mAb or by inhibition of PTK with
herbimycin A. However, these agents suppressed LPS-induced TNF-a
secretion and TNF-a mRNA accumulation. The group suggest that
LPS stimulated TNF-a and IL-lp secretion requires the activation of
PTK and PKC, upstream to the activation of gene transcription in
human monocytes. The activation of PKC by LPS, they suggest, is
probably mediated by a DAG-independent pathway. Other groups
have also shown that TNF-a and IL-ip secretion in LPS-stimulated
human monocytes are dependent on both PTK (Dong et al., 1993a &
b; Geng et al., 1993) and PKC activity (Novotney et al., 1991; Chung
et al., 1992).
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A number of endogenous agents are known to increase intracellular
cAMP levels in the monocyte/macrophage (Hurme, 1990). Among
these, the prostaglandins are possible compounds in vivo due to their
high levels in inflamed rheumatoid arthritic joints (Seitz & Hunstein,
1985). It has been shown that exposure of human peripheral blood
monocytes to the non-hydrolisable analogue of cAMP, dibutyryl
cAMP, resulted in the induction of IL-1 p mRNA production (Serkkola
et ah, 1992).
Of the known intracellular second messengers, PKC activated by DAG
is clearly involved in the activation of IL-1 gene expression: phorbol
esters, which are structural analogues of DAG, bind to and activate
PKC (Nishizuka, 1984), and are potent inducers of IL-1 production
(Krakauer 85 Oppenheim, 1983; Strulovici et al, 1989). In LPS- or IL-
2-stimulated macrophages, IL-1 production can be down-regulated by
pharmacological inhibitors of PKC (Kovacs et al., 1988, 1989; Hurme
85 Serkkola, 1991). The role of cAMP as a second messenger in the
induction of IL-1 expression has been extensively investigated and
cAMP can also be an up-regulating signal: elevated cAMP levels
induced either by prostaglandins or cell permeant structural cAMP
analogues did not themselves activate the IL-1 p gene but greatly
potentiated the phorbol ester-induced IL-1 p transcription and protein
production both in human monocytes (Hurme, 1990) and in myeloid
leukaemia cells (Hurme et al., 1990).
Recent studies revealed that cAMP can also negatively regulate gene
transcription for the human platelet activating factor, IL-2 receptor
genes and LPS-induced transcription of tissue factor and TNF-a
(Anastassiou et al., 1992; Thivierge et al., 1993; Bouvier et al., 1989;
Stockert, 1993; Taffet et al., 1989; Ollivier et al., 1993). IL-1 p and
TNF-a, once induced by LPS stimulation, activate secondary lipid
mediators that elevate intracellular cAMP (Dinarello, 1989; Knudsen
et al., 1986) and it is possible that elevation of cAMP may mediate
either a negative or a positive feedback mechanism on LPS-induced
biosynthesis of specific cytokines in particular cell types (Knudsen et
al., 1986; Tannenbaum 85 Hamilton, 1989; Bailly et al., 1990).
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Peripheral monocytes and myelomonocytic cell lines stimulated by
LPS or the phorbol ester PMA have been demonstrated to express IL-
1 mRNA (Sung et al., 1991). The group found that dibutyryl cAMP, 8-
bromo-cAMP, forskolin, cholera toxin, PGEi and PGE2 synergised
with PMA or LPS to increase the accumulation in cell lines of IL-la
mRNA by up to 50-fold and that of IL-lp mRNA by 10- to 20-fold
compared to LPS or PMA alone and suggested that the synergistic
stimulation was due to enhanced IL-1 gene transcription rate rather
than increased IL-1 mRNA stability. However, the same group found
that the IL-1 protein synthesis in these cells was increased by only 2-
fold by the cAMP elevating agents compared with the observed mRNA
level and they suggest that IL-1 synthesis is under strict translational
control.
The above experiments suggest that IL-1 mRNA production is
positively regulated by cAMP. TNF-a is regulated translationally (Han
et al. 1990) with the regulatory sequence residing in the 3'-
untranslated region of TNF-a mRNA. IL-1 mRNA shares a number of
sequence motifs with TNF-a mRNA in this 3'-untranslated region. It is
possible therefore that similar mechanisms regulate IL-1 and TNF-a
transcription and translation.
Human monocytes exposed to LPS generated a concentration- and
time-dependent increase of IL-1 secretion in culture supernatants
(Kassis et al., 1989). PGEi, PGE2, cholera toxin and the PDE inhibitor
IBMX, when added with LPS, resulted in a concentration-dependent
increase in cellular cAMP and in secreted IL-1. Maximal levels of
secreted IL-1 were 2.5-5.0-fold greater than that induced by LPS
alone. These agents alone exhibited marginal effect on cell-associated
IL-1. It was concluded by Kassis and co-workers that in adherent
monocytes, IL-1 release is potentiated, and not inhibited, by
prostaglandins or agents that elevate cellular cAMP, which differed
from other groups results (Kunkel 8s Chensue, 1985; Brandwein,
1986; Knudsen et al., 1986). They proposed the difference to be that
they sampled from fresh adherent monocytes rather than mouse
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resident macrophages (Kunkel & Chensue, 1985; Brandwein, 1986)
or the U937 cell line (Knudsen et al., 1986).
A more recent study showed in LPS-activated human monocytes that
elevated cAMP concentrations, induced by PGE2, forskolin or
dibutyryl cAMP, reduced only secreted IL-ip, while the cell-associated
level remained unchanged (Viherluoto et al., 1991). cAMP also
inhibited TNF-a production by monocytes, but the decrease was of
the same magnitude in the extracellular and intracellular
compartments indicating that the effect of cAMP on IL-ip release is
due to the modification of the secretory process typical only for IL-ip.
It has also been demonstrated that the IL-ip production by LPS-
activated human monocytes is readily inhibited by dibutyryl cAMP,
without a significant change in the steady-state levels of IL-ip mRNA
(Hurme, 1990,). By contrast, the same study showed that in PMA-
activated monocytes dibutyryl cAMP increased IL-ip production ~4-
fold, and the steady-state levels of IL-ip mRNA were also
simultaneously increased. Interestingly, another study measuring the
levels of TNF-a and IL-1 in response to LPS in human monocytes
showed dibutyryl cAMP to have no effect on IL-1 production, but that
dibutyryl cAMP did suppress concentration-dependently the
production of TNF-a (Sato et al., 1993).
Knudsen and co-workers showed that release of IL-1 p activity by LPS
can be completely blocked by dexamethasone in the monocyte-like
tumour cell line, U937 (Knudsen et al., 1987). Northern blot
hybridisation analysis indicated that dexamethasone completely
blocked accumulation of IL-ip-encoding mRNA. In addition, when
cells were pre-stimulated with LPS, dexamethasone, did not change
IL-ip mRNA levels, but completely blocked IL-lp release and induced
a transient increase in cellular cAMP. This suggests that
glucocorticoids suppress IL-ip synthesis by two distinct mechanisms,
blocking transcription of IL-1 P mRNA during monocyte activation and
blocking post-transcriptional IL-ip via cAMP.
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TNF-a is strongly implicated as an in vivo inducer of IL-lp. In
monocytes, TNF-a appears to be an inducer of IL-ip production but
only in the presence of dibutyryl cAMP or agents such as PGs which
elevate intracellular cAMP (Lorenz et al., 1995). The group found that
this TNF-a/cAMP pathway regulates IL-ip production at the level of
transcription, and requires a cAMP response element located between
-2762 and -2755 bp in the upstream regulatory sequence of IL-lp. As
PGs, which are known to increase cAMP levels in vivo, and TNF-a are
both found in significant quantities in the synovial fluid of
rheumatoid joints, this observed synergy may provide valuable
insight into the potential pathways involved in the continuous
production of IL-ip in the chronically inflamed joint.
PDE IV activity has been reported in monocytes and macrophages
(Livi et al., 1990). Verghese and co-workers have shown that the
selective type IV cAMP-PDE inhibitor, rolipram, enhanced cAMP levels
and inhibited the release of TNF-a and IL-ip in human monocytes
(Verghese et al., 1995). The non-selective PDE inhibitors IBMX and
pentoxifylline were significantly less potent.
Another group studied the effect of selective PDE isozyme inhibitors
on LPS-stimulated human monocyte viability and production of TNF-
a and IL-ip (Molnar-Kimber et al., 1993). The inhibitors used were
vinpocetine (PDE-I), CI-930 and milrinone (PDE-III), rolipram and
nitraquazone (PDE-IV) and zaprinast (PDE-V). None of the inhibitors
affected monocyte viability at 10 pM or lower concentrations and only
high concentrations of PDE-IV inhibitors modestly suppressed IL-ip
production. PDE-IV inhibitors, and to a lesser extent PDE-III
inhibitors, suppressed TNF-a production showing that selective PDE
inhibitors can differentially affect the secretion of TNF-a and IL-ip
from endotoxin-stimulated human monocytes.
The above results indicate that the control of IL-1 release is inducer-
dependent, as well as second messenger-dependent. It is also likely
that IL-1 production is affected differently by cAMP at its
transcription, translation and release stages. The above data are also
consistent with previous studies which show that TNF-a and IL-ip
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are differentially regulated (Endres et al., 1991; Tannenbaum 86
Hamilton, 1989). It is also feasible that PDE IV inhibition is a way of
consistently inhibiting IL-1 release.
PGE2 and PGI2 analogues have been compared for their potency to
influence LPS-stimulated production of IL-ip and TNF-a by human
mononuclear cells (Eisenhut et al., 1993). The stable analogues of
PGI2, iloprost and cicaprost, markedly suppressed TNF-a synthesis in
LPS-stimulated mononuclear cells, without effect on IL-lp
production. Although there was no significant difference in maximal
suppression of TNF-a, iloprost and cicaprost suppressed synthesis to
50% of control at 20-fold lower concentrations than did PGE2. The
IC50 values for iloprost and cicaprost were 8 nM and 5 nM,
respectively, compared to 125 nM for PGE2 and elevated cAMP levels
were observed with PGE2 and cicaprost in this system. It is likely that
human mononuclear cells also contain the IP receptor and that this
is positively coupled to AC activation.
The ability to control IL-1 production either positively or negatively
has great human implications. Decreased IL-1 production has been
reported in patients with systemic lupus erythematosus (Whicher et
al., 1986), scleroderma, and malnutrition (Kauffman et al., 1986),
whereas in vitro production of IL-1 appears to be increased in patients
with rheumatoid arthritis (Wood et al., 1985), idiopathic osteoporosis
(Pacifici et al., 1987), or major burns. It has also been observed that
CNS microglia cells produce IL-lp, TNF-a, IL-6 and PGEi, and that
spontaneous and IFNy-induced IL-1 p secretion was greater in
monocytes from patients with multiple sclerosis than in monocytes
from normal patients (Porrini et al., 1994).
Endothelial cells are also a target for IL-1, as IL-1 itself stimulates the
proliferation of vascular smooth muscle cells. Hogquist and co¬
workers (1991) also demonstrated that while necrotic cell injury did
not lead to the release of active IL-1 p, apoptotic cell injury did.
Pleiotropic cytokines such as IL-1a have multiple effects on peripheral
blood monocytes. Lee and co-workers examined the ability of in vivo
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recombinant human IL-la therapy to enhance clinically important
monocyte functions in ovarian cancer patients prior to chemotherapy
(Lee et al., 1993). After 4 days of continuous infusion, in vivo IL-la
therapy amplified both the number and activity of monocytes.
Therapy with IL-la increased the number of monocytes six-fold, and
these monocytes had a significantly increased ability to produce
superoxide anion in response to phorbol 12,13-dibutyrate
stimulation. Their ability to secrete spontaneously IL-la and IL-ip
was also significantly increased. The effects of IL-la infusion
demonstrated here should at least transiently increase the ability of
monocytes to combat infection and enhance host immune response.
The aim of the present study was to find a receptor-mediated
physiological event which was altered by PGE2 and EP-receptor
mimetics. This would allow the study of the EP-receptor function in a
physiological system and also to study the second messenger system
involved as well as investigate whether there is a correlation between
increased intracellular cAMP and functional efficacy. If a working
experimental system was obtained we then hoped to investigate
further the EP4-receptor present on human monocytes and to
characterise the functional efficacy of EP-receptor mimetics studied
previously. The effects of the EP4-receptor antagonist AH23848B were
also investigated.
IL-1 has been measured by RIA. Lonneman and co-workers (1988) set
up a RIA for IL-la, and Lisi and colleagues (1987) used one for IL-1 p.
Rordorf-Adam and co-workers (1989) have used an ELISA
immunoassay to measure IL-la and IL-ip from monocytes stimulated
with LPS. Secreted IL-ip represented 31 to 86% of the total IL-1 p and
more IL-la than IL-ip was produced but, unlike IL-ip, IL-la was
poorly secreted. IL release was measured here using ELISA kits
selective for IL-la and IL-1 p.
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LPS, the cytokine stimulus used in all experiments, was chosen
because most current work on monocytes has been done using LPS.
Other cytokine stimulants such as TNF-a, IL-6, A23197 (a Ca2+
ionophore) and opsonized zymosan have all been used in some
experiments but the data are less complete and for initial studies,




Lipopolysaccharide (LPS) - LPS (Escherichia coli serotype 026:B6)
was used in all experiments as the stimulatory agent at
concentrations of 100 ng/ml (chosen after initial concentration-
response curves, data not shown).
RPMI 1640 medium - Nutrient Mixture RPMI 1640, stored at 4°C.
Penicillin/Streptomycin (Pen/Strep) - Penicilin/Streptomycin
solution, containing 10000 U/ml Penicillin and 10000 pg/ml
Streptomycin, stored at 20°C.
Foetal Calf Serum (FCS) - Foetal Calf Serum Heat Inactivated.
Mycoplasma and virus screened, stored at -20°C.
Cell Culture Medium - Cell culture medium was made up of RPMI
1640 medium (500 ml), FCS (50 ml) and Pen/Strep (5 ml), and stored
at 4°C. The medium was always warmed to 37°C before use.
Culture plates - 12-well plates.
ELISA kits - IL-1a and IL-ip kits purchased from Cayman Chemicals,
USA.
Drugs - All drugs were made up fresh each day in RPMI 1640
medium without FCS or Pen/Strep. These were warmed to 37°C in a
water bath before use.
The antagonist AH23848B was made up at 1 mM and dissolved by
sonicating for 15 min. After sonication the drug was immediately
used.
Preparation ofmonocytes
Monocytes are very sensitive to trace amounts of LPS (Northoff et al,
1987), so the possibility of LPS contamination in the reagents has to
be considered. Human monocytes were purified from human blood as
for cAMP studies, Chapter 3.2. Cells were again seeded to 12-well
plates, and allowed to adhere overnight in cell culture medium.
Monocytes were washed twice with 0.9% saline to remove any non¬
adherent contaminating cells.
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Assay ofmonocytes for IL-1a and IL-lf
Studies involving cytokine production from human monocytes have
used many different protocols. Some workers seed mononuclear cells
to flasks, purify the monocytes by adhesion, and assay directly the
pure monocytes in the flask. Other groups purify the monocytes by
adhesion and scrape off the monocytes before assaying them in
suspension at known concentration.
Initially, the monocytes were purified by adhesion and the flask
scraped. The collected cells were centrifuged to give a monocyte pellet
and, after counting, seeded at known concentration in 12 well plates.
The cells were left to re-adhere before assaying. The advantage of
having adhered monocytes was that they could be assayed for 24 hr
in even contact with a drug without the need for a plate shaker. The
cellular fraction could also easily be separated from the medium and
by scraping the wells the concentration of adhered cells could be
determined.
After initially adhering the cells however, it was apparent that there
was a high concentration of dead cells after scraping (10-20%
compared with <1% in the mononuclear cells before plating). It was
decided to seed the mononuclear cell population directly to the 12
well plates at ~5 x 105 mononuclear cells per well. As the monocytes
comprise 20-40% of the mononuclear cell fraction this usually left 1-
2 x 105 monocytes per well.
The reaction was stopped by freezing. The medium was aliquoted
from the wells to numbered tubes and the cellular fraction frozen dry.
To resuspend the cellular fraction, HAMS-F12 (1 ml) was added
before scraping with a rubber policeman.
Endres and co-workers (1988) found that lysing cells by repeated
freeze-thawing yields maximal recovery of total (i.e., secreted plus
cell-associated) immunoreactive IL-ip, when compared to extraction
with the detergent CHAPS or addition of protease inhibitors. They
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also observed that the soluble stimulus endotoxin induced twofold
more IL-la than IL-lp or TNF-a.
From these initial observations the decided protocol is outlined below.
After 1 hr incubation, to allow the monocytes to adhere, all wells were
gently washed with 0.9% saline. HAMS-F12 (1 ml) without FCS or
Penicillin/Streptomycin was added containing LPS (100 ng/ml) and
the cells incubated (2-12 hr). Drugs were added, in 1 ml aliquots of
HAMS-F12, 5 min prior to addition of LPS (100 pi). In antagonist
studies, antagonist was added 10 min before drug and LPS added 5
min after drug. All studies were carried out in the presence of 5 pM
indomethacin.
The reaction was stopped on ice, and the cell supernatant removed to
4 ml plastic tubes and centrifuged at 320g for 10 min at 4°C to pellet
any contaminating cells before storing at -20°C. The cellular fraction
was removed by adding a further 1 ml of RPMI to each well and
scraping with the rubber policeman. Samples were then removed to 4
ml plastic tubes, and frozen as for the supernatant. They were then
defrosted on ice and assayed immediately for IL-1 using ELISA kits.
Initially, time course experiments were carried out to determine the
optimum conditions and length of incubation with LPS. Time courses
were stopped at 4, 8, 12 and 24 hr.
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3.3.3.- Enzyme Linked Immunosorbant Assay (ELISA)
ELISA is based on a double-antibody 'sandwich' technique. Each well
of the microtitre plates has been coated with either a monoclonal
antibody specific for human IL-la or ip (capture antibody) depending
on the kit. These antibodies will specifically bind any of their
respective human IL-1 introduced into the well. An
acetylcholinesterase: Fab' Conjugate (AChE:Fabj, which binds
selectively to a different epitope on the IL-1 molecule is also added
and 'sandwiches' the IL molecule between itself and the pre-coated
monoclonal antibody. This effectively immobilises the bound IL on the
plate and allows excess reagents to be washed away. The
concentration of analyte can then be determined by measuring the
enzymatic activity of the AChE with Ellman's Reagent which produces
a yellow-coloured product absorbent at 412 nm.
Ellman's reagent consists of acetylthiocholine and 5,5'dithio-bis(2-
nitrobenzoic acid). Hydrolysis of acetylthiocholine by acetyl¬
cholinesterase produces thiocholine and non-enzymatic reaction of
thiocholine with 5,5'dithio-bis(2-nitrobenzoic acid) produces 5-thio-2-
nitrobenzoic acid, which has a strong absorbency at 412 nm. The
intensity of the colour is directly proportional to the amount of bound
AChE:Fab' conjugate which is in turn proportional to the
concentration of IL. Therefore by using a standard curve of human IL,
the concentration of each sample can be accurately determined.
Acetylcholinesterase as the conjugate-linked enzyme has several
advantages over other enzymes commonly used for enzyme
immunoassays. Unlike horseradish peroxidase, acetylcholinesterase
does not auto-inactivate during turnover. This property of
acetylcholinesterase allows multiple development of the assay. In
addition, the enzyme is highly stable under assay conditions, has a
wide pH range (pH 5-10), and is not inhibited by common buffer salts
and preservatives. The particular acetylcholinesterase used in this
assay is from the electric organ of the electric eel Electrophorus




All water used for buffers and reagents was carbon filtered deionized
water and all solutions were stored at 4°C unless otherwise specified.
EIA Buffer- The contents of one EIA buffer packet were dissolved in
500 ml of water.
Wash Buffer- The contents of one Wash buffer packet were dissolved
in 500 ml of water and the packet rinsed twice. 0.25 ml of Tween 20
was added by a syringe.
Sample Matrix Blank (SMB)- This is the medium used for assaying
the sample and standards. It is very important that this is IL free and
matches the unknown samples to be assayed. As all my samples were
in RPMI buffer, which is free of IL-1, I used this as my SMB and all
the standard curve dilutions of IL-1 are made up in RPMI.
Interleukin Standards- The kit is supplied with 10 ng of IL-1. This is
suspended in 2 ml of EIA buffer to give a stock solution of 5 ng/ml.
An aliquot of 50 pi to 1 ml with SMB gives the first standard (SI) of
250 pg/ml the highest point on the standard curve. Sequential
dilutions of SI with SMB give 125, 62.5, 31.3, 15.6, 7.8 and 3.9
pg/ml making up standards S2-S7. The last standard S8 is only 500
pi of SMB and is the zero point of the standard curve.
Assay
1- 100 pi of standards and unknowns was added to each well in the
plate followed by 100 pi of AChE:Fab' conjugate except the blank
wells which were left dry.
2- The plate was then covered with plastic film and incubated
overnight at 4°C.
3- To develop the plate the wells were emptied and rinsed five to six
times with Wash buffer. Once dry Ellman's reagent (200 pi) was
added to each well, including the blanks, and the plate covered with
plastic film. The plates were always developed in the dark to limit the
breakdown of Ellman's reagent.
4- Once the highest concentrations on the standard curve were
visibly yellow (after 30 min) it was possible to obtain values for the
141
relatively concentrated samples by reading at 412 nm (405-420 nm).
Longer development times, about 2 h, were necessary to obtain an
accurate plot for the lower range of the standard curve and
statistically significant values for sample concentrations near the
detection limit of the assay (-1.5 pg/ml). The effect of the developing
time is shown in Figure 3.3.1a.
5- After first subtracting the average blank value from each point, the
result can be calculated by plotting a standard curve of absorbency
versus concentration for the standards S1-S8 and constructing a
best-fit line through the points, as shown in Figure 3.3.1b.
Specificity
The specificity of this assay is essentially 100% for IL-la or IL-1(3,
depending on the assay kit used, and <0.01% for the other IL-1




2 hr incubation with LPS (100 ng/ml) produced more IL-1 (3 in the
cellular fraction than was released, Figure 3.3.2a. PGE2 had no effect
on released IL-1 p but at 10 pM a slight inhibition in cellular IL-1 p was
observed. The amount of IL-1 p released in the blank cells was the same
as that for cells stimulated with LPS.
4 hr incubation with LPS (100 ng/ml) again produced high blank
values in both fractions, Figure 3.3.2b. LPS produced 222 ± 47 pg IL-
ip/105 monocytes , compared to 148 ± 50 pg IL-ip/105 monocytes in
the blank cells and this LPS peak was significantly reduced by PGE2
10 pM to 123 ± 31 pg IL-ip/105 monocytes.
Incubation for 8 hr with LPS (100 ng/ml) produced a similar profile to
4 hr incubation, Figure 3.3.3a. LPS significantly increased IL-1 p
production to 204 ± 54 pg IL-ip/105 monocytes from 100 ± 35 pg IL-
ip/105 monocytes basal production and PGE2 10 pM significantly
decreased this LPS stimulated IL-1 p production to 103 ± 27 pg IL-
1P/ 105 monocytes.
12 hr incubation with LPS (100 ng/ml) produced only a slight
increase in the cellular fraction IL-1 p levels compared to the basal
value and PGE2 100 nM-10 pM had no effect, Figure 3.3.3b.
4 hr was chosen as the incubation time and was used for the rest of
the experiments with both the cellular and medium fractions were
sampled.
Agonist studies
4 hr incubation with LPS did not significantly increase the IL-la
production in the cellular or medium fractions compared to the basal
value and PGE2 (100 nM-10 pM) had no significant inhibitory effect
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Figure 3.3.1.- (a) The effect of developing time on the standard curve,
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Figure 3.3.2.- (a) Effect of LPS 100 ng/ml (2 hours), n=4, and (b) LPS
100 ng/ml(4 hours), n=4, stimulation on cellular (shaded) and released
(open) IL-ip production in the human monocyte.
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Figure 3.3.3.- (a) Effect of LPS 100 ng/ml (8 hours), n=4, and (b) LPS
100 ng/ml (12 hours), n=4, stimulation on cellular (shaded) and
released (open) IL-ip production in the human monocyte.
*- p<0.05 compared to blank value, paired two-tailed Student t-test.
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Figure 3.3.4.- Effect of LPS 100 ng/ml (4 hours), n=4, stimulation on
cellular (shaded) and released (open) IL-la production in the human
monocyte.
Antagonist studies
Antagonist studies with AH23848B were performed to determine if
the EP receptor mediating the inhibition of LPS induced IL-1
production was of the EP4-subtype.
LPS, AH23848B and PGE2 had no significant effect on the released
levels of IL-1 a, Figure 3.3.5a. However, in the cellular fraction PGE2
alone produced no significant inhibition of the LPS induced IL-1a
production but in the presence of AH23848B (1 |aM) reduced the IL-1a
levels to below basal production, Figure 3.3.5b. AH23848B alone had





Figure 3.3.5.- (a) Effect of control (open) and AH23848B (lpM)
(shaded) on released and (b) cellular IL-la production in the human
monocyte after stimulation with LPS 100 ng/ml (4 hours), n=3.
M
1200 -|
Blank 100ng/mh-100nM +1pM +10pM+100ijM
LPS AH23848 AH23848AH23848AH23848
Figure 3.3.6.- Effect of AH23848B (100nM-100|jM) on released (open)
and cellular (shaded) IL-la production in the human monocyte after
stimulation with LPS 100 ng/ml (4 hours), n=2.
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3.3.5.- Discussion
Experiments were carried out using this system to try an identify a
functional inhibitory role for PGE2 in the human monocyte and to
provide a functional assay system to characterise the EP receptor
involved. Our results demonstrated a significant production in IL-1(3
synthesis which was significantly inhibited by PGE2, Figure 3.3.3.a.
The results obtained in this system were, however, disappointing. In
general the basal value was very high and LPS did not consistently
stimulate the production of IL-la or IL-1 p.
The most intriguing finding in this study was that the cellular fraction
generated higher levels of IL-1 activity compared to the medium, or
released fraction. A possible explanation, for this relates to the nature
of IL-1 activity. As preIL-1 is manufactured in the cytoplasm, and only
converted to active IL-1 upon release, it could be possible that there
are larger amounts of preIL-1, compared to active IL-1, in the cells
which are converted to active IL-1 when the cells are lysed to assay for
IL-1 production. This would explain the higher values observed in the
cellular, over the released, fraction. Another possibility could be that
the released active IL-1 remains bound to the cellular membrane and
is thus detected in the cellular fraction rather than the medium. IL-la
activity has been detected on the surface of activated human
monocytes by flow cytometry using specific monoclonal antibodies
(Conlon et al., 1987).
The blank values for IL-1 were very high in all the experiments. One
reason for this could be that the monocytes were 'primed' before
starting the experiments. It is likely then that they would be
constitutively producing large amounts of IL-1 without an external
stimulus. Lepe-Zuniga et al., 1984, found that human monocytes,
separated by adherence, and cultured in plastic wells, produced
'spontaneously' high levels of intracellular IL-1 during the first 20 hr
in culture while releasing in most cases less than 10% of it into the
medium. However, unlike our study, they found that the addition of
LPS, quartz silica particles, opsonized zymosan, or PMA enhanced 3-
to 50-times the overall production and 25- to 2000-times the release
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of IL-1. They suggested that the reason for the different patterns of
production and release observed with time might be that the
synthesis and secretion of IL-1 by human monocytes axe two distinct
biological events, as mentioned in the Introduction 3.3.1. A possible
reason for our small result was that Lepe-Zuniga and co-workers
were using a thymocyte proliferation assay to measure IL-1 activity
rather than an ELISA. With a thymocyte proliferation assay it is
possible that factors other than IL-1 can stimulate proliferation.
Bacterial infection of our media was ruled out, as fresh monocytes
were used for each experiment and media with FCS was never stored.
Lepe-Zuniga and colleagues also measured a high level of IL-1 activity
in the cellular fraction compared to the medium where as later studies
indicate no IL-1 activity in cellular fractions (Giri et al., 1985; Bayne et
al., 1986; Limjuco et al., 1986). It seems likely that ICE activity is an
important factor in these results as well as the use of ELISA to
measure IL-1 activity compared with the older lymphocyte proliferation
assays.
The functions of cAMP at regulating LPS induced IL-1 production have
been hypothesised in Figure 3.3.7. This is a schematic drawing of the
putative regulatory functions that cAMP exhibits against IL-1 synthesis
and release in monocyte/macrophage populations. From this diagram
it can be seen that, in general, increases in intracellular cAMP
augment IL-1 mRNA synthesis by LPS but inhibit the translation and
conversion/release of pre-IL-1 to its active 17.5 kDa form.
Interestingly, prolonged elevation of intracellular cAMP can induce IL-
ip synthesis in human monocytes (Serkkola et al., 1992).
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Figure3.3.7-Schematicillustrationsuggestingomofteffecin r s dtrac llular cAMPonEL-1synthesisa drelease
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Post-transcriptionally, however, the two isoforms of IL-1 differ, as do
the functions of cAMP on their LPS induced synthesis. In general, IL-ip
release is inhibited by increases in cAMP (Viherluoto et al., 1991;
Molnar-Kimber et al., 1993; Shapira et al., 1994; Verghese et al., 1995),
but this may simply reflect the number of publications as most
research has focused on IL-1 (3 over IL-1 a and earlier studies quoted
generic IL-1 as assay systems did not differentiate between the two
isoforms (Kunkel & Chensue, 1985; Brandwein, 1985; Knudsen et al.,
1986; Kassis et al., 1989). Translationally, few studies have been
carried, but it seems that IL-1 a and IL-ip synthesis are under tight
translational control as large increases in IL-1 mRNA do not produce
similar increases in preIL-1, or released active IL-1 (Sung et al., 1991).
This assay system did not seem suitable for our primary aim of
receptor classification. Since IL-1 release is complex involving
synthesis of a storage pool and release from that pool, it is difficult
with this ELISA assay to discriminate between effects to inhibit
synthesis or inhibit release. Additionally, a very small effect with LPS
was observed due to a consistently high basal values. An assay
measuring superoxide anion generation from human neutrophils was
already being used in our laboratory (Talpain et al., 1995), and it was
decided to investigate this system in the human monocyte.
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CHAPTER 3.4
Investigation of the EP-receptor mediating inhibition of
superoxide anion release in human monocytes
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3.4.1.- Introduction
Superoxide anion (02-) generation is an important defence
mechanism used by the monocyte. When monocytes are activated or
ingest a foreign particle it is one of the reactive oxygen metabolites
formed during the resulting respiratory burst and is generated in the
monocyte by NADPH oxidase. NADPH oxidase is a membrane-bound
flavoprotein which utilises NADPH as an electron donor and is helped
by cytochrome bsss- The reaction catalysed is:
402 + 2NADPH -» 402- + 2NADP+ + 2H+
202" + 2H+ H202 + 02
The NADPH is consumed to produce 02- and by a glutathione-
dependent H202 detoxifying system, is regenerated at the same time
from glucose through the hexose monophosphate shunt. This
reaction is characterised by the production of a large quantities of the
oxygen radical 02" and hydrogen peroxide (H202) (Baehner &
Johnston, 1971).
The products of the respiratory burst can react with endogenous
products of oxidation to form, with halide cofactors such as bromide
or chloride, highly toxic mediators, such as hydrobromous acid
(HBrO), hydrochlorous acid (HCIO) and other toxic products
(Klebanoff et al., 1980). These toxic reagents are able to kill parasites
and bacteria (Klebanoff et al., 1980), viruses (Belding et al., 1970),
mycoplasma (Jacobs et al., 1972), and fungi (Lehrer, 1969). These
metabolites can also destroy different kinds of human cells such as
tumour cells and mast cells. They can also damage surrounding
tissues (Spry & Tai, 1988) and act as proinflammatory agents
(Baggiolini, 1984; Halliwell et al., 1988). However, they have also been
shown to inactivate mediators of inflammation such as leukotrienes
(Henderson etal., 1982).
Macrophages are 'primed' for enhanced oxygen radical release by
macrophage activators like IFNy and LPS (Pabst & Johnston, 1980;
Nathan et al., 1983), which do not themselves cause release of oxygen
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radicals. Actual production of oxygen radicals by monocytes can be
'triggered' by phagocytosis, by contact with abnormal surfaces, or by
exposure to chemical stimuli like FMLP, TNF-a, IL-la, IL-ip and
opsonized zymosan. Superoxide anion generation can also be
stimulated in monocytes by direct PKC activation with PMA or PDBu.
The interaction between IFNy and LPS on release of oxygen radicals
by human monocytes cultured in vitro has been studied (Szefler et al,
1989). After 48 hr culture, the group found that monocytes released
low amounts of superoxide anion when stimulated by PMA or FMLP,
however, monocytes incubated with either IFNy or LPS became
"primed" and released greater amounts of superoxide anion in
response to PMA of FMLP. A similar observation was seen in a study
measuring the induction of superoxide production and PKC
activation in monocytes (Wolfson et al., 1993). Wolfson and colleagues
observed a strict correlation between superoxide production and PKC
activation by PMA but found no correlation with IFNy. However, pre-
treatment of the monocytes with IFNy for 10 to 15 hr enhanced both
superoxide production and PKC activation with PMA. Using protein
kinase inhibitors, they observed that while PMA exerted its effect by
activating PKC, IFNy operated via activation of a Ca2+/calmodulin-
dependent or some other Ca2+-dependent protein kinases. Priming
has also been demonstrated with GM-CSF, M-CSF, and IL-3 pre-
treatment for 10 min which primed human monocytes and enhanced
superoxide release stimulated by the receptor-mediated agonists,
FMLP and concanavalin A, but not by PMA (Yuo et al., 1992).
However, Yuo and co-workers found that pre-treatment of monocytes
with G-CSF, INFy, or IL-4 had no effect on superoxide release
stimulated by FMLP or concanavalin A. Thus, it would seem that
monocyte priming may depend on the conditions of culture and
length of exposure.
Human monocytes have been shown to contain the PDE IV isozyme
with a Km of 1.3 pM for cAMP and no cGMP hydrolytic activity
(Thompson et al., 1976; Elliott et al., 1989). The involvement of cAMP
in the reduction of superoxide anion generation is still unclear. It has
been reported that sustained increases in intracellular cAMP induced
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by PGEi, IBMX, or dibutyryl cAMP inhibited FMLP-induced
stimulation of superoxide (Smolen et al., 1980). Interestingly, Elliott
and co-workers measured the cellular content of cyclic AMP in
monocytes treated with FMLP and adenosine, either singly or in
combination (Elliott et al., 1986). They found that FMLP induced a
sustained increase in cellular cAMP compared with adenosine. The
group suggested that the rise in cAMP produced by FMLP was via
inhibition of PDE because the addition of FMLP to monocytes in the
presence of adenosine caused a rise in cAMP that exceeded by a
factor of two the sum of the increase seen with each agent alone.
This, they argue, would not be expected if FMLP activated AC. It has
also been shown in neutrophils that the FMLP induced rise in cAMP
was not accompanied by an increase in the AC activity of neutrophil
membranes (Verghese et al., 1985). However, Elliott and co-workers
showed that the increase in cAMP generated by FMLP was
dramatically potentiated by the PDE inhibitor, rolipram, suggesting
that PDE inhibition was not the mechanism by which FMLP induced
a rise in cAMP (Elliott et al., 1986).
Other groups have also investigated this phenomenon. One team
showed that addition of the chemotactic peptide, FMLP, to a
suspension of human monocytes caused a burst of superoxide
release associated with a rise in intracellular cAMP, which occured
within the first min of the burst (Leonard et al., 1987). They also
found that theophylline, a methylxanthine-derived PDE inhibitor, was
a potent inhibitor of superoxide generation in monocytes. However,
the rises in cAMP induced by theophylline or adenosine, which also
inhibited superoxide generation, were small compared with that
produced by the non-methylxanthine, PDE IV specific inhibitor,
rolipram, which itself produced only a small inhibition of superoxide
production.
In 1989, Elliott and co-workers looked more closely at the activity of
the PDE IV isozyme and its relationship to the inhibition of
superoxide anion generation (Elliott et al., 1989). The action of
oxidative burst inhibitors did not correlate with cAMP levels:
rolipram, a PDE IV inhibitor, increased cAMP six-fold, with minimal
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effects on superoxide generation, whereas theophylline increased
cAMP less than two-fold but inhibited the oxidative burst by greater
than 50%. Although theophylline and the AC activator, adenosine,
inhibited FMLP-induced superoxide release, they did not inhibit
production of inositol phosphates which suggests that their inhibitory
activity is via the cAMP pathway.
To date, the cause of the increase in cell cAMP seen with FMLP has
not been fully established. The relationship between cAMP production
and inhibition of superoxide anion generation is still tenable, as all
inhibitory compounds produce increases in intracellular cAMP.
However, the exact relationship remains unclear, because the
amount of intracellular cAMP generated, and the amount of inhibition
observed do not correlate.
Pulmonary surfactant is known to have an inhibitory effect on the
functions of monocytes. Geertsma and co-workers, examined its
effect on human monocyte, and concluded that two protein kinases
play a role in the regulation of the bactericidal functions of these
cells. cAMP-dependent PKA is involved in inhibition, and
Ca2+/phospholipid-dependent PKC is involved in stimulation of these
functions (Geertsma et al, 1994). The significance of increased
activation of PKA was demonstrated by the findings that surfactant
induced a sustained rise in the intracellular cAMP concentration in
monocytes, and that dibutyryl-cAMP mimicked the inhibitory effects
of surfactant on both the killing capacity and the production of
reactive oxygen intermediates by monocytes. Furthermore H-89, an
inhibitor of PKA, partially restored the impaired bactericidal functions
of monocytes incubated with surfactant. The same group also
demonstrated the involvement of decreased activation of PKC in
human monocytes treated with pulmonary surfactant. The group
found that surfactant attenuated the PMA-mediated translocation of
PKC, and that surfactant inhibited the production of superoxide by
monocytes upon stimulation with PMA. Therefore, surfactant-induced
inhibition of monocytes involves both activation of an inhibitory
pathway, which includes cAMP and PKA, and inactivation of a
stimulatory pathway, in which PKC is involved. PKA activation and
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PKC inhibition, they suggest, may be mediated via a common
pathway.
Li and Cathcart have studied the ability of human monocytes to
oxidise native LDL and transform it to a cytotoxin (Li & Cathcart,
1994). They found that there was substantial protein phosphorylation
induced upon monocyte activation. Pharmacological inhibition of PKC
activity with the PKC inhibitors H-7, calphostin C, and GF109203X
caused a concentration-dependent inhibition of cellular protein
phosphorylation, including that of several previously identified PKC
substrates. These inhibitors of PKC activity also substantially
inhibited LDL lipid oxidation by activated monocytes which correlated
very well with a profound suppression of superoxide anion production
by these cells. Therefore it is possible that some of the potent
substances which inhibit superoxide anion generation as described
previously (Leonard et ah, 1987; Elliott et ah, 1986; Elliott et al.,
1989) may also act by inhibiting the activation of PKC.
The inhibitory effect observed on human monocytes by pulmonary
surfactant (Geertsma et al., 1994) is also present in other biological
media. Skibinski and co-workers studied the effect of prostasomes,
multilamellar vesicles produced by the acinar cells of the human
prostate, on human polymorphonuclear cell and monocyte function
(Skibinski et al., 1992). They found that interaction of prostasomes
with neutrophils and monocytes effectively inhibited superoxide
anion generation in response to activation by PMA and FMLP. This
interesting observation indicates that prostasomes, via inhibition of
lymphocytes, may help prolong the life of sperm cells and enhance
the chance of conception.
Monocyte viability in vivo is very important in the body, especially
when there is exposure to external opportunistic infections. It is
interesting to note how many biological systems exert inhibitory
effects on mononuclear cells. A study found that VIP inhibited
superoxide generation from FMLP-stimulated neutrophils,
mononuclear cells and U937 cells in a concentration-dependent
manner (Ishizuka etal., 1992).
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When working with monocytes in vitro, the effects of culture must
also be considered. It has been described previously that monocytes
cultured for 48 hr release low amounts of superoxide anion when
stimulated with either PMA or FMLP and required stimulation with a
'priming' agent to elicit a greater response (Szefler et ah, 1989).
A group studying freshly isolated human monocytes found these were
spontaneously cytotoxic towards K562 tumour cells (Martin &
Edwards, 1993). They also found that superoxide radical production
in response to either FMLP or PMA remained fairly constant for the
first few days in vitro and then declined. NO2" concentration, however,
in monocyte-conditioned medium was fairly constant during the first
few days in vitro and increased after 6 days. They showed that this
return to tumoricidal competence after 3 to 4 days in culture was
decreased by the addition of L-NMMA. These results indicate that
reactive oxygen intermediates are employed by monocytes in the
killing of tumour cells and, after in vitro maturation of monocytes to
macrophages, this mechanism becomes less important and reactive
nitrogen intermediates are employed in mediating macrophage
cytotoxicity.
Pabst and co-workers found that monocytes cultured in endotoxin-
free medium M199 with or without 5% heat-inactivated autologous
serum gradually lost their ability to produce superoxide anion in
response to PMA over the course of 4 days (Pabst et ah, 1982), and
that this diminished responsiveness to PMA was accompanied by
decreased adherence and viability. The group found it was possible to
prevent the loss of function, adherence, and viability by
supplementing the culture medium with either bacterial LPS or
muramyl dipeptide. They also found that the oxidative burst of
monocytes cultured for several days without bacterial products could
be partially restored by the addition of LPS on day 2 or 3 of culture.
As described above and by Bennett & Cohen, 1965, it is likely that
the adherent monocytes used in these experiments are activated and
have undergone some maturation to macrophages. They are likely
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then to be 'primed' and will therefore elicit a larger superoxide anion
generation in response to stimuli than quiescent monocytes in
circulation.
As mentioned previously, phorbol esters and FMLP can stimulate
superoxide anion generation in monocytes (Szefler et at, 1989; Yuo et
at, 1992; Wolfson et al., 1993). There has been no previous work
looking specifically at the EP-receptor mediating inhibition of
superoxide anion generation in monocytes, although it has been
shown that PGEi, PGE2, PDE inhibitors and cAMP mimetics all
inhibit FMLP-induced superoxide anion generation (Smolen et al.,
1980; Leonard et al., 1987; Elliott et al., 1989).
The aims of this chapter were, to measure the ability of PGE2 and EP-
receptor agonists to inhibit superoxide anion generation in human
monocytes stimulated with phorbol esters or FMLP. We have also
attempted to characterise which EP-receptor subtype(s) mediates
inhibition of superoxide anion generation. Finally, the hypothesis that
cAMP was the second messenger mediating the inhibitory effects of




Monocytes were obtained as described in the Chapter 3.2 methods,
the only difference being that 24-well plates were used instead of 12-
well plates
Measurement of superoxide anion generation
1- HBSS (900 pi) containing cytochrome C (2.5 mg/ml) containing
indomethacin 5 pM was added directly to each well immediately after
washing, and left to equilibrate for 10 min at 37°C.
2- Drug dilutions were all made up in HBSS with Ca2+ and Mg2+ and
added in 100 pi aliquots to each well, and plates were incubated for 5
min. If antagonist studies were being carried out, these were added
10 min prior to the drug addition to allow the antagonist time to
equilibrate. Blank wells with 100 pi of HBSS were always run in each
assay, and in initial studies, superoxide dismutase (SOD) 90 U/ml
blanks were also used.
3- Stimulant was then added to each well, and the plates left to
incubate for 1 hr.
4- The reaction was stopped by aliquoting the medium to tubes on ice
and leaving for 5 min. Tubes were then centrifuged for 10 min at
320g at 4°C.
5- After centrifugation, 200 pi aliquots of supernatants was
dispensed into a 96-well plate, and the absorbance measured at 550
nm. The basal absorbance was taken as the average values from the
blank wells. All experimental conditions were carried out in duplicate
and all samples were assayed in duplicate. These were averaged to
give a mean superoxide anion production from each experiment
giving one n-value.
It has been reported that colchicine and other microtubule-disrupting
agents stimulate IL-la and IL-1(3 synthesis in human monocytes
(Manie et al, 1993). It is therefore likely that cytochalasin B, another
microtubule disrupting agent used extensively in neutrophil
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superoxide assays will do the same, and because of this cytochalasin
B was not used in these experiments.
Statistical analysis
The Paired Student's t-test was used to measure the statistical
difference between two points at a single drug dilution as this was
analysing the effect of a drug on one/variable. ANOVA was carried out
on the concentration-response curve data for antagonist studies.
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3.4.3.- Results
Superoxide anion generation can be stimulated by many compounds
e.g. chemotactic peptides, zymosans and phorbol esters. Initially
experiments were run using phorbol 12,13-dibutyrate.
Phorbol ester stimulated superoxide anion generation
Phorbol 12,13-dibutyrate (PDBu) stimulated superoxide generation of
human monocytes in a concentration-dependent manner (EC50 = 33 ±
6 nM; maximum increase of 120 ± 10 nmol O2"/ 106 cells/ hr), Figure
3.4.1. From this curve it can be seen that 30 nM is a sub-maximal
concentration and in further studies this was the concentration used.
Five min pre-incubation with PGE2, the standard agonist, had no
significant inhibitory effect on superoxide anion generation induced by
PDBu, producing a maximum inhibition of about 9%, Figure 3.4.2a.
Nocloprost, however, produced slight inhibition of PDBu activated
superoxide release, 1 pM nocloprost caused a significant inhibition of
24 ± 7%, p<0.05 Paired Student t-test, Figure 3.4.2a. Butaprost, like
PGE2, had no significant effect on superoxide anion generation by
human monocytes, Figure 3.4.2b.
FMLP stimulated superoxide anion generation
FMLP induced a concentration-dependent increase in superoxide anion
generation (EC50 = 126 ± 110 nM; maximum increase of 90 ± 10 nmol
O2-/IO& cells/hr), Figure 3.4.1. From this curve 1 pM was selected as
the stimulatory concentration and was used in all the subsequent
studies. In comparison with PDBu, FMLP produced a similar
concentration-response curve for superoxide anion generation.
Interestingly, both stimulants at 10 pM produced a decreased maximal
response, Figure 3.4.1.
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Figure 3.4.1.- Comparison of PDBu (•), n=7, and FMLP (■),n=4,
stimulated superoxide anion generation in human monocytes. PDBu
and FMLP generated maximum increases in superoxide anion
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Figure 3.4.2.- (a) Effect of PGE2 (•), n=7, and nocloprost (■), n=6, and
(b) PGE2 (•), n=7 and butaprost (■), n=6, on PDBu 30 nM induced
superoxide anion generation in human monocytes. Nocloprost 10 pM
induced a significant inhibition of 23 ± 7%.
*- p<0.05 compared to basal values, paired two-tailed Student f-test.
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Figure 3.4.3.- (a) Effect of PGE2 (•), n=5, 11-deoxy PGEi (■), n=4, and
16,16-dimethyl PGE2 (A), n=4, and (b) PGE2 (•), n=5, butaprost (■),
n=3, and AH 13205 (A), n=5, on FMLP 1 gM induced superoxide anion
generation in human monocytes.
*- p<0.05 compared to basal values for PGE2, 11-deoxy PGEi, 16,16
dimethyl PGE2 and AH 13205, paired two-tailed Student f-test.
f- p<0.05 compared to basal values for butaprost, paired one-tailed
Student f-test.
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PGE2, the standard agonist, concentration-dependently inhibited
superoxide anion generation induced by FMLP, Figure 3.4.3a, Table
3.4.1. 16,16 dimethyl PGE2 and 11-deoxy PGEi also concentration-
dependently inhibited superoxide anion release, Figure 3.4.3a, and all
agonists inhibited superoxide anion generation by greater than 75%.
Butaprost and AH 13205 concentration-dependently inhibited FMLP-
induced superoxide anion generation, but were not as potent as PGE2,
Figure 3.4.3b, Table 3.4.1. Interestingly, these compounds produced a
greater percentage inhibition of superoxide anion generation than
PGE2.
Nocloprost was examined in this preparation and generated an
unusual, but reproducible, inhibitory profile with a maximum
inhibition of only 50%, Figure 3.4.4a, Table 3.4.1. Misoprostol,
interestingly, inhibited superoxide anion generation with a lower EEC
than PGE2 of 0.3, Figure 3.4.4b, Table 3.4.1. and M&B 28767 induced
a concentration-dependent inhibition of superoxide anion generation
with a similar potency as PGE2, EEC = 1.5, Figure 3.4.5a, Table 3.4.1.
GR63799X had no effect in this preparation whereas PGF2a produced
inhibition of superoxide anion generation , maximum inhibition of 53 ±
27%, but only at 10 pM, Figure 3.4.5b.
The EP4-receptor antagonist AH23848B (10-100 pM) tended to
potentiate the inhibition of superoxide anion generation by PGE2,
Figure 3.4.6a 8s b, however, these effects were non-significant. No effect
was observed with AH23848B in the blank samples, or the FMLP
induced superoxide anion generation, data not shown, which shows
that AH23848B alone had no effect on the system. Interestingly, in
these studies PGE2 still generated a maximum inhibition of about 75%
inhibition of FMLP induced superoxide anion, even when potentiated
by AH23848B.
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Figure 3.4.4.- (a) Effect of PGE2 (#), n=5, and nocloprost (■), n=4, and
(b) PGE2 (•), n=5, and misoprostol (■), n=4, on FMLP 1 pM induced
superoxide anion generation in human monocytes.
*- p<0.05 compared to basal values nocloprost and misoprostol, paired
two-tailed Student f-test.
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Figure 3.4.5.- (a) Effect of PGE2 (•), n=5, and M&B 28767 (■), n=3,
and (b) of PGE2 (•), n=5, GR63799X (■), n=5, and PGF2a (A), n=4, on
FMLP 1 pM induced superoxide anion generation in human
monocytes.
*- p<0.05 compared to basal values for M&B 28767, paired two-tailed
Student t-test.
\n
0.01 0.10 1.00 10.00
PGE2 Concentration (pM)
0.01 0.10 1.00 10.00
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Figure 3.4.6.- Effect of the EP4-receptor antagonist AH23848B 10 |uM
(■), n=4, and (b) AH23848B 100 pM (■), n=4, on the PGE2 (•)
concentration- response curves in human monocytes. AH23848B,
alone, had no effect on the FMLP-induced 02~ generation, data not
shown.
p>0.05 with ANOVA for both graphs.
ll-X




pge2 0.56 ± 0.20 78.1 ± 7.4 1.0
16,16 dime pge2 0.25 ± 0.19 97.1 ± 2.2 0.5
11-deoxy pgei 0.56 ± 0.35 99.5 ± 0.4 1.1
nocloprost 1.7 ± 1.1 50.8 ± 11.0 2.9
butaprost 3.6 ± 1.9 98.8 ± 0.6 6.5
AH13205 2.8 ± 1.7 92.6 ± 24.3 5.0
misoprostol 0.14 ± 0.06 98.3 ± 1.1 0.3
M&B 28767 0.84 ± 0.49 98.6 ± 1.1 1.5
Table 3.4.1. - The ability of EP agonists (0.01-10 pM) to inhibit o2"
generation induced by FMLP (1 pM) (n>4).
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Second messenger studies
8-bromo cAMP (1 pM - 100 pM) produced no significant reduction in
superoxide anion generation after stimulation with FMLP, however, in
one experiment, Figure 3.4.7a, 100 pM caused a 44% reduction, Figure
3.4.7a-d.
Monocytes were preincubated for 5 min with IBMX before the addition
of FMLP, and IBMX produced very large decreases in the basal
absorbance as shown in Figure 3.4.8a-c, 2 out of 3 blank values are
decreased in the presence of IBMX (0.25 mM). Analysed separately
with the percentage inhibitions being relative to the individual curves,
i.e. results without IBMX taken relative to the FMLP control without
IBMX and results with IBMX expressed relative to the FMLP peak in
the presence of IBMX, a non-significant potentiation of the PGE2
inhibition can be seen. PGE2 (10 nM) inhibited the FMLP peak by 15 ±
24% which was increased to a 33 ± 8% reduction in the presence of
IBMX, Figure 3.4.9.
Rolipram (1 nM), a selective PDE IV isozyme inhibitor induced a
decrease in the basal absorbance values like IBMX, as illustrated in
the separate absorbance curves, Figure 3.4.10a-d. When each
absorbance curve is analysed separately, as for IBMX, rolipram tended
to potentiate the effects of PGE2, Figure 3.4.11. Analysis with ANOVA,
however, shows these effects to be non-significant, p>0.05.
SQ22536, an AC inhibitor, was studied in this preparation and
SQ22536 (100 pM) caused a marked drop in the absorbance levels as
seen for both IBMX and rolipram, Figure 3.4.12a-d. Analysed
separately these data shows SQ22536 to significantly potentiate the
effects of PGE2, p<0.05 with ANOVA, Figure 3.4.13.
A PKA inhibitor H-89 was also investigated and H-89 (10 pM) and
added 5 min before PGE2 produced a significant potentiation of the
response to PGE2 10 nM, p<0.05, and a significant inhibition of PGE2 1
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Figure 3.4.7a-d- Effect of 8-bromo cAMP (•) on FMLP 1 juM induced
superoxide anion generation in human monocytes. Each figure
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Figure 3.4.8a-c- Effect of PGE2 on FMLP-induced superoxide anion
generation in human monocytes in the absence (•) and presence (■) of




Figure 3.4.9.- Effect of PGE2 on FMLP-induced superoxide anion
generation in human monocytes in the absence (•) and presence (■) of
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Figure 3.4. lOa-d- Effect of PGE2 on FMLP-induced superoxide anion
generation in human monocytes in the absence (•) and presence (■) of




















Figure 3.4.11.- Effect of PGE2 on FMLP-induced superoxide anion
generation in human monocytes in the absence (•) and presence (■) of
rolipram (1 nM), n=4 (p>0.05 with ANOVA).
m
1 r i r
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Figure 3.4.12a-d- Effect of PGE2 on FMLP-induced superoxide anion
generation in human monocytes in the absence (•) and presence (■) of
SQ22536 (100 pM) expressed as raw absorbance (A550) data. Each
figure represents one experiment.
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Figure 3.4.13.- Effect of PGE2 on FMLP-induced superoxide anion
generation in human monocytes in the absence (•) and presence (■) of
SQ22536 (100 pM), n=4. SQ22536 significantly potentiated the effects
of PGE2, p<0.05 with ANOVA.
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Figure 3.4.14- Effect of PGE2 on FMLP-induced superoxide anion
generation in human monocytes in the absence (•) and presence (■) of
H-89 (10 pM), n=6.
*- p<0.05 compared to PGE2, paired Student two-tailed t-test.
f- p=0.05 compared to PGE2, paired Student one-tailed f-test.
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Comparison of SOD and Blank wells
The optical density readings were compared for the SOD 90 U/ml cells,
mean OD = 0.573 ± 0.022, against blank cells, mean OD = 0.584 ±
0.021, where equal volumes of HBSS were added instead of drugs. A
two-tailed paired Student f-test of the two samples produced a p<0.05
(n=28) against the Null hypothesis that the cells were different and
from these data it was decided to stop using SOD 90 U/ml as the total
blank and used an HBSS blank instead.
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3.4.4.- Discussion
The effects of PKC activators previously described as stimulants of
superoxide anion generation were studied (Szelfer et al., 1989; Yuo
et al., 1992; Wolfson et al., 1993). No EP-receptor agonists caused
any inhibition of PDBu stimulated superoxide anion generation, and
only nocloprost produced a reduction of 21%. Thus, activation of the
AC coupled EP-receptor present on human monocytes is insufficient
a stimulus to inhibit direct PKC activated superoxide anion
generation.
FMLP, whereas, produced concentration-dependent increases in
superoxide anion generation which could be inhibited with a range
of EP-receptor agonists. The finding that EP2 and EP4 receptor
agonists such as 11-deoxy PGEi and 16,16-dimethyl PGE2 (Milne et
al., 1995) and EP2 selective agonists, butaprost and AH13205 were
equipotent in this preparation suggests the involvement of EP2
rather than EP4-receptors. EEC values for these compounds at EP2
and EP4 containing preparations are shown in Table 3.4.2.
Misoprostol, an EP2- and EP3-receptor agonist also potently
inhibited superoxide anion generation, being more potent than PGE2
and M&B 28767, an EP3-selective agonist, induced complete
inhibition. These effects seen with M&B 28767 could be mediated
via activation of EP3 receptor splice variants but are more likely to
be cross-reactivity with the AC coupled EP receptors expressed in
the human monocyte as GR63799X, another selective EP3-receptor
agonist, produced no inhibition of superoxide anion generation.
PGF2a produced inhibition at its top concentration, but rather than
acting via inhibitory FP receptors this effect is again probably
mediated via cross-reactivity with the AC coupled EP-receptor in the
human monocyte.
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Analogue EP21 EP42 human
monocyte
11-deoxy PGEi 13 2.0-7.3 1.1
16,16 dime PGE2 9.4-20 2.8-7.3 0.5
butaprost 17 42-1200 6.5
AH 13205 29 1120-11,000 5.0
Table 3.4.2. - Comparison of EEC values for a range of EP-receptor
agonists at the EP2 and EP4 receptor, and in the human monocyte at
inhibiting superoxide anion generation, PGE2 = 1.0.
1 - cat trachea (Dong et al., 1986; Gardiner, 1986; Coleman et al.,
1988; Nials et al., 1993)
2 - PSV, RIT and cloned EP4 receptor (Chapter 2.2; Louttit et al.,
1992b; Coleman et al., 1994; Lydford & McKechnie, 1994; Nishigaki
et al., 1995)
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The EP4 receptor antagonist AH23848B was found to potentiate
rather than block, inhibition of superoxide observed with PGE2. This
was an unusual observation and suggests that AH23848B has other
activities along with its known TP and EP4 receptor antagonism.
Interestingly, AH23848B also potentiates inhibition of superoxide
anion release with both PGE2 and the non-prostanoid, 5'-N-
ethylcarboxamido-adenosine in human neutrophils (Talpain et al.,
1995) as well as ECP release in a mixed polymorphonuclear cell
population (E. M. Milne, personal communication). AH23848B has
also been found to potentiate prostanoid-mediated responses in T-
lymphocytes (D. F. Woodward, personal communication). AH23848B
has also been demonstrated to be a partial agonist at the TP
receptor (Brittain et al., 1985; Lumley et al., 1986) and may be,
somehow, potentiating the effect of PGE2. To ascertain if this effect
is mediated by TP receptor activation, agonists, such as U-46619,
need to be examined in this preparation.
As mentioned, the EP agonist data obtained in the cAMP studies on
human monocytes do not correlate with the physiological effects
observed in vitro. cAMP measurements suggested the involvement of
the EP4 receptor, whereas physiological inhibition of FMLP stimulated
superoxide anion generation appears to be mediated via the EP2
receptor. Misoprostol, for example, was shown to generate no cAMP in
the monocyte, Figure 3.2.5a, and yet produced greater physiological
inhibition of FMLP-mediated superoxide anion generation than PGE2,
Figure 3.4.4b, Table 3.4.1.
It is likely that the human monocytes contain a population of EP2
receptors which mediate inhibition of FMLP-induced superoxide
anion generation, and a population of EP4 receptors positively
coupled to AC which may or may not inhibit superoxide anion
generation. Experiments using compounds which directly affect
second messenger systems were carried out to try and clarify these
conflicting data.
8-bromo cAMP is a cAMP mimetic, and was used to see if it could
mimic the inhibition of superoxide anion generation observed with AC
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activating agonists. No inhibition was observed on average but, when
the experiments were examined separately, Figure 3.4.7a-d, it can be
seen that 8-bromo cAMP 100 gM partially inhibited the FMLP-induced
superoxide anion generation in one experiment only. Other
investigators have looked at 8-bromo cAMP in the human monocyte
and found it mimics the effect of other cAMP elevating agents (Sung et
al., 1991; Takii et al., 1992) but does not induce complete inhibition.
Interestingly, 8-bromo cAMP was inactive in the human neutrophils,
whereas another cAMP mimetic, dibutyryl cAMP, was active and
mimicked the effects of cAMP elevation (Dr. R. A. Armstrong, personal
communication).
IBMX, a non-selective PDE isozyme inhibitor, was examined to look at
the effect of PDE inhibition in the human monocyte. IBMX
considerably reduced the absorbance in each experiment but did not
affect the FMLP-induced superoxide anion generation, Figure 3.4.8a-c.
When the absorbance data are analysed separately and pooled, Figure
4.3.9, IBMX potentiated the PGE2 10 nM induced inhibition of
superoxide anion generation suggesting some role for cAMP.
Rolipram, a selective PDE IV isozyme inhibitor, was investigated in this
preparation as monocytes have been shown to express the PDE IV
isozyme (Thompson et al., 1976; Elliott et al., 1989; Verghese et al.,
1995). Similarly to IBMX, rolipram caused a marked reduction in the
baseline absorbance without affecting the increase in absorbance
induced by FMLP, Figure 3.4.10a-d & 11. This was not due to any
affect on the viability of the cells. Molnar-Kimber and co-workers
(1993) measured the effects of selective PDE isozyme inhibitors on
monocyte viability. They used vinpocetine (PDE-I), CI-930 and
milrinone (PDE-III), rolipram and nitraquazone (PDE-IV) and
zaprinast (PDE-V) and found that none of the inhibitors affected
monocyte viability at 10 gM or lower concentrations. Taken together,
however, rolipram did not significantly affect the PGE2 inhibition of
FMLP-induced superoxide anion generation, Figure 3.4.11. Overall, the
results with the PDE inhibitors suggest only a minimal role for cAMP in
the inhibition of superoxide anion generation by PGE2.
187
The large decreases in baseline absorbance measured with IBMX and
rolipram are unusual and it could be that the PDE inhibitors generate
a physiological antagonism against an unknown endogenous stimulus
in this system. However, SOD, which removes all endogenous
superoxide anion, produced a similar absorbance to the blank wells
and suggests that the monocytes are not already generating superoxide
anion. Another possibility is that these compounds are affecting the
redox potential of the cytochrome c since the decrease is observed in
all samples. If these compounds are affecting the redox status of
cytochrome c then the results are only valid as long as FMLP generates
the same increase in absorbance, which has been shown to be the
case.
It has already been demonstrated that PGE2 elevates the levels of
cAMP in macrophages derived from granuloma and that SQ22536, an
AC inhibitor, markedly diminishes this rise in cAMP (Bonta et al,
1981). In this study SQ22536 100 gM caused a marked drop in the
absorbance levels similar to IBMX and rolipram, Figure 3.4.25a-d,
however, analysed separately these data show a significant
potentiation of the PGE2 concentration-effect curve, Figure 3.4.13. If
PGE2 was causing inhibition of FMLP-induced superoxide anion
generation via activation of AC then SQ22536 should have inhibited,
rather than potentiated, the effects of PGE2. PGE2 may instead be
inducing activation of a negative pathway of inhibition via an
alternative route involving PKA activation at the same time as
stimulating AC activity. This PKA linked pathway may then be
potentiated in some way by SQ22536 leading to a physiological
potentiation of PGE2 mediated inhibition.
The PKA inhibitor H-89 was examined in this preparation to try and
address the unusual result observed with SQ22536. H-89 10 gM
significantly potentiated the inhibitory effect of PGE2 10 nM. In
contrast, H-89 significantly reduced the inhibition observed with PGE2
1 gM. Therefore, PGE2 may be mediating some of its inhibitory actions
via PKA activation which could explain the lack of inhibition with
SQ22536, but does not explain the potentiation seen with this
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compound. However, these data are difficult to interpret and further
studies are required with other PKA inhibitors.
In conclusion, it seems likely that both EP2 and EP4 receptors are
present on the human peripheral blood monocyte and although the
EP4 receptors are positively coupled to AC, it is mainly EP2 receptors
which mediate inhibition of FMLP induced superoxide anion
generation. The exact nature of the second messenger system which
mediates PGE2-induced inhibition of FMLP induced superoxide anion
generation in the human monocyte needs further investigation to fully
explain the results observed above.
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3.5- Conclusion
The human monocyte has been shown to express the EP4 receptor
positively coupled to AC, whereas, PGE2, and other EP-receptor
agonists mediate inhibition of FMLP-induced superoxide anion
generation via EP2 receptors. No correlation was observed between
cAMP generation and inhibition of physiological functions with EP2
agonists such as butaprost, AH 13205 and misoprostol producing no
significant cAMP generation but inhibiting FMLP-induced superoxide
anion release with a similar potency than PGE2, Table 3.5.1.
Second messenger studies in the human monocyte indicated that
PGE2 was mediating the inhibition of superoxide anion generation by
routes other than AC activation. Interestingly, it has been shown that
FMLP activation ofmonocytes is accompanied by a rise in intracellular
cAMP (Elliott et al., 1986; Leonard et al., 1987). If AC activation is
involved in FMLP-induced superoxide anion generation, it could be
that a component of PGE2-induced inhibition might be via AC
desensitisation.
The inhibitory effects of pulmonary surfactant have been
demonstrated to be mediated both by activation of an inhibitory
pathway involving cAMP and PKA, and inhibition of an activatory
pathway involving PKC (Geertsma et al., 1994). It could be that PGE2
and other EP-agonists are acting in the same way which would help
explain the lack of correlation with the cAMP data but not the results
seen in the second messenger studies.
Another possible explanation for the results seen in the second
messenger studies could depend on the activity of PGE2, rather than
the second messenger system. Only PGE2 was used in the studies
because it was the standard agonist but it may have been acting via
other EP-receptors present in the human monocyte such as the EP3
receptor. It has been observed in these studies that PGE2, and
nocloprost, induced inhibition of FMLP-induced superoxide anion
generation but did not reach 100%. It could be that there is a
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Table 3.5.1. - Comparison of EEC values for a range of EP-receptor
agonists at increasing intracellular cAMP levels and at inhibiting
FMLP-induced superoxide anion generation in the human monocyte,
PGE2 = 1.0.
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blocks physiologically the inhibition by PGE2. However, evidence
against this theory is that other broad spectrum agonists like 16,16
dimethyl PGE2 inhibited completely FMLP activity. Further studies
using AC activating agents to increase cAMP before the addition of EP-
agonists are required to ascertain whether EP3 receptors are also
expressed in human monocytes.
In conclusion, the human monocyte contains a population of AC
coupled EP receptors of the EP4 receptor subtype and a population of
EP2 receptors mediating inhibition of FMLP-induced superoxide anion
by a non-cAMP pathway. Further work with second messenger
systems is required to fully elucidate the actions of PGE2 on the
human monocyte. Molecular biological techniques may also help
elucidate the EP receptors endogenously expressed in the human
monocyte. However, this suggests that there may be little scope to
develop a monocyte-selective EP agonist since full inhibition requires






The aims of this thesis were to investigate further the EP receptor
subtype(s) present in the native CHO cell, RJV and PSV and, using the
information obtained in these preparations, attempt to characterise
which EP receptor subtype(s) were present in the human monocyte.
The EP receptor subtype(s) present on the human monocyte were also
studied to see if there was a functional inhibitory role which could be
a target for drug development.
The results of these experiments indicate that the CHO and human
monocyte both express EP4 receptors positively coupled to AC. These
are novel findings and indicate that the EP4 receptor does couple to
AC and increase intracellular cAMP.
The RJV was initially classified as an atypical EP2 receptor containing
preparation because of the inactivity of the selective EP2 receptor
agonist butaprost (Lawrence & Jones, 1992). Our studies confirm the
inactivity of butaprost in this preparation as well as the inactivity of
another EP2 selective agonist AH 13205. Unfortunately, however, no
antagonism with AH23848B, an EP4 receptor antagonist (Louttit et ah,
1992a), was observed. Comparison of the agonist potency profiles of
the RJV with other EP4 receptor containing preparations, Table 2.3.1.
show similar profiles of PGE2 > 11-deoxy PGEi = 15,16 dimethyl PGE2
> butaprost >> AH 13205, and from this it could be suggested that the
RJV is actually an atypical EP4 preparation showing no antagonist
activity with AH23848B. Further work with other published EP4
receptor antagonists (Coleman et al, 1994) may explain these results.
Interestingly, when the data obtained in the native CHO cell, RJV and
PSV is compared with the EP2 and EP4 cloned receptors, and other
EP2 or EP4 receptor containing preparations, is seems that
endogenously the EP2 and EP4 receptors might be co-expressed. If this
is correct then many published observations can be explained such as
the potency of butaprost in the PSV but complete inability of
butaprost to displace bound [3H]PGE2 from the cloned EP4 receptor.
As well as this, the observations that butaprost and AH 13205 can act
as antagonists in EP4 receptor containing preparations may be
explained by receptor co-expression. Our findings in the human
monocyte suggest that both EP2 and EP4 receptors are expressed.
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Interestingly, it seems that only EP4 receptors are involved in cAMP
generation by EP agonists whereas EP2 receptors are mainly involved
in mediating inhibition of FMLP-induced superoxide anion generation.
Studies with human monocytes, as described above, show these cells
express the EP4 receptor positively coupled to AC. Physiological
investigations, however, indicate that the cells express the EP2
receptor and the antagonist AH23848B potentiated the inhibitory
effects of PGE2, Chapter 3.4. Studies were carried out to investigate if
cAMP was the second messenger mediating the inhibitory effects of
PGE2. The results were conflicting, and suggested that PGE2 induced
effects in the human monocyte other than EP receptor-mediated AC
activation. It was observed that SQ22536, an AC inhibitor, potentiated
the effects of PGE2 and H-89, a PKA inhibitor mediated both
stimulatory and inhibitory activity with PGE2. From these results, and
the observation that PGE2 did not induce complete inhibition
compared with other broad spectrum EP-agonists, it is likely that
PGE2 activates many second messenger systems in the human
monocyte. Further work is required with other EP-agonists and
modulators of second messenger pathways to elucidate the actions of
PGE2.
We have purified mRNA from human monocytes and sent the samples
to Prof. John Regan in Arizona, USA, to investigate which EP-receptor
subtypes were expressed in these cells using molecular biological
techniques, see Appendix I. Unfortunately, Prof. John Regan and his
team have been too busy to process our samples and we are currently
attempting to set up these experiments in our own laboratories. It is
hoped that these studies will confirm our findings and indicate which
EP-receptor subtype(s) are being expressed by the human monocyte.
Currently it is difficult to clearly indicate which systems are involved
as most of the compounds used have activity at many EP-receptor
subtypes and molecular biology may provide a valuable approach to
support pharmacological experiments.
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In conclusion, this work has demonstrated a role for PGE2 and other
EP-receptor agonists at inhibiting physiological functions of the
human monocyte. The development of more selective agonists at
prostanoid receptors may lead to the discovery of drugs which can aid
in the treatment of inflammatory diseases.
This work highlights the limitations of the selective agonists at our
disposal. Even with more selective agonists, previous data suggest
that functional inhibition of the human monocyte is mediated by the
same receptor subtype as for neutrophils and eosinophils.
Unfortunately, these findings are not encouraging since the presence
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DEPC-H2O- diethyl pyrocarbonate (DEPC) 0.1% v/v is added to
distilled water and left overnight at 4°C. The treated water was then
autoclaved twice to break down any remaining DEPC.
0.3 M sodium acetate buffer pH 6.0- made up in DEPC-H2O
3 M sodium acetate buffer pH 6.0- made up in DEPC-H2O
GIT buffer- 94.53g guanidine isothiocyanate (GIT) (4M final), 1.67 ml
3M sodium acetate buffer pH 6.0, DEPC-H2O to 200 ml and 1.67 ml
2-mercaptoethanol
CsCl buffer- 95.97g CsCl (5.7 M final), 0.83 ml 3 M sodium acetate




1- 3 ml CsCl buffer was added to 6 tubes and -7.5 ml of the GIT
samples layered on top. The tubes were then centrifuged at 32,000
rpm for 18 hr at 20°C.
2- The supernatant was aspirated off to within 1 ml and the tube
tipped horizontally to remove the remaining buffer. The pellet was
then resuspended in 200 pi DEPC-H2O by repeated pipetting before
transferring to a 1.5 ml microfuge tube. 20 pi of 3M sodium acetate
buffer was added and 440 pi 100% ethanol and the tubes left at -
20°C for at least 30 min to precipitate the RNA.
3- Eppendorfs were centrifuged at 12,000 g for 10 min at 4°C. The
supernatant discarded and 1 ml ethanol 80% added. The tubes were
centrifuged again, as above, and the supernatant again discarded.
The pellets were then dried at 37°C for 1-2 hr.
4- The pellets were resuspended in 100 pi DEPC-H2O and 5 pi placed
in 500 pi of H2O for measurement. The samples can then be stored at
-80°C under 3 volumes of absolute ethanol.
5- To measure the amount of RNA obtained the OD of the 500 pi
sample was measured at 260 and 280 nm (pure RNA has a ratio of




Total RNA was extracted from two donors as described above. This
was counted and a value of 0.023 was obtained for OD260 and 0.014
for OD280.
This gives a ratio of 1.64 which implies some protein contamination
of the RNA. This is likely caused at the initial stage when all the CsCl
and GIT buffer must be adequately removed.
The OD260 value of 0.023 for the 5 pi sample diluted to 500 pi water
means that there was 0.92 pg/ml, or 0.46 pg total in the 5 pi aliquot.




Comparison of the EP Receptor Subtypes
Mediating Relaxation of the Rabbit
Jugular and Pig Saphenous Veins
Stuart A. Milne,* Roma A. Armstrong,* and
David F. Woodwardf
'Department of Pharmacology, University of Edinburgh, Edinburgh,
Scotland; tAllergan Inc., Irvine, California, USA.
A fourth PGE receptor subtype, the EP4 receptor, has recently been de¬
scribed in the pig saphenous vein (PSV). Similar to the EP2 receptor, it
mediates relaxation and is linked to stimulation of adenylate cyclase.
The aim of this study was to determine whether or not the EP recep¬
tor present in the rabbit jugular vein (RJV), currently classified as an
atypical EP2 receptor, is of the EP4 subtype. The relaxant activities of
four EP2 agonists, 11-deoxy PGE1, 16,16-dimethyl PGE2, butaprost,
and AH 13205, on the RfV and PSV have been examined, and the ef¬
fect of the EP4 receptor antagonist AH 23,848B studied. The EP2 ago¬
nists showed a similar order of potency on the two preparations. 11-
Deoxy PGE: and 16,16-dimethyl PGE2 were potent agonists on the EP4
receptors of the PSV and on the RfV giving approximately equi-effec-
tive concentration ratios (EECs) of 2.0-6.6 and 2.8-9.9, respectively,
compared to PGE2 (EEC = 1), and so do not discriminate between EP2
and EP4 receptors. Butaprost was less active on these preparations
(EEC 42—43) than on classical EP2 receptors, and AH 13205 was much
less active (EEC 3100-2780). While these results suggest that the EP
receptors on the RfV are of the EP4 subtype, this was not confirmed
using the EP4 receptors antagonist AH 23,848B.
Keywords: receptor; rabbit jugular vein; pig saphenous vein; relaxation
Introduction
It is proposed that the naturally occurring prostanoids PGD2/ PGE2,
PGF2a, PGI2, and TXA2 act on distinct receptor sites termed DP, EP, FP,
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IP, and TP receptors, to elicit a variety of biological responses. Such
receptors were originally classified pharmacologically on smooth muscle
preparations1 using a wide range of selective agonists and, where possible,
receptor antagonists. They have subsequently been cloned2-5 and are rho-
dopsin-type receptors6 with seven putative transmembrane domains,
consistent with being G-protein-linked. In addition, the EP-receptor is
further classified into four receptor subtypes, EP^ EP2, EP3, and EP4.
Typically, EP! receptors mediate contraction (e.g., guinea-pig gastric fun¬
dus) and EP2 receptors mediate relaxation of smooth muscle (e.g., rabbit
ear artery, cat trachea), via activation of phospholipase C and adenylate
cyclase, respectively. EP3 receptor activation is more varied and includes
inhibition of neuronally mediated contractions (e.g., guinea-pig vas def¬
erens), potentiation of platelet aggregation, inhibition of gastric acid se¬
cretion, and contraction of some smooth muscle preparations (e.g., chick
ileum), linked either to activation of phospholipase C or inhibition of
adenylate cyclase. Identification of the most recently described subtype,
the EP4 receptor,7 was based mainly on the use of the novel antagonist
AH 23,848 (originally synthesised as a TP receptor antagonist), and ana¬
lyzed using the pig saphenous vein (PSV) where PGE2 was relaxant. Each
of these receptor subtypes has now been cloned.8-13
The rabbit jugular vein (RJV) relaxes in response to PGE2 and is cur¬
rently classified as an atypical EP2 preparation, based on the low activity
of the EP2 agonist butaprost.14 The demonstration that another moder¬
ately potent and highly selective EP2 agonist, AH 13205,15 was only
weakly active at EP4 receptors of the PSV7 led us to investigate further the
nature of the EP receptor subtype(s) of the RJV.
The aim of this study was to compare relaxation *of the isolated RJV
and PSV by a range of EP agonists, 16,16-dimethyl PGE2,14 nocloprost,16
11-deoxy PGEl,17 butaprost,18 and AH 13205.15 Possible antagonism by
AH 23,848, AH 6809,19 and BWA 868C20 has also been investigated.
Materials and Methods
Smooth Muscle Preparations
Rabbit Jugular Vein (RJV). Male New Zealand white rabbits (2-3 kg)
were anesthetised with 30 mg/kg Sagatal (pentobarbitone) injected into a
marginal ear vein. The external jugular veins were exposed, tied proxi-
mally to allow the vessels to fill before being tied distally, and the inflated
sections (2—3 cm) removed, cleared of fat, and cut into rings 3-5 mm
wide. Each ring was suspended in an overflow organ bath between two
silver alloy hooks at 0.75-1.25 g tension and washed with Krebs' solution
(composition, mM: NaCl 118, KCl 5.4, CaCl2 2.5, MgSQ4 1.0, NaH2P04
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1.1, NaHC03 25, glucose 10) containing 1 [xM indomethacin, bubbled
with 02/C02 (95/5 v/v) and maintained at 37°C. Changes in tension were
measured using Grass FT03 isometric transducers connected to a Maclab
data acquisition system using Maclab v3.3 software.
After equilibration of the tissues for 1 h, the maximum contraction to
10 p.M histamine was measured, and a concentration was selected, usu¬
ally 2 p.M (range 1—5 jxM), that produced 60-80% of the maximum con¬
traction. When a contraction had plateaued, cumulative doses of a PG
analog were added to the organ bath, and each resulting relaxation was
allowed to flatten before the next dose. All relaxant prostanoids were
tested in the presence of GR 32191, 10 |xM, to block any contractile
action at TP receptors.21
Concentration-response curves for PGE2 were carried out at the start
and finish of each experiment. PGE2 was used as the control in all exper¬
iments and complete relaxation of the precontracted tissues by PGE2 was
taken as the maximal relaxation (100%). All subsequent results were
expressed as percentages of the PGE2 maximum. Log concentration-
response curves were plotted and the IC50 values determined using Ka-
leidagraph software. Each mean equi-effective concentration ratio (EEC)
was calculated as the IC50 for the EP agonist/the IC50 for PGE2.
Pig Saphenous Vein (PSV). External saphenous veins were removed
from freshly culled Chinese Meishan pigs and set up as for the RJV,
except that tissues were set at an initial tension of 2-3 g, phenylephrine
(PE) was used as the contactile agent, and adenosine deaminase (1 U/mL)
was added to limit fade. An initial concentration of 10 pM PE was used
to determine the maximal contraction,- subsequent concentrations which
gave 60-80% of the maximum were 0.5—1 p.M.
Statistical tests. Results are given as the mean ± SEM. Student's paired
or unpaired 2-tailed £-tests were used for comparison of IC50 data.
Compounds. The following compounds were gifts which we gratefully
acknowledge: nocloprost from Dr. E. Schillinger, Schering AG, Berlin;
butaprost from Dr. P. Gardiner, Bayer, U.K.; AH 13205, AH 6809 and AH
23,848B from Dr. B. Bain, Glaxo, U.K.; BW A868C and L-NMMA from Dr.
B. Whittle, Wellcome, U.K. PGE2 and indomethacin were purchased from
Sigma; 11-deoxy PGEt and 16,16-dimethyl PGE2 were purchased from
Cayman Chemicals.
Ethanolic stock solutions of the prostanoids (10-30 mM) were stored at
— 20°C and diluted with 154 mM NaCl for use. AH 23,848 B (1 mM) was
made up daily by sonication in phosphate buffered saline (PBS, pH 7.15,
Sigma).
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Results
Rabbit Jugular Vein: Effect of Selective Antagonists
PGE2 could relax the precontracted jugular vein completely (IC50 8.73 ±
1.90 nM, Figure la). Preincubation with the EP4 antagonist AH 23;848B
(30 pM, 30 min) did not block the relaxant effect of PGE2 (IC50 9.09 ± 5.3
nM, n = 5, concentration-ratio (CR) 1.75 ± 0.67, P = 0.42, Figure la).
Similarly, preincubation with the EP^DP antagonist AH 6809 (10 (jlM, 10
min) and the selective DP antagonist BW A868C (5.4 pM, 10 min) had no
significant effect on the PGE2 relaxation curve (IC50 = 5.5 ±1.12 nM, n
= 4, and 4.10 ± 2.31 nM, n = 3, CR 0.78 ± 0.33 and 1.75 ± 0.84, P = 0.34
and 0.77, respectively). CRs of 10,000 and 10 would have been predicted
with BW A868C20 and AH 6809,19 respectively, on the basis of their
reported pKBs of 9.3 and 6.0 for DP receptors, if relaxation induced by
PGE2 resulted from an interaction with DP receptors.
Effect of Selective Agonists
A comparison of the ability of various agonists with activity at EP2 re¬
ceptors to relax the RJV is shown in Figures lb and lc. The rank order of
potency is PGE2 3= nocloprost > 11-deoxy PGEi > 16,16-dimethyl PGE2
> butaprost AH 13205. Table 1 gives IC50 and EEC values of agonists.
11-Deoxy PGEX achieved a maximal relaxation of 73.1 ± 7.24%, whereas
other EP2 agonists of similar potency, 16,16-dimethyl PGE2 and noclo¬
prost, gave between 90% and 104% of the PGE2 maximum.
Endothelium Dependency
NG-monomethyl-L-arginine (L-NMMA), a stable NO synthase inhibi¬
tor,22 was used in the RJV preparation to examine the dependency of an
intact endothelial layer. At a concentration of 100 pM (15 min pre¬
incubation), L-NMMA had no significant effect (P = 0.33) on relaxation
induced by PGE2 in the RJV (PGE2 IC50 9.48 ± 4.07 nM; PGE2 +
L-NMMA IC50 6.18 ± 2.11 nM, Figure 2).
Pig Saphenous Vein: Effect of Selective Antagonists
The PSV was slightly more sensitive than the RJV to relaxation induced
by PGE2 (IC50 2.05 ± 0.93 nM, P = 0.05; Figure 3a). Preincubation with
the EP4 antagonist AH 23,848B (30 p.M, 30 min) shifted the concentration-
response curve for PGE2 to the right, (IC50 6.48 ± 2.91 nM compared to
2.67 ± 1.89 nM, n = 5, giving a CR of 5.94 ± 1.45, P = 0.048, and a pA2
of 5.27). Preincubation with the EP^DP antagonist AH 6809 (10 pM, 10
min) did not antagonize PGE2 (IC50 3.28 ± 1.39 and 3.85 ± 3.09 nM) in the
presence and absence of AH 6809, P = 0.87.
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Figure 1. Log concentration-response curves for the effects of PGE2 and PGE analogs on
the RJV precontracted with histamine. Relaxation is expressed as a percent of the max¬
imum relaxation induced by PGE2 (100%). (a) PGE2 in the presence and absence of the
EP4 receptor antagonist AH 23.848B (30 m-M, 30 min, n = 4). (b) PGE2, nocloprost, 11-
deoxy PGE„ and 16,16-dimethyl PGE2. (c) PGE2, butaprost, and AH 13205. Results are
expressed as means ± SEM.
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Table 1. Inhibitory concentrations (IC50) and equi-effective concentrations (EEC,
PGE2 = 1) for the pig saphenous vein (PSV) and the rabbit jugular vein (RJV)
IC50 EEC
PSV RJV PSV RJV
pge2 2.05 0.93 nM 8.73 1.90 nM 1.0 1.0
11-Deoxy pge, 3.17 1.41 nM 61.32 52.91 nM 2.0 6.6
16,16-Dime pge2 3.37 ± 1.23 nM 87.03 34.18 nM 2.8 9.9
Butaprost 83.9 21.8 nM 381.0 240.5 nM 42 43
AH13205 6.36 Hh 2.58 m-M 20.26 8.30 (iM 3100 2780
IC50 = value ± SEM (n 3= 4).
Effect of Selective Agonists
A comparison of the ability of various agonists with activity at EP2 re¬
ceptors to relax the PSV is shown in Figures 3b and 3c. The rank order of
potency is PGE2 2= 11-deoxy PGEX 3= 16,16-dimethyl PGE2 > butaprost ^>
AH 13205. Relaxation of at least 95% of the maximum induced by PGE2
was achieved by all the EP agonists tested. IC50 values and EECs are given
in Table 1.
Discussion
The purpose of these experiments was to further characterize the EP
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Figure 2. Relaxation of precontraction of the RJV by PGE2 in the presence and absence
of the inhibitor of nitric oxide synthesis L-NMMA (100 (o,M, 15 min, n = 8).
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Figure 3. Log concentration-response curves for the effects of PGE2 and PGE analogs on
the PSV precontracted with phenylephrine. Relaxation is expressed as a percent of the
maximum relaxation induced by PGE2 (100%). (a) PGE2 in the presence and absence of
the EP4 receptor antagonist AH 23.848B (30 (jlM, 30 min, n = 4), P - 0.048. (b) PGE2,
11-deoxy PGE1: and 16,16-dimethyl PGE2. (c) PGE2, butaprost, and AH 13205. Results are
expressed as means ± SEM.
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EP4-receptor-containing preparation to confirm the activity of the antag¬
onist AH 23,848 and to determine the activities of four commonly used EP
agonists at EP4 receptors. Quantification of agonist action ideally requires
estimation of both affinity and efficacy, since these measurements ex¬
plain in more detail the IC50 values. The most reliable method for deter¬
mining these variables involves irreversible receptor blockade,23 but un¬
fortunately no irreversible antagonist at prostanoid receptors is available.
Therefore in this study the comparison of the relative potencies of four EP
agonists, and possible block by receptor antagonists where available, have
been used in an attempt to characterize the receptor subtypes involved.
Rabbit Jugular Vein
The RJV is known to contain a heterogeneous population of prostanoid
receptors,24,25,14 namely thromboxane (TP) receptors mediating contrac¬
tion (blocked here with the TP receptor antagonist GR 32191) and recep¬
tors for PGE2, PGD2, and PGI2 mediating relaxation. Similar to these
other authors, we found that the selective DP receptor antagonist BW
A868C failed to antagonize the response to PGE2 at a concentration
10,000 times greater than its pKB at DP receptors. Similarly, AH 6809
which is less selective and has weaker DP receptor block, failed to an¬
tagonize the PGE2 response. This suggests that PGE2 does not mediate
relaxation via an interaction at DP receptors. The exclusion of an inter¬
action of PGE2 at IP receptors has not been addressed here as there are no
selective IP receptor antagonists available, but this mechanism seems
unlikely as PGE2 is more potent on the RJV than are PGI2 or selective IP
analogs.24,14 Furthermore, as would be expected, this EP receptor is on the
smooth muscle and so relaxation is not endothelium-dependent. Thus,
the NO synthase inhibitor L-NMMA did not significantly affect relax¬
ation induced by PGE2 (Figure 2). This was also seen when the tissue was
denuded of endothelium (n = 2, data not shown).
Agonist data in Table 1 confirm the relatively low potency of butaprost
on the RJV.14 However, although the IC50 values for butaprost are similar
in the two studies, 381.0 ± 240.5 nM here compared to 199.5 nM, the
EEC values of 43 and 685 are different and reflect the potency of PGE2 in
the two studies (IC50s of 8.73 ±1.9 nM and 0.46 nM, respectively).
The reasons for the difference in sensitivity of the RJV to PGE2 in these
two studies are still not entirely clear, but we have a few considerations
which might help to explain this disparity:
1. The concentration of histamine used in our studies, while submaxi-
mally effective, was usually 2-5 jxM, whereas Lawrence and Jones14 typ¬
ically used 1 (jlM. Relaxation by PGE2 of the histamine-induced contrac¬
tion is a form of functional antagonism, so perhaps a smaller contraction
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is easier to block than a larger contraction.26 This can be seen to a limited
extent in Figure 4, where significantly more relaxation was observed with
0.14 |jlM and 0.45 pM PGE2 using 2 (jlM compared with 5 pM histamine
(P = 0.04).
2. Definition of the maximal relaxation induced by PGE2 is different
in the two studies. Lawrence and Jones14 used relaxation by PGE2 of the
contractile response to histamine as 100% relaxation, whereas we have
used the complete relaxation induced by PGE2 as 100%. Since the tissues
are already under tension before the addition of histamine, PGE2 usually
relaxes the tissue to below the basal tension prior to the addition of
histamine (Figure 5). Calculating the IC50 value for PGE2 by these two
methods in the same preparations gives values of 7.9 ± 2.4 nM using the
observed relaxation induced by PGE2 as the maximum, and 3.8 ±1.5 nM
when relaxation of the precontraction induced by histamine is taken as
the maximum (P - 0.09, n = 4). While these points may partly explain
the lower sensitivity to PGE2 in our experiments compared to those of
Lawrence and Jones, this should not affect the EEC values calculated in
both studies and so does not explain the greater sensitivity to butaprost
seen here. The EECs of 6.6 and 9.9 for 11-deoxy PGEi and 16,16-dimethyl
PGE2 found in this study (Figures lb and lc) compare more favorablywith
those of 1.4 and 2.1 found by Lawrence and Jones. AH 13205 had not been
tested previously on the RJV, and was only weakly active (IC50 = 20.26
± 8.30 pM). Similarly, nocloprost had not been tested previously, and was
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Figure 4. Log concentration-response curves for PGE2 on the PSV, precontracted by 2 or
5 pM histamine, n = 4. PGE2 (1 nM-10 pM) was a more effective relaxant agent with the
lower concentration of histamine than at the higher concentration *P < 0.05.
2 pM histamine
5 pM histamine
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Kreb's solution - containing PGE2
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, Figure 5. Example of a typical RJV trace. Contraction was induced by 2 histamine and
v the preparation relaxed by cumulative doses of PGE2. The preparation relaxed to below
the original set tension.
Pig Saphenous Vein
The PSV has been confirmed to contain EP4 receptors, with the antago¬
nist AH 23,848B (Figure 3a) giving a pA2 of 5.27 which is similar to the 5.4
previously described.7 A pA2 value measures antagonist potency27 but
does not give any information about the nature of antagonism, as to
whether or not it is competitive. For competitive antagonists, pA2—pA10
should equal log 9, and then the pA2 value can be taken to be equal to the
pKB. However, it is not possible with a low affinity antagonist such as AH
23848 to look for greater block, as this would require using concentra¬
tions of antagonist higher than 30 p.M, and so the KB value for AH 23,848
cannot be determined for EP4 receptors. No block was observed with the
DP/EPj receptor antagonist AH 6809, suggesting that PGE2 does not me¬
diate relaxation by an interaction with DP receptors in the PSV. The IC50
determined for PGE2 on this preparation is 2.05 ± 0.93 nM, which agrees
well with the value of 2.5 nM determined by Coleman,28 but is 10-fold
higher than he originally reported.7 The PSV was used to test the EP4
activity of four commonly used EP2 receptor agonists (Figure 3b). Relative
activities of these compounds on the PSV were PGE2 3= 11-deoxy PGE! =
16,16-dimethyl PGE2 > butaprost §> AH 13205. The profile of the relative
activities of the EP agonists on the RJV and PSV (Table 1) is very similar.
Butaprost was less active in both preparations than would be predicted
from its EP2 receptor activity, but was more active than the EP2 agonist
AH 13205. 11-Deoxy PGE]^ and 16,16-dimethyl PGE2 were potent ago-
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nists on both EP2 and EP4 receptors and therefore are not useful agonists
for discriminating between these receptor subtypes.
The agonist data would suggest that the RJV is a preparation contain¬
ing EP4 receptors, but in contrast no antagonism was observed with AH
23,848B on this tissue (Figure la). The reason for this lack of antagonism
is unclear, although it has been documented elsewhere that TP antago¬
nists have lower affinity for thromboxane receptors in the rabbit than for
other TP receptor-containing preparations,29 and this may be true here for
EP receptors. Unfortunately it is difficult to test AH 23848B at concen¬
trations above 30 pM in the organ bath. Experiments with the more
recently described EP4 receptor antagonist AH 22,92128 may help to re¬
solve the nature of the EP receptor subtype in the RJV.
In conclusion, the EP receptor agonists 11-deoxy PGE1; 16,16-dimethyl
PGE2, butaprost, and AH 13205 show similar activities on the RJV and on
the EP4 receptors of the PSV. Butaprost was less active on these prepara¬
tions (EEC 42-43) than on classical EP2 receptors, but AH 13205 was
dramatically less active (EEC 3100-2780). While the results with the
agonists suggest that the EP receptors on the RJV are of the EP4 subtype,
this was not confirmed using the EP4 receptor antagonist AH 23,848B.
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